<SEC-DOCUMENT>0001144204-12-060041.txt : 20121107
<SEC-HEADER>0001144204-12-060041.hdr.sgml : 20121107
<ACCEPTANCE-DATETIME>20121107160628
ACCESSION NUMBER:		0001144204-12-060041
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20120930
FILED AS OF DATE:		20121107
DATE AS OF CHANGE:		20121107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		121186817

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v325765_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>FORM 10-Q</B>&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY
                                                                                                             REPORT PURSUANT TO
                                                                                                             SECTION 13 OR 15(d)
                                                                                                             OF THE SECURITIES
                                                                                                             EXCHANGE ACT OF 1934
                                                                                                             </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the quarterly period ended September 30,
2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; color: black"><B>&uml;</B></FONT></TD><TD><B>TRANSITION
                                                                                                                               REPORT
                                                                                                                               PURSUANT
                                                                                                                               TO
                                                                                                                               SECTION
                                                                                                                               13
                                                                                                                               OR
                                                                                                                               15(d)
                                                                                                                               OF
                                                                                                                               THE
                                                                                                                               SECURITIES
                                                                                                                               EXCHANGE
                                                                                                                               ACT
                                                                                                                               OF
                                                                                                                               1934
                                                                                                                               </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U>to <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Florida</TD>
    <TD STYLE="text-align: center"><B>__<U>65-0643773</U>__</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(State or other jurisdiction</TD>
    <TD STYLE="font-weight: bold; text-align: center">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">of incorporation or organization)</TD>
    <TD STYLE="font-weight: bold; text-align: center">Identification No.)</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">2 Snunit Street</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">Science Park</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">POB 455</TD>
    <TD STYLE="font-weight: bold; text-align: center"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-decoration: underline; text-align: center">Carmiel, Israel</TD>
    <TD STYLE="text-align: center"><B><U>20100</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="font-weight: bold; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>+972-4-988-9488</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Registrant&rsquo;s telephone number,
including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B><BR>
<FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been
subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT>&nbsp; No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of <FONT STYLE="text-transform: uppercase">&quot;</FONT>large
accelerated filer<FONT STYLE="text-transform: uppercase">&quot;</FONT> and <FONT STYLE="text-transform: uppercase">&quot;</FONT>accelerated
filer<FONT STYLE="text-transform: uppercase">&quot;</FONT> in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%; text-indent: 0in">Large accelerated filer <FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD STYLE="width: 5%; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 36%; text-indent: 0in">Accelerated filer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer&nbsp;&nbsp; <FONT STYLE="font-family: Wingdings; color: black">&uml; </FONT>(Do
    not check if a smaller reporting company)</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company <FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On November 4, 2012, approximately 93,465,169
shares of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 82%">&nbsp;</TD>
    <TD STYLE="width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Page</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">PART I &ndash; FINANCIAL INFORMATION</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="font-weight: bold">Cautionary Statement Regarding Forward-Looking Statements</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">ii</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom">Financial Statements</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Balance Sheets &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">As of September 30, 2012 (Unaudited) and
        December 31, 2011</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">1</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Statements of Operations
        (Unaudited) &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">For the Nine Months and the Three Months
        Ended September 30, 2012 and 2011</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">2</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Statement of Changes
        in Shareholders&rsquo; Equity (Capital</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Deficiency) (Unaudited) &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">For the Nine Months Ended September 30,
        2012 and 2011</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">3</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">Condensed Consolidated Statements of Cash
        Flows (Unaudited) &ndash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.45in">For the Nine Months Ended September 30,
        2012 and 2011</P></TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">4</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0.3in">Notes to Condensed Consolidated Financial Statements</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">6</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">10</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item 3.</TD>
    <TD STYLE="vertical-align: bottom">Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">17</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom">Controls and Procedures</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">18</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.1in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">PART II &ndash; OTHER INFORMATION</TD>
    <TD STYLE="padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;1.</TD>
    <TD STYLE="vertical-align: bottom">Legal Proceedings</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;1A.</TD>
    <TD STYLE="vertical-align: bottom">Risk Factors</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;2.</TD>
    <TD STYLE="vertical-align: bottom">Unregistered Sales of Equity Securities and Use of Proceeds</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;3.</TD>
    <TD STYLE="vertical-align: bottom">Defaults Upon Senior Securities</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;4.</TD>
    <TD STYLE="vertical-align: bottom">Mine Safety Disclosures</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">Item&nbsp;5.</TD>
    <TD STYLE="vertical-align: bottom">Other Information</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top">Item&nbsp;6.</TD>
    <TD STYLE="vertical-align: bottom">Exhibits</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">19</TD></TR>
<TR STYLE="background-color: rgb(204,255,204)">
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top">Signatures</TD>
    <TD NOWRAP STYLE="vertical-align: bottom; padding-left: 0.1in; text-align: center">21</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms,
<FONT STYLE="text-transform: uppercase">&quot;</FONT>we,<FONT STYLE="text-transform: uppercase">&quot;</FONT> <FONT STYLE="text-transform: uppercase">&quot;</FONT>us,<FONT STYLE="text-transform: uppercase">&quot;
&quot;</FONT>our<FONT STYLE="text-transform: uppercase">&quot;</FONT> or <FONT STYLE="text-transform: uppercase">&quot;</FONT>the
Company,<FONT STYLE="text-transform: uppercase">&quot;</FONT> refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and <FONT STYLE="text-transform: uppercase">&quot;</FONT>Protalix<FONT STYLE="text-transform: uppercase">&quot;
</FONT>or <FONT STYLE="text-transform: uppercase">&quot;</FONT>Protalix Ltd.<FONT STYLE="text-transform: uppercase">&quot;</FONT>
refers to the business of Protalix Ltd., our wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions <FONT STYLE="text-transform: uppercase">&quot;</FONT>Business,<FONT STYLE="text-transform: uppercase">&quot;
&quot;</FONT>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations<FONT STYLE="text-transform: uppercase">&quot;
</FONT>and <FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors,<FONT STYLE="text-transform: uppercase">&quot;</FONT>
and other statements included elsewhere in this Quarterly Report on Form 10-Q which are not historical constitute <FONT STYLE="text-transform: uppercase">&quot;</FONT>forward-looking
statements<FONT STYLE="text-transform: uppercase">&quot;</FONT> within the meaning of Section 27A of the Securities Act of 1933,
as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including
statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms <FONT STYLE="text-transform: uppercase">&quot;</FONT>anticipate,<FONT STYLE="text-transform: uppercase">&quot;
&quot;</FONT>believe,<FONT STYLE="text-transform: uppercase">&quot;</FONT> <FONT STYLE="text-transform: uppercase">&quot;</FONT>estimate,<FONT STYLE="text-transform: uppercase">&quot;
&quot;</FONT>expect,<FONT STYLE="text-transform: uppercase">&quot;</FONT> &quot;plan&quot; and <FONT STYLE="text-transform: uppercase">&quot;</FONT>intend<FONT STYLE="text-transform: uppercase">&quot;
</FONT>and words or phrases of similar import, as they relate to our company, our subsidiaries and our management, are intended
to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our
views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to
update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances
after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required
under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results
to differ materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks
                                                                                                         related to the commercialization
                                                                                                         efforts for taliglucerase
                                                                                                         alfa in the United States
                                                                                                         and Israel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         risk of significant delays
                                                                                                         in the commercial introduction
                                                                                                         of taliglucerase alfa
                                                                                                         in the United States,
                                                                                                         Israel and other markets
                                                                                                         as planned, if at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         risk that we will not
                                                                                                         be able to develop a
                                                                                                         successful sales and
                                                                                                         marketing organization
                                                                                                         for taliglucerase alfa
                                                                                                         in Israel or for any
                                                                                                         other product candidate
                                                                                                         in a timely manner, if
                                                                                                         at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks
                                                                                                         related to the acceptance
                                                                                                         and use of taliglucerase
                                                                                                         alfa by physicians, patients
                                                                                                         and third-party payors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks
                                                                                                         related to the market
                                                                                                         exclusivity issued to
                                                                                                         Shire plc for velaglucerase
                                                                                                         alfa in the European
                                                                                                         Union</FONT> and the effects thereof;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays
                                                                                                         in the approval or the
                                                                                                         potential rejection of
                                                                                                         any application filed
                                                                                                         with or submitted to
                                                                                                         the regulatory authorities
                                                                                                         reviewing taliglucerase
                                                                                                         alfa outside of the United
                                                                                                         States and Israel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                                                                                         ability to enter into
                                                                                                         supply arrangements with
                                                                                                         the Ministry of Health
                                                                                                         of Brazil or other parties
                                                                                                         and to supply drug product
                                                                                                         pursuant to such arrangements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         availability of reimbursement
                                                                                                         to patients from health
                                                                                                         care payors for any of
                                                                                                         our other product candidates,
                                                                                                         if approved;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">risks
                                                                                                         relating to our ability
                                                                                                         to finance our research
                                                                                                         programs, the expansion
                                                                                                         of our manufacturing
                                                                                                         capabilities and the
                                                                                                         ongoing costs in the
                                                                                                         case of delays in regulatory
                                                                                                         approvals for taliglucerase
                                                                                                         alfa outside of the United
                                                                                                         States and Israel;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         risk that products that
                                                                                                         are competitive to our
                                                                                                         product candidates may
                                                                                                         be granted orphan drug
                                                                                                         status in certain territories
                                                                                                         and, therefore, will
                                                                                                         be subject to potential
                                                                                                         marketing and commercialization
                                                                                                         restrictions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         impact of development
                                                                                                         of competing therapies
                                                                                                         and/or technologies by
                                                                                                         other companies; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays
                                                                                                         in our preparation and
                                                                                                         filing of applications
                                                                                                         for regulatory approval
                                                                                                         of our other product
                                                                                                         candidates in the United
                                                                                                         States, the European
                                                                                                         Union and elsewhere;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                                                                                         lack of progress of our
                                                                                                         research and development
                                                                                                         activities and our clinical
                                                                                                         activities with respect
                                                                                                         to any product candidate;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                                                                                         ability to establish
                                                                                                         and maintain strategic
                                                                                                         license, collaboration
                                                                                                         and distribution arrangements,
                                                                                                         and to manage our relationships
                                                                                                         with Pfizer Inc., or
                                                                                                         Pfizer, Teva Ltd. or
                                                                                                         any other collaborator,
                                                                                                         distributor or partner;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to
                                                                                                         biosimilar legislation
                                                                                                         and/or healthcare reform
                                                                                                         in the United States
                                                                                                         or elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         inherent risks and uncertainties
                                                                                                         in developing the types
                                                                                                         of drug platforms and
                                                                                                         products we are developing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">potential
                                                                                                         product liability risks,
                                                                                                         and risks of securing
                                                                                                         adequate levels of product
                                                                                                         liability and clinical
                                                                                                         trial insurance coverage;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         possibility of infringing
                                                                                                         a third party&rsquo;s
                                                                                                         patents or other intellectual
                                                                                                         property rights;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         uncertainty of obtaining
                                                                                                         patents covering our
                                                                                                         products and processes
                                                                                                         and in successfully enforcing
                                                                                                         our intellectual property
                                                                                                         rights against third
                                                                                                         parties; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                                                                                         possible disruption of
                                                                                                         our operations due to
                                                                                                         terrorist activities
                                                                                                         and armed conflict, including
                                                                                                         as a result of the disruption
                                                                                                         of the operations of
                                                                                                         regulatory authorities,
                                                                                                         our subsidiaries, our
                                                                                                         manufacturing facilities
                                                                                                         and our customers, suppliers,
                                                                                                         distributors, collaborative
                                                                                                         partners, licensees and
                                                                                                         clinical trial sites.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology
company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views
with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed
under the heading <FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&quot;
</FONT>beginning Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and in Section&nbsp;1A,
under the heading <FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors,<FONT STYLE="text-transform: uppercase">&quot;
</FONT>in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2011, and are described from time to time in
the reports we file with the Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1. Financial
Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT><BR>
(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 9pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">50,216</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">27,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts receivable:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,025</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,281</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,837</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,058</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">279</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 27pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,580</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">32,491</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">FUNDS IN RESPECT
    OF EMPLOYEE RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,043</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,664</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,271</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">77,378</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 14.2pt">LIABILITIES AND SHAREHOLDERS' EQUITY (NET OF CAPITAL
    DEFICIENCY)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,427</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,032</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,444</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,121</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,435</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,693</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,923</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Long term liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,794</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,878</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,700</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">59,189</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">72,606</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">77,882</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,772</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,077</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 27pt">Total liabilities and shareholders' equity (net of
    capital deficiency)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">77,378</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">51,805</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROTALIX
BIOTHERAPEUTICS, INC. </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT><BR>
<FONT STYLE="font-size: 10pt">(U.S. dollars in thousands, except share data)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Nine
    Months Ended</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">Three
    Months Ended</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 8pt">
    <TD NOWRAP STYLE="font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">September
    30, 2012</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">September
    30, 2011</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">September
    30, 2012</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt"><FONT STYLE="font-size: 8pt">September
    30, 2011</FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="width: 56%; font-weight: bold; font-size: 8pt"><FONT STYLE="font-size: 8pt">REVENUES</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">33,698</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">6,024</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">3,724</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 8%; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,132</FONT></TD><TD STYLE="width: 1%; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">COMPANY&rsquo;S SHARE IN COLLABORATION
    AGREEMENT</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">678</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(3,745</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,666</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(235</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">COST OF REVENUES (1)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(6,966</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(1,130</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(2,367</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(220</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">GROSS PROFIT</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">27,410</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,149</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">3,023</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">677</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt"><B>RESEARCH AND DEVELOPMENT EXPENSES
    <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: black">(2)</FONT></B></FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(27,717</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(28,671</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(8,326</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(9,340</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">less
    &ndash; grants<B> </B>and reimbursements</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">5,655</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">5,163</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,963</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,422</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">RESEARCH
    AND DEVELOPMENT EXPENSES, NET</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(22,062</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(23,508</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(6,363</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(7,918</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt"><B>GENERAL
    AND ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: black">EXPENSES
    (3)</FONT></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(7,353</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(5,314</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(2,220</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(1,526</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="color: black; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt; text-transform: uppercase; color: black"><B>OPERATING
LOSS</B></FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(2,005</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(27,673</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(5,560</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(8,767</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">FINANCIAL
    INCOME (EXPENSES) &ndash; NET</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">264</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">57</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">81</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(108</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">NET LOSS FOR THE PERIOD</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(1,741</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(27,616</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(5,479</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(8,875</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-indent: -12.6pt; padding-left: 12.6pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">LOSS
    PER SHARE OF COMMON STOCK:</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; font-size: 8pt; padding-left: 0.12in">&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">BASIC
    AND DILUTED</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.02</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.33</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.06</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">(0.10</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="font-weight: bold; text-indent: -12pt; padding-left: 12.6pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">WEIGHTED
    AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">BASIC
    AND DILUTED</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">90,491,421</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">84,351,420</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">91,929,445</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">85,585,777</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">(1) Includes
    share-based compensation</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">220</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">220</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">0</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204); font-size: 8pt">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">(2) Includes
    share-based compensation</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">3,690</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">348</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">1,247</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">92</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-size: 8pt">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12.6pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">(3) Includes
    share-based compensation</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">2,155</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">382</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">840</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt"><FONT STYLE="font-size: 8pt">117</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0"><B>The accompanying notes
are an integral part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN SHAREHOLDERS&rsquo; EQUITY (CAPITAL DEFICIENCY) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(U.S. dollars in thousands, except
share data)<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 45%; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2010</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">81,248,472</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">81</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">124,044</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(135,448</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(11,323</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt"><B>Changes during the nine-month period ended September 30, 2011 </B>(Unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issued for cash (net of issuance costs of
    $1,410)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,586</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,590</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Exercise of options granted to<B> </B>employees and non-employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">265</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt; padding-bottom: 1pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,616</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Balance at September 30, 2011 (Unaudited)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">85,598,517</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">86</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">145,625</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(163,064</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(17,353</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance at December 31, 2011</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">85,630,157</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">86</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">145,814</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(171,977</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(26,077</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt"><B>Changes during the nine-month period ended September 30, 2012</B> (Unaudited):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Common stock issued for cash (net of issuance costs of
    $1,780) (see note 3a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.6pt; text-align: center">&nbsp;</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,217</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,217</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Exercise of options granted &nbsp;to employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,156,184</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,137</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based&nbsp; compensation related to restricted stock
    award</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,500,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,847</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1,848</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net loss for the period</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,741</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt; text-indent: -9pt">Balance at September 30, 2012 (Unaudited)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">93,461,341</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">93</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">178,397</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(173,718</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,772</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Common Stock, $0.001
                                                                               par value; Authorized &ndash; as of September 30,
                                                                               2012 and September 30, 2011 - 150,000,000 shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>The accompanying
notes are an integral part of the condensed consolidated financial statements. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(U.S. dollars
in thousands)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, <BR>
    2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,<BR> 2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 9pt; text-indent: -9pt">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,741</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(27,616</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Adjustments required to reconcile net loss to net cash
    used in operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,065</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Depreciation and write down of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,772</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,698</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Financial income, net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.1pt; padding-left: 9.4pt">Gain on amounts funded in respect of employee rights
    upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Loss on sale of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 7.1pt">Decrease in deferred revenues (including non-current portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,981</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(991</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 7.1pt">Decrease (increase) in accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,099</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 7.1pt">Decrease (increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,779</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">762</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 7.1pt">Increase in accounts payable and &nbsp;accruals (including
    long term)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">369</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,388</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,186</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,958</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -11.6pt; padding-left: 11.6pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,817</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,001</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Proceeds from sale of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Amounts funded in respect of employee
    rights upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(122</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net cash used in investing activities&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,910</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,121</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -9pt; padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -9pt; padding-left: 9pt">Issuance of shares, net of issuance cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,650</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,096</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">263</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,913</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">EFFECT OF EXCHANGE
    RATE CHANGES ON CASH</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(113</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">NET INCREASE (DECREASE) IN CASH AND
    CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,336</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">BALANCE OF CASH
    AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,001</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">35,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">BALANCE OF CASH
    AND CASH EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">50,216</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,564</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">(U.S. dollars
in thousands)</FONT><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">September 30,<BR>
    2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">September 30, <BR>
    2011</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">SUPPLEMENTARY INFORMATION ON INVESTING
    AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-bottom: 1pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">821</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 10%; text-align: right; border-bottom: Black 1pt solid">1,477</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Issuance cost not yet paid and accruals &ndash; other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">60</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exercise of options granted to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">72</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">12</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>The
accompanying notes are an integral part of the condensed consolidated financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD>Operation</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Protalix BioTherapeutics, Inc. (collectively
with its subsidiaries, the &quot;Company&quot;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies
focused on the development and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary
ProCellEx<SUP>&reg;</SUP> protein expression system (&quot;ProCellEx&quot;). In September 2009, Protalix Ltd. formed another wholly-owned
subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&quot;EMA&quot;)
application process in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &quot;Subsidiaries.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">On May 1, 2012, the U.S. Food and
Drug Administration (<FONT STYLE="text-transform: uppercase">&quot;</FONT>FDA<FONT STYLE="text-transform: uppercase">&quot;</FONT>)
approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement therapy (ERT)
for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary,
recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved
by the Israeli Ministry of Health (the &quot;Israeli MOH&quot;) in September 2012. Taliglucerase alfa is the first plant cell-based
recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Taliglucerase alfa is being marketed in the United
States under the brand name ELELYSO&trade; by Pfizer Inc. (<FONT STYLE="text-transform: uppercase">&quot;</FONT>Pfizer<FONT STYLE="text-transform: uppercase">&quot;</FONT>),
the Company's commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd.
and Pfizer (the <FONT STYLE="text-transform: uppercase">&quot;</FONT>Pfizer Agreement<FONT STYLE="text-transform: uppercase">&quot;</FONT>).
The Company, through Protalix Ltd., markets ELELYSO in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. granted Pfizer an exclusive,
worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in
Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for
the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0
million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical
development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with
the FDA's approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for
purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which  the milestone was
achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and
commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses
related to commercialization efforts in Israel. <FONT STYLE="color: black">In calculating the net profits under the
agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and
costs of goods sold</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company is cooperating with Pfizer to obtain marketing
approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have
been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization
for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency's Committee for
Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa.
While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan
market exclusivity granted to VPRIV<SUP>&reg;</SUP>, Shire plc's Gaucher disease treatment. It was not based on the safety and
efficacy profile of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to taliglucerase alfa, the Company is working
on the development of certain other products using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Currently, patients are being treated with
taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in
Israel shortly. In addition, patients are being treated globally through the Company's clinical trials and related studies,
compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that
treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the
Company announced that the French regulatory authority had granted an Autorisation Temporaire d'Utilisation (ATU), or
Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory
mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France
when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase
alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been
secured through government allocations to hospitals. Notwithstanding the EC's decision not to approve the market
authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa
as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In
addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special
access agreements or named patient provisions in Brazil and in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On August 10, 2010, Pfizer entered into a short-term
supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa
to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter
of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011,
Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health
requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012
resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of
Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions
of the Pfizer Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD>Liquidity and Financial Resources</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the FDA approval of taliglucerase alfa,
successful completion of the Company&rsquo;s development programs and its transition to normal operations is dependent upon obtaining
the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of
the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA's approval of taliglucerase
alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support
its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval
process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect
to any product candidate is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required
to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these
activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Based on its current cash resources and commitments,
the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures
for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time.
If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may
need to seek additional financing during the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of Presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (<FONT STYLE="text-transform: uppercase">&quot;</FONT>GAAP<FONT STYLE="text-transform: uppercase">&quot;</FONT>) for interim
financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial
statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement
of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily
indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K
for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance
sheet at December 31, 2011 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-indent: -17.85pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 17.85pt"><B>c.</B></TD><TD><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s common stock, par value $.001
per share (the &ldquo;Common Stock&rdquo;), outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt">Shares of restricted Common Stock and the shares
of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the
effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS does not include 7,498,026 and 7,169,035
shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September&nbsp;30,
2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted
shares of Common Stock for the three months ended September&nbsp;30, 2011 and 2012, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 &ndash; INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Inventory at September 30, 2012 and December&nbsp;31,
2011 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">September 30,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">December 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 74%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,294</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">279</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">466</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,058</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">279</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 &ndash; INVENTORIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="color: black">Prior to the FDA's approval
of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed
as research and development expenses</FONT>. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company
capitalizes all manufacturing costs associated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 - STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-indent: -21.25pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><FONT STYLE="color: black">On February 22,&nbsp;2012,
                                                                         the Company issued and sold 5,175,000 shares of Common
                                                                         Stock in an underwritten public offering at a price to
                                                                         the public of $5.25 per share. The net proceeds to the
                                                                         Company were approximately $25,388,000&nbsp;(net of underwriting
                                                                         commissions and issuance costs of approximately $1,780,000).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-indent: -21.25pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: black"><B>b.</B></FONT></TD><TD><FONT STYLE="color: black">During
                                                                                                           the nine months ended
                                                                                                           September 30, 2012,
                                                                                                           the Company issued
                                                                                                           a total of </FONT>1,156,184
                                                                                                           <FONT STYLE="color: black">shares
                                                                                                           of Common Stock in
                                                                                                           connection with the
                                                                                                           exercise of a total
                                                                                                           of </FONT>1,156,184
                                                                                                           <FONT STYLE="color: black">options
                                                                                                           by certain officers
                                                                                                           and employees of the
                                                                                                           Company. The Company
                                                                                                           received aggregate
                                                                                                           cash proceeds equal
                                                                                                           to approximately $</FONT>1,137,000
                                                                                                           <FONT STYLE="color: black">in
                                                                                                           connection with such
                                                                                                           exercises.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-indent: -21.25pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: black"><B>c.</B></FONT></TD><TD><FONT STYLE="color: black">Following
                                                                                                           FDA </FONT>approval
                                                                                                           of taliglucerase alfa
                                                                                                           on May 1, 2012<FONT STYLE="color: black">,
                                                                                                           the Company started
                                                                                                           recognizing compensation
                                                                                                           costs in relation to
                                                                                                           performance-based awards
                                                                                                           that were granted in
                                                                                                           February 2010 to certain
                                                                                                           officers and employees
                                                                                                           of the Company, which
                                                                                                           vest over a three-year
                                                                                                           period commencing upon
                                                                                                           the FDA's approval
                                                                                                           of </FONT>taliglucerase
                                                                                                           alfa<FONT STYLE="color: black">.
                                                                                                           During the second and
                                                                                                           third quarter of 2012,
                                                                                                           the Company recorded
                                                                                                           an expense in the amount
                                                                                                           of approximately $3,900,000
                                                                                                           for the cumulative
                                                                                                           period from the date
                                                                                                           of grant.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-indent: -21.25pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="color: black"><B>d.</B></FONT></TD><TD>On July 16, 2012,
                                                                                                           the Company&rsquo;s
                                                                                                           Board of Directors
                                                                                                           approved the grant
                                                                                                           of 1,500,000 shares
                                                                                                           of restricted Common
                                                                                                           Stock to its officers
                                                                                                           and certain other employees.
                                                                                                           Of such restricted
                                                                                                           shares, 1,100,000 of
                                                                                                           the shares were issued
                                                                                                           to the Company's named
                                                                                                           executive officers
                                                                                                           and vest in 16 equal,
                                                                                                           quarterly increments
                                                                                                           over a four-year period,
                                                                                                           commencing upon the
                                                                                                           date of grant, and
                                                                                                           are subject to a 24-month
                                                                                                           lock-up period, commencing
                                                                                                           upon the applicable
                                                                                                           vesting dates. Immediately
                                                                                                           and automatically in
                                                                                                           the event of a Change
                                                                                                           in Control, as such
                                                                                                           term is defined in
                                                                                                           the Company's 2006
                                                                                                           Stock Incentive Plan,
                                                                                                           as amended, all of
                                                                                                           the shares of restricted
                                                                                                           Common Stock issued
                                                                                                           to the named executive
                                                                                                           officers shall vest,
                                                                                                           and the lock-up periods
                                                                                                           shall terminate, subject
                                                                                                           to certain exceptions.
                                                                                                           The remaining 400,000
                                                                                                           shares of restricted
                                                                                                           Common Stock were issued
                                                                                                           to other employees
                                                                                                           of the Company and
                                                                                                           vest in 12 equal, quarterly
                                                                                                           increments over a three-year
                                                                                                           period, commencing
                                                                                                           upon the date of grant.
                                                                                                           The Company estimated
                                                                                                           the fair value of the
                                                                                                           restricted stock on
                                                                                                           the date of grant to
                                                                                                           be approximately $8,580,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 4 - SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">During October and November 2012, the Company
issued a total of 3,828 shares of Common Stock in connection with the exercise of options to purchase 3,828 shares of Common Stock
by an employee of the Company. The aggregate cash proceeds in connection with the exercise of the options were $5,187.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;2. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated
financial statements and the related notes included elsewhere in this Form 10-Q, our Quarterly Reports on Form 10-Q for the quarters
ended March 31, 2012 and June 30, 2012 and our Annual Report on Form 10-K for the year ended December 31, 2011. Some of the information
contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing,
includes forward-looking statements that involve risks and uncertainties. You should read <FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk
Factors<FONT STYLE="text-transform: uppercase">&quot;</FONT> in our Annual Report on Form 10-K for the year ended December 31,
2011 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 for a discussion of important factors that could
cause actual results to differ materially from the results described in or implied by the forward-looking statements contained
in the following discussion and analysis. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar versions of recombinant
therapeutic proteins based on our plant cell-based expression technology that target large, established pharmaceutical markets
and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins,
including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx
protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior
to existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically
equivalent versions of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development
process is associated with relatively less risk compared to other biopharmaceutical development processes for completely novel
therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the FDA approved taliglucerase alfa for injection,
which is being marketed under the brand name ELELYSO&trade;, as an enzyme replacement therapy (ERT) for the long-term treatment
of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The Israeli Ministry of Health, or the Israeli MOH, approved
taliglucerase alfa in September 2012. Taliglucerase alfa, our first approved drug product, is a proprietary, recombinant form
of glucocerebrosidase (GCD) that we developed using ProCellEx. Taliglucerase alfa is the first plant cell-based recombinant therapeutic
protein to be approved by each of the FDA and the Israeli MOH. Gaucher disease is a rare and serious lysosomal storage disorder
with severe and debilitating symptoms. Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that is naturally
found in human cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement by and between
Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer an exclusive,
worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel.
We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities for the continued development
efforts for taliglucerase alfa outside of Israel. To date, we have received an upfront payment of $60.0 million in connection
with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million payment in connection with a clinical
development-related milestone. We also received a $25.0 million milestone payment from Pfizer in connection with the FDA's approval
of taliglucerase alfa in the United States. The agreement provides that we share with Pfizer the future net profits or loss for
the development and commercialization of taliglucerase alfa worldwide (except in Israel) on a 40% and 60% basis, respectively.
<FONT STYLE="color: black">In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts
that may be deducted from gross sales for certain expenses and costs of goods sold</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing
approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications
have been filed with <FONT STYLE="font-family: Times New Roman, Times, Serif">the National Sanitary Vigilance Agency, or
ANVISA, an agency of the Brazilian Ministry of Health</FONT>, as well as in other countries. In November 2012, we announced
that the European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the
European Union. This decision is an endorsement of the European Medicines Agency's Committee for Medicinal Products for Human
Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a
positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity
granted to VPRIV<SUP>&reg;</SUP>, Shire plc's, or Shire's, Gaucher disease treatment. It was not based on the safety and
efficacy profile of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">The FDA and foreign regulators require
manufacturers of drug products to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities
to confirm compliance with </FONT>good manufacturing practices, or GMP<FONT STYLE="color: black">, or similar requirements that
the FDA or foreign regulators establish. </FONT>In December 2011, following the submission of the taliglucerase alfa MAA to the
EMA, the Irish Medicines Board, or IMB, completed a successful GMP audit of our facility and issued a Certificate of GMP Compliance
of a Manufacturer for the facility. The IMB certificate is accepted by all health authorities in the European Union under the
European Union's centralized marketing authorization procedure, and by authorities of several other countries that recognize EU
certification.<FONT STYLE="color: black"> </FONT>In February 2010, the Israeli MOH completed a successful GMP audit of our manufacturing
facilities in Carmiel, Israel. On February 20, 2011, we received a letter from the FDA notifying us that the FDA had completed
its review of the Establishment Inspection Report in connection with the FDA's inspection of our facility in Carmiel, Israel,
and that the FDA had classified our facility as acceptable. In June 2011, ANVISA completed a successful GMP audit of our facility
and determined that the facility is acceptable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the completed phase III clinical trial we completed
in September 2009, we initiated a double-blind, follow-on extension study as part of the trial during the second quarter of 2008.
Eligible patients who completed nine months of treatment in our phase III clinical trial were offered the opportunity to participate
in the extension study and continue to receive taliglucerase alfa at the same dose they received in the phase III clinical trial
for an additional 15 months in a blinded manner. In February 2012, we announced data from 26 adult patients enrolled in the trial.
According to the data, after 24 months, patients continued to demonstrate statistically significant improvement in all parameters
with a similar safety profile as seen in the phase III clinical trial. Furthermore, those patients who were followed specifically
for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over
time. We have also initiated a home care treatment program for patients enrolled in the extension study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the second quarter of 2011, we successfully completed a
nine-month, worldwide, multi-center, open-label, switch-over clinical study evaluating the safety and efficacy of switching Gaucher
patients currently treated with Cerezyme<SUP>&reg;</SUP>, which is produced by Genzyme Corporation, or Genzyme (A Sanofi-Aventis
company), with taliglucerase alfa. The results of the switchover trial demonstrate that over the nine-month treatment period,
patients remained stable with regard to spleen volume, liver volume, platelet count and hemoglobin concentration, the efficacy
endpoints of the switchover trial, after switching from Cerezyme to taliglucerase alfa. The safety analysis of the switchover
trial demonstrated that taliglucerase alfa was well tolerated, and no drug-related serious adverse events were reported. The switchover
study demonstrates that taliglucerase alfa is an alternative treatment for adult patients with Gaucher disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2009, we filed a proposed pediatric investigation
plan to the Pediatric Committee of the EMA, which was approved during the first quarter of 2010. We have since concluded enrollment
all of the na&iuml;ve and switchover pediatric patients required according to the study protocol. All of the na&iuml;ve patients
have concluded the study and we anticipate that the remaining patients will conclude the study by the end of 2012. The primary
endpoint of the study was change in hemoglobin concentration, and the secondary endpoints were change of spleen volume, liver
volume, platelet count and chitotriosidase activity. Patients were enrolled in clinics in Israel, Paraguay and South Africa. Patients
that completed the trial continued treatment in the extension trial. Preliminary data regarding pediatric patients that were treated
for 12 months was released in July 2012. After 12 months of treatment with taliglucerase alfa, improvements were seen in the primary
endpoint and all secondary endpoints. The majority of treatment-related adverse events were mild or moderate in intensity, and
transient in nature. The preliminary results of this study suggest that taliglucerase alfa has the potential to provide alternative
therapy in pediatric patients with Gaucher disease, as with adults. We expect to report the data from the study shortly after
the conclusion of the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patients in the extension trial and the switchover trial are
still being treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The current standard of care for Gaucher patients is enzyme
replacement therapy. Enzyme replacement therapy is a medical treatment in which recombinant enzymes are infused into patients
in whom the enzyme is lacking or dysfunctional. Taliglucerase alfa has an amino acid, glycan and three-dimensional structure that
is very similar to Cerezyme, which is a mammalian cell expressed version of the same protein. We believe taliglucerase alfa may
prove more cost-effective than the currently marketed alternatives due to the cost benefits of expression through our ProCellEx
protein expression system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with taliglucerase alfa
on a commercial basis in the United States, and, we anticipate that patients will be treated on a commercial basis in Israel shortly.
Globally, patients are being treated through our clinical trials and related studies, compassionate use programs, special access
agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in
light of recent shortages of approved treatments. On July 13, 2010, we announced that the French regulatory authority had granted
an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of
Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved
drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to
receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment
for taliglucerase alfa has been secured through government allocations to hospitals.
In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special
access agreements or named patient provisions in Brazil and in other countries. Hundreds of patients, in the aggregate, have been
treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 10, 2010, Pfizer entered into a $30 million short-term
supply agreement with the Brazilian Ministry of Health pursuant to which Protalix and Pfizer have provided taliglucerase alfa
to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter
of 2011, we and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer
recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested
that Pfizer consider the replacement of certain vials that might expire during 2012. Revenue, net of allowance for sales returns,
generated from the Brazilian Ministry of Health was recorded by Pfizer, and we recorded our share of such revenues in accordance
with the terms and conditions of the Pfizer Agreement. As such vials are replaced, revenues are recorded upon the supply of the
replaced vials, and if it is determined that there is no longer a need for the replacement of vials, the allowance will be reversed
and the revenues will be recognized accordingly. During the third quarter of 2012, we and Pfizer resupplied a portion of the returned
vials for which an allowance for return was made during 2011 and, as a result, Pfizer reversed the allowance related to such resupplied
vials. In addition, we and the Ministry of Health of Brazil are in discussions relating to a possible long-term supply agreement
that contemplates, among other matters, providing certain components of our manufacturing technology to the Brazilian Ministry
of Health for implementation by it in Brazil. We are currently unable to assess whether these discussions will result in an agreement
and we can make no assurance that we will be able to enter into such an agreement on favorable terms, if at all. In any event,
we do not expect to supply the Brazilian Ministry of Health taliglucerase alfa until we receive marketing approval of taliglucerase
alfa from ANVISA, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:
(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans;
(2) PRX-105, a plant cell expressed pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications;
(3) an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant
enzyme produced within carrot cells; (4) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein made from the
soluble form of the human TNF receptor (TNFR) and an antibody portion, which is being developed as a treatment of certain immune
diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, spondylitis, psoriatic arthritis and plaque psoriasis; and
(5) two additional undisclosed therapeutic proteins, both of which are being evaluated in animal studies. We participated in a
pre-investigational new drug, or IND, meeting with respect to one of the undisclosed product candidates in the first quarter of
2012 and a pre-IND meeting for the second candidate is planned for the first half of 2013. In March 2010, we initiated a preliminary
phase I clinical trial of PRX-105 which we completed in June 2010. We are currently preparing for further efficacy trials of this
product candidate in larger animals. In our preclinical studies we utilized an analogue to nerve gas. However, we anticipate that
we will use live nerve gas rather than an analogue in the proposed additional efficacy trials in animals. In August 2012, the
FDA accepted and approved our IND for a phase I/II clinical study of PRX-102 in Fabry patients. We expect to initiate the trial
before the end of 2012. We are also conducting pre-clinical trials of our orally-administrated glucocerebrosidase enzyme for the
treatment of Gaucher disease in small and large animals. We plan to apply, by the end of 2012, for regulatory approval of the
initiation of a clinical trial in Gaucher patients designed to demonstrate safety and achieve the first ever proof in concept
regarding orally-administrated glucocerebrosidase enzyme. In December 2011, we held a pre-IND meeting with respect to PRX-106
and we expect to submit an IND during the first half of 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Except for the rights to commercialize taliglucerase
alfa worldwide (other than Israel) which we licensed to Pfizer, we hold the worldwide commercialization rights to our proprietary
development candidates. We have built an internal marketing team designed to serve the Israeli market for taliglucerase alfa and
we intend to establish internal commercialization and marketing teams for our other product candidates in North America, the European
Union and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition,
we continuously evaluate potential strategic marketing partnerships.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have not been any changes to our significant accounting
policies since the Annual Report on Form 10-K for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and
results of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting
principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements,
as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and
judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that
are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended September 30, 2012 compared to the
three months ended September 30, 2011</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $3.7&nbsp;million during the three
months ended September 30, 2012, an increase of $2.6 million, or 229%, from revenues of $1.1 million for the three months ended
September 30, 2011. The revenues represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone payments of
$1.1&nbsp;million in each quarterly period and revenues recognized during the three months ended on September 30, 2012 for drugs
supplied to Pfizer at cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $1.7 million as our share in net income
from the collaboration under the Pfizer Agreement during the three months ended September 30, 2012, compared to loss of $235,000
for the three months ended September 30, 2011. Our share in the collaboration agreement recorded during the three months ended
September 30, 2012 represents our 40% share of the net income generated during the period, which was primarily the result of revenues
generated by Pfizer in the United States and resupply in Brazil which exceeded the expenses during such period. Our share in the
collaboration includes a loss generated during the three months ended September 30, 2011 which resulted primarily from certain
clinical-related expenses. Under the terms and conditions of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries
that operate outside the United States is included based on the fiscal year ending November&nbsp;30, while financial information
for the U.S. entity is included based on the fiscal year ending December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $2.4 million and $220,000 for the three
months ended September 30, 2012 and September 30, 2011, respectively. Cost of revenues for the three months ended September 30,
2012 includes approximately $2.1&nbsp;million primarily for certain fixed costs relating to our manufacturing facility, including
rent, depreciation, salary and maintenance expenses, and to a much lesser extent, the direct cost of products delivered to Pfizer
for which revenues were recognized during the period. Cost of revenues also includes $314,000, representing royalties due to the
Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor, or the OCS, and to a certain academic institution
in connection with gross sales of taliglucerase alfa during the period. Prior to the FDA's approval of taliglucerase alfa, manufacturing
costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses.
Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, we capitalize all manufacturing costs associated
with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $6.4&nbsp;million for
the three months ended September 30, 2012, a decrease of $1.5&nbsp;million, or 20%, from $7.9&nbsp;million for the three months
ended September 30, 2011. The decrease resulted primarily from a decrease of $789,000 in rent and other overhead costs and $630,000
in materials which have been classified as cost of revenues or capitalized as inventory after the FDA's approval of taliglucerase
alfa in May 2012, and due to $366,000 in costs related to consulting and subcontractors associated with research and development
activities. The decrease was partially offset by an increase of $598,000 in salaries expense resulting primarily from bonuses
paid in connection with the FDA's approval of taliglucerase alfa on May 1, 2012 and share-based compensation. The decrease also
resulted from increased reimbursement of expenses equal to $1.2 million in accordance with the terms and conditions of the Pfizer
Agreement during the three months ended September 30, 2012, compared to the total reimbursement of approximately $564,000 from
Pfizer, during the three months ended September 30, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">General and administrative expenses were
$2.2&nbsp;million for the three months ended September 30, 2012, an increase of $694,000, or 45%, from $1.5&nbsp;million for the
three months ended September 30, 2011. The increase resulted primarily from an increase of $856,000 in salaries expense primarily
due to share-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Income, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial income was $81,000 for the three
months ended September 30, 2012, compared to financial expenses of $108,000 for the three months ended September 30, 2011 primarily
due to the exchange rate differences between the NIS and the US dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Nine months ended September 30, 2012
compared to the nine months ended September 30, 2011</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $33.7&nbsp;million during the nine
months ended September 30, 2012, an increase of $27.7&nbsp;million from revenues of $6.0&nbsp;million for the nine months ended
September 30, 2011. The revenues represent the $25.0 million payment we received from Pfizer under the Pfizer Agreement in connection
with the FDA approval of taliglucerase alfa on May 1, 2012 and a pro rata amortization of the $65.0&nbsp;million upfront and milestone
payments of $1.1&nbsp;million in each quarterly period and the cost of drug supplied to Pfizer during the relevant period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $678,000 as our share in net income
from the collaboration under the Pfizer Agreement during the nine months ended September 30, 2012, compared to loss of $3.7 million
for the nine months ended September 30, 2011. Our share in the collaboration agreement recorded during the nine months ended September
30, 2012 represents our 40% share of the net income generated during the period, which was primarily the result of revenues generated
by Pfizer in the United States and the resupply in Brazil, which exceeded the expenses during such period. Our share in the collaboration
includes a loss generated during the nine months ended September 30, 2011 which resulted primarily from certain clinical-related
expenses. Under the terms and conditions of the Pfizer Agreement, financial information of Pfizer&rsquo;s subsidiaries that operate
outside the United States is included based on the fiscal year ending November&nbsp;30, while financial information for the U.S.
entity is included based on the fiscal year ending December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $7.0 million and $1.1 million for the
nine months ended September 30, 2012 and September 30, 2011, respectively. Cost of revenues for the nine months ended September
30, 2012 includes approximately $2.1 million for royalties due to the OCS and a certain academic institution in connection with
gross sales of taliglucerase alfa during the period and $4.9 million primarily for certain fixed costs relating to our manufacturing
facility, including rent, depreciation, salary and maintenance expenses, and to a much lesser extent, the direct cost of products
delivered to Pfizer during the period. Cost of revenues for the nine months ended September 30, 2011 includes primarily the direct
cost of products delivered to Pfizer during the period. Prior to the FDA's approval of taliglucerase alfa, manufacturing costs
related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses. Effective
as of the FDA approval of taliglucerase alfa on May 1, 2012, we capitalize all manufacturing costs associated with taliglucerase
alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $22.1&nbsp;million for
the nine months ended September 30, 2012, a decrease of $1.4 million, or 6%, from $23.5&nbsp;million for the nine months ended
September 30, 2011. The decrease resulted primarily from a decrease of $1.1 million in costs related to consulting and subcontractors
associated with research and development activities, a decrease of $647,000 representing costs related to materials and $2.2 million
in certain expenses, such as rent, depreciation and maintenance, that were classified as cost of revenues or capitalized as inventory
after the FDA's approval of taliglucerase alfa. The decrease was partially offset by $3.3 million in salaries expense resulting
primarily from bonuses paid in connection with the FDA's approval of taliglucerase alfa on May 1, 2012 and share-based compensation.
The decrease was also the result of grants received from the OCS of approximately $3.2 million during the nine months ended September
30, 2012, compared to the total of grants of $2.6 million received from the OCS, during the nine months ended September 30, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">General and administrative expenses were
$7.4&nbsp;million for the nine months ended September 30, 2012, an increase of $2.1 million, or 38%, from $5.3&nbsp;million for
the nine months ended September 30, 2011. The increase resulted primarily from an increase of $2.5&nbsp;million in salaries expense
primarily due to bonuses paid in connection with the FDA's approval of taliglucerase alfa on May 1, 2012 and share-based compensation.
The increase was partially offset by a decrease of $423,000 in legal and accounting expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Income</I>, <I>Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial income was $264,000 for the nine months ended September
30, 2012, compared to financial income of $57,000 for the nine months ended September 30, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research and
development expenditures and the lack of any approved product (prior to the May 2012 approval of taliglucerase alfa in the United
States and the September 2012 approval by the Israeli MOH) to generate significant product sales revenue, we have not been profitable,
with the exception of the second quarter of 2012, for which profits were recorded that were primarily the result of the $25.0
million milestone payment we received in connection with the FDA's approval of taliglucerase alfa on May 1, 2012, and have generated
operating losses since our inception. To date, we have funded our operations primarily with proceeds equal to $31.3 million from
the private sale of shares of our common stock and from sales of convertible preferred and ordinary shares of Protalix Ltd., and
an additional $14.1 million in connection with the exercise of warrants issued in connection with the sale of such ordinary shares,
through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50.0 million in connection with an
underwritten public offering of our common stock; on March 23, 2011, we generated gross proceeds of $22.0 million in connection
with an underwritten public offering of our common stock; and on February 22, 2012, we generated gross proceeds of $27.2 million
in connection with an underwritten public offering of our common stock. In 2012, the OCS awarded us a grant of up to approximately
$4.3 million for the calendar years 2011 and 2012. The OCS awarded the grant to promote the advancement of our drug development
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Furthermore, on November 30, 2009, we entered
into an exclusive license and supply agreement with Pfizer pursuant to which Pfizer made an upfront payment to Protalix Ltd. of
$60.0 million in connection with the execution of the agreement and subsequently paid Protalix Ltd. an additional $5.0 million
upon our achievement of a certain milestone, as provided in the agreement. In addition, we received a $25.0 million milestone
payment in connection with the FDA's approval of taliglucerase alfa in May 2012. Protalix Ltd. is entitled to payments equal to
40% of the net profits earned by Pfizer on Pfizer's sales of taliglucerase alfa. In calculating net profits there are certain
agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that the funds currently available
to us as are sufficient to satisfy our capital needs for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $1.2 million
for the nine months ended September 30, 2012. The net loss for the nine months ended September 30, 2012 of $1.7 million decreased
primarily due to $6.1 million in share-based compensation and $2.8 million in depreciation, which was partially offset by a decrease
of $5.0 million in deferred revenues and increase of $2.1 million in accounts receivable and increase of $1.8 million in inventory.
Net cash used in investing activities for the nine months ended September 30, 2012 was $1.9 million and consisted primarily of
purchases of property and equipment. Net cash provided by financing activities was $26.4 million, consisting primarily of net
proceeds from our February 2012 underwritten public offering of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $17.0 million
for the nine months ended September 30, 2011. The net loss for the nine months ended September 30, 2011 of $27.6 million decreased
mainly due to a decrease of $2.8 million in accounts receivable and an increase of $4.4 million in accounts payable and accruals
and $2.7 million in depreciation. Net cash used in investing activities for the nine months ended September 30, 2011 was $5.1
million and consisted primarily of purchases of property and equipment. Net cash provided from financing activities was $20.9
million mainly due to the March 2011 underwritten public offering of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to incur operating losses in the near
future. However, we anticipate that we will generate revenues to offset any such losses as Pfizer's commercialization efforts
for taliglucerase alfa progress after the FDA's approval in May 2012, and as we begin to generate revenues from the commercialization
of taliglucerase alfa in Israel after the Israeli MOH' approval in September 2012. We also anticipate that we will generate additional
revenues to offset any losses after additional anticipated marketing approvals of taliglucerase alfa are granted outside of the
United States and Israel, including, primarily, in Brazil. We expect to continue to incur significant research and development
expenses, including expenses related to the hiring of personnel and the advancement of the product candidates in our pipeline
into clinical trials. We expect that general and administrative expenses will increase as we expand our administrative staff,
add infrastructure and incur additional costs related to the continued progression of the commercialization of taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.
We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be required to use
our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with
the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays
and operating expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer's commercialization efforts in the United States, the progress of our commercialization
efforts in Israel<FONT STYLE="color: black"> and, if anticipated marketing approvals of taliglucerase alfa</FONT> are granted
in other jurisdictions, the progress of Pfizer's global commercialization efforts, the progress and results of our clinical trials,
the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates,
the timing and outcome of regulatory review of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining,
defending and enforcing patent claims and other intellectual property rights, the number and development requirements of other
product candidates that we pursue and the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements. We currently
do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or more of
our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently
anticipate. We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable.
Any sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional
equity or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms,
if at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and
development programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or
others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize
independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the nine months ended September 30, 2012 or the nine months ended September 30, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the nine months ended September 30, 2012 or the nine months ended September 30, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of September 30, 2012 and September 30, 2011.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the U.S. dollar. We currently have no significant source of revenues; therefore we consider
the currency of the primary economic environment to be the currency in which we expend cash. Approximately 50% of our expenses
and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars.
Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using
the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates.
Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign
currency translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended <BR>
    September 30,</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year ended <BR>
    December 31,</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">2011</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>Average rate for period</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">3.861</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">3.530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">3.578</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at period end</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">3.912</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">3.712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">3.821</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; width: 55%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: center; width: 12%">&nbsp;</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects
due to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve
principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances
primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes
in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains
may decline in the future as a result of changes in the financial markets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the
effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this
Quarterly Report on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management,
including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures
designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this
Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on the controls evaluation,
our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly
Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required
to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified
by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management,
including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are
being prepared.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to
their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute
assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within
a company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty
and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of
some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls
is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness
to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration
in the degree of compliance with policies or procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes to our internal controls over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September 30,
2012 that has materially affected, or that is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 25.9pt"><B>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2011 and in our Quarterly
Report on Form 10-Q for the quarter ended March 31, 2012.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>Unregistered Sales of Equity
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">There were
no unregistered sales of equity securities during the nine months ended September 30, 2012. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;5. Other Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Exhibits</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Incorporated by Reference</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 9%; text-align: center; vertical-align: bottom">Exhibit
    <BR>
    Number</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 41%; text-align: center; vertical-align: bottom">&nbsp;Exhibit
    Description</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 10%; text-align: center; vertical-align: bottom">&nbsp;Form</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 12%; text-align: center; vertical-align: bottom">File
    Number</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 6%; text-align: center; vertical-align: bottom">Exhibit</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 7%; text-align: center; vertical-align: bottom">Date</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; width: 1%; text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 9%; text-align: center; vertical-align: bottom">Filed<BR>
    Herewith</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Amended and Restated Articles of Incorporation of the
        Company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">333-48677</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 26, 1998</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        June 9, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        December 13, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        December 26, 2006</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Article of Amendment to Articles of Incorporation dated
        February 26, 2007</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">8-A</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company, as amended July 15, 2012</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">8-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.1</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">July 18,
        2012</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%">31.2</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 41%">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section
    302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive
    Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial
    Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>X</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0.84in">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November 7, 2012</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: November 7, 2012</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer, Treasurer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v325765_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, David Aviezer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">Date: November 7, 2012</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ David Aviezer</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">President and Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v325765_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">Date: November 7, 2012</TD>
    <TD STYLE="width: 3%; font-size: 10pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: Black 1pt solid">/s/Yossi Maimon</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; padding-bottom: 1pt">Yossi Maimon</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12pt; text-indent: -12pt">Chief Financial Officer, Treasurer</P></TD>
    <TD STYLE="padding-left: 12pt; font-size: 10pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v325765_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the <FONT STYLE="text-transform: uppercase">&quot;</FONT>Company<FONT STYLE="text-transform: uppercase">&quot;</FONT>) on
Form 10-Q for the period ended September 30, 2012 as filed with the Securities and Exchange Commission (the <FONT STYLE="text-transform: uppercase">&quot;</FONT>Report<FONT STYLE="text-transform: uppercase">&quot;</FONT>),
I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes
of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, <FONT STYLE="text-transform: uppercase">&quot;</FONT>filed<FONT STYLE="text-transform: uppercase">&quot;</FONT>
with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 7, 2012</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v325765_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the <FONT STYLE="text-transform: uppercase">&quot;</FONT>Company<FONT STYLE="text-transform: uppercase">&quot;</FONT>) on
Form 10-Q for the period ended September 30, 2012 as filed with the Securities and Exchange Commission (the <FONT STYLE="text-transform: uppercase">&quot;</FONT>Report<FONT STYLE="text-transform: uppercase">&quot;</FONT>),
I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the
purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, <FONT STYLE="text-transform: uppercase">&quot;</FONT>filed<FONT STYLE="text-transform: uppercase">&quot;</FONT>
with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Date: November 7, 2012</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President and Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.1in; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20120930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Vintage Filings Powered By P3XBRL http://www.p3xbrl.com-->
<!--version 4.1.21 -->
<!--produced on 2012-11-05 @ 12:37 PM-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plx="http://www.protalix.com/20120930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:ISO4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20120930.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">2012-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.690.0.0.0.0.0.0" contextRef="as-of-2012-11-04.690.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">93465169</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:TradingSymbol id="TradingSymbol.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">PLX</dei:TradingSymbol>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">72000</plx:CashlessExerciseOfStockOptions>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12000</plx:CashlessExerciseOfStockOptions>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.691.20890.999.0.0.0.0" contextRef="as-of-2012-09-30.691.0.20890.999.0.0.0.0" unitRef="UPure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.691.20891.999.0.0.0.0" contextRef="as-of-2012-09-30.691.0.20891.999.0.0.0.0" unitRef="UPure" decimals="1">0.6</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2772000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2698000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5655000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5163000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1963000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1422000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">821000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1477000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:MilestonePayment id="MilestonePayment.693.20883.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20883.4951.0.0.0.0" unitRef="USD" decimals="-5">25000000</plx:MilestonePayment>
  <plx:NatureOfOperationsPolicyTextBlock id="NatureOfOperationsPolicyTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Operation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 1, 2012, the U.S. Food and Drug Administration (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;FDA&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was recorded as revenue during the period in which it was received. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. &lt;font style="COLOR: black"&gt;In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency&amp;#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV&lt;sup&gt;&amp;reg;&lt;/sup&gt;, Shire plc&amp;#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in Israel shortly. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. [Notwithstanding the EC&amp;#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, is prepared to continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities.] In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the FDA approval of taliglucerase alfa, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:NumberOfSubsidiaries id="NumberOfSubsidiaries.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="Entity" decimals="0">2</plx:NumberOfSubsidiaries>
  <plx:OtherGainsLosses id="OtherGainsLosses.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">678000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3745000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1666000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-235000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25328000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20650000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">22062000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23508000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6363000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7918000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.706.22155.344.0.0.0.0" contextRef="as-of-2012-07-16.706.0.22155.344.0.0.0.0" unitRef="USD" decimals="-3">8580000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm id="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0" unitRef="Month" decimals="0">24</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0" unitRef="Installment" decimals="0">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.707.22155.344.22161.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0" unitRef="Installment" decimals="0">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.693.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11444000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7540000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4427000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5032000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4025000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1374000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">4217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.694.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4217000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.693.4381.1063.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">3690000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.694.4381.1063.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">348000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.695.4381.1063.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">1247000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.696.4381.1063.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.4381.1063.0.0.0.0" unitRef="USD" decimals="-3">92000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.693.2354.1063.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">2155000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.694.2354.1063.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">382000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.695.2354.1063.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">840000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.696.2354.1063.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.2354.1063.0.0.0.0" unitRef="USD" decimals="-3">117000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.693.26156.1063.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.694.26156.1063.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.695.26156.1063.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.696.26156.1063.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.26156.1063.0.0.0.0" unitRef="USD" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.693.26237.560.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7169035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.694.26237.560.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7498026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.695.26237.560.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7508240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.696.26237.560.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.26237.560.0.0.0.0" unitRef="UShares" decimals="0">7428201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Assets.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77378000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51805000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">59580000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">32491000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;GAAP&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Operation&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 1, 2012, the U.S. Food and Drug Administration (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;FDA&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. &lt;font style="COLOR: black"&gt;In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency&amp;#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV&lt;sup&gt;&amp;reg;&lt;/sup&gt;, Shire plc&amp;#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in Israel shortly. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. Notwithstanding the EC&amp;#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the FDA approval of taliglucerase alfa, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;GAAP&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;p style="TEXT-INDENT: -17.85pt; MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 36pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 17.85pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s common stock, par value $.001 per share (the "Common Stock"), outstanding for each period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Shares of restricted Common Stock and the shares of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,498,026 and 7,169,035 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September 30, 2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the three months ended September 30, 2011 and 2012, respectively.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50216000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.697.0.0.0.0.0.0" contextRef="as-of-2010-12-31.697.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">35900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">34564000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">23215000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1336000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.691.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.692.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.710.0.0.0.0.0.0" contextRef="as-of-2012-02-22.710.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">5175000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CostOfRevenue id="CostOfRevenue.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6966000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1130000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2367000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">220000</us-gaap:CostOfRevenue>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4564000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6121000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">47499000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">50923000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1134000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1043000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="3">-0.033</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="1">-0.1</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 17.85pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s common stock, par value $.001 per share (the "Common Stock"), outstanding for each period.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; Shares of restricted Common Stock and the shares of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the effect would be anti-dilutive.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,498,026 and 7,169,035 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September 30, 2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the three months ended September 30, 2011 and 2012, respectively.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-113000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-170000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">264000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">57000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-108000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-14000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-156000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.693.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="GainLossOnSaleOfPropertyPlantEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7353000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5314000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2220000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1526000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit id="GrossProfit.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27410000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1149000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3023000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">677000</us-gaap:GrossProfit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">369000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4388000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2099000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2810000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4981000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-991000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1779000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-762000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:InventoryDisclosureTextBlock id="InventoryDisclosureTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 2 - INVENTORIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Inventory at September 30, 2012 and December 31, 2011 consisted of the following:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,294&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;298&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 466&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2,058&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="COLOR: black"&gt;Prior to the FDA&amp;#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses&lt;/font&gt;. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">466000</us-gaap:InventoryFinishedGoodsNetOfReserves>
  <us-gaap:InventoryFinishedGoodsNetOfReserves id="InventoryFinishedGoodsNetOfReserves.692.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:InventoryNet id="InventoryNet.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2058000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">279000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1294000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryRawMaterialsNetOfReserves id="InventoryRawMaterialsNetOfReserves.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">279000</us-gaap:InventoryRawMaterialsNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">298000</us-gaap:InventoryWorkInProcessNetOfReserves>
  <us-gaap:InventoryWorkInProcessNetOfReserves id="InventoryWorkInProcessNetOfReserves.692.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:Liabilities id="Liabilities.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">72606000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77882000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">77378000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51805000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20435000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18693000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52171000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">59189000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2794000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6566000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">26424000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20913000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1910000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5121000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1186000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-16958000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1741000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-27616000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5479000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8875000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.693.4458.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-1741000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.694.4458.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-27616000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2005000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-27673000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5560000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-8767000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3281000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3837000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">122000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsOfStockIssuanceCosts id="PaymentsOfStockIssuanceCosts.709.0.0.0.0.0.0" contextRef="from-2012-02-01-to-2012-02-29.709.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5001000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1878000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1700000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">24000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">218000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">115000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.704.0.0.0.0.0.0" contextRef="from-2009-12-01-to-2012-09-30.704.0.0.0.0.0.0.0" unitRef="USD" decimals="-5">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.693.20882.4951.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20882.4951.0.0.0.0" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.709.0.0.0.0.0.0" contextRef="from-2012-02-01-to-2012-02-29.709.0.0.0.0.0.0.0" unitRef="USD" decimals="0">25388000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.693.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="ProceedsFromSaleOfPropertyPlantAndEquipment.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1096000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">263000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.693.20907.3555.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0" unitRef="USD" decimals="-3">1137000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.1877.21244.3555.21242.5007.0.0" contextRef="from-2012-10-01-to-2012-11-30.1877.0.21244.3555.21242.5007.0.0" unitRef="USD" decimals="-3">5187000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16664000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18271000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27717000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28671000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8326000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9340000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="Revenues.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">33698000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6024000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3724000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1132000</us-gaap:Revenues>
  <us-gaap:SaleOfStockPricePerShare id="SaleOfStockPricePerShare.710.0.0.0.0.0.0" contextRef="as-of-2012-02-22.710.0.0.0.0.0.0.0" unitRef="UPerShare" decimals="2">5.25</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="ScheduleOfInventoryCurrentTableTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;September 30,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2011&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 74%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,294&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;298&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 466&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; -&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 2,058&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 279&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6065000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">730000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.695.3865.344.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.3865.344.0.0.0.0" unitRef="USD" decimals="-3">3900000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.1772.3865.344.0.0.0.0" contextRef="from-2012-04-01-to-2012-06-30.1772.0.3865.344.0.0.0.0" unitRef="USD" decimals="-3">3900000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.707.22155.344.22161.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.695.3865.344.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.3865.344.0.0.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.1772.3865.344.0.0.0.0" contextRef="from-2012-04-01-to-2012-06-30.1772.0.3865.344.0.0.0.0">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.707.22155.344.1817.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0" unitRef="UShares" decimals="0">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.707.22155.344.22161.1319.0.0" contextRef="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0" unitRef="UShares" decimals="0">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.706.22155.344.1817.1319.0.0" contextRef="as-of-2012-07-16.706.0.22155.344.1817.1319.0.0" unitRef="UShares" decimals="0">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharesOutstanding id="SharesOutstanding.691.1033.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">93461341</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.692.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">85630157</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.697.1033.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">81248472</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.698.1033.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">85598517</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.0.0.0.0.0.0" contextRef="as-of-2012-09-30.691.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4772000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.0.0.0.0.0.0" contextRef="as-of-2011-12-31.692.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.0.0.0.0.0.0" contextRef="as-of-2010-12-31.697.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-11323000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.0.0.0.0.0.0" contextRef="as-of-2011-09-30.698.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-17353000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.1033.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.1033.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.1033.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.461.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">178397000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.461.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.461.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">124044000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.461.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">145625000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.691.4458.4957.0.0.0.0" contextRef="as-of-2012-09-30.691.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-173718000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.692.4458.4957.0.0.0.0" contextRef="as-of-2011-12-31.692.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.697.4458.4957.0.0.0.0" contextRef="as-of-2010-12-31.697.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-135448000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.698.4458.4957.0.0.0.0" contextRef="as-of-2011-09-30.698.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-163064000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 3 - STOCK TRANSACTIONS&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 21.25pt"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td style="COLOR: black"&gt;On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25,388,000 (net of underwriting commissions and issuance costs of approximately $1,780,000).&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; WIDTH: 21.25pt"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;font style="COLOR: black"&gt;During the nine months ended September 30, 2012, the Company issued a total of&lt;/font&gt; 1,156,184 &lt;font style="COLOR: black"&gt;shares of Common Stock in connection with the exercise of a total of&lt;/font&gt; 1,156,184 &lt;font style="COLOR: black"&gt;options by certain officers and employees of the Company. The Company received aggregate cash proceeds equal to approximately $&lt;/font&gt;1,137,000 &lt;font style="COLOR: black"&gt;in connection with such exercises.&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; WIDTH: 21.25pt"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;font style="COLOR: black"&gt;Following FDA&lt;/font&gt; approval of taliglucerase alfa on May 1, 2012&lt;font style="COLOR: black"&gt;, the Company started recognizing compensation costs in relation to performance-based awards that were granted in February 2010 to certain officers and employees of the Company, which vest over a three-year period commencing upon the FDA&amp;#39;s approval of&lt;/font&gt; taliglucerase alfa&lt;font style="COLOR: black"&gt;. During the second and third quarter of 2012, the Company recorded an expense in the amount of approximately $3,900,000 for the cumulative period from the date of grant.&lt;/font&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif"&gt;&amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 49.65pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="COLOR: black; WIDTH: 21.25pt"&gt;&lt;strong&gt;d.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;On July 16, 2012, the Company&amp;#39;s Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted shares, 1,100,000 of the shares were issued to the Company&amp;#39;s named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Company&amp;#39;s 2006 Stock Incentive Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8,580,000.&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices id="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">1500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="StockIssuedDuringPeriodSharesShareBasedCompensation.693.20907.3555.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0" unitRef="UShares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="UShares" decimals="0">350045</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.1877.21244.3555.21242.5007.0.0" contextRef="from-2012-10-01-to-2012-11-30.1877.0.21244.3555.21242.5007.0.0" unitRef="UShares" decimals="0">3828</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.693.20907.3555.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0" unitRef="UShares" decimals="0">1156184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1847000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1848000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">25383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.694.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">20586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">20590000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.693.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.694.1033.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.693.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1136000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.694.461.4957.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">265000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1137000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">266000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:SubsequentEventsTextBlock id="SubsequentEventsTextBlock.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 4 - SUBSEQUENT EVENTS&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; During October and November 2012, the Company issued a total of 3,828 shares of Common Stock in connection with the exercise of options to purchase 3,828 shares of Common Stock by an employee of the Company. The aggregate cash proceeds in connection with the exercise of the options were $5,187.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.693.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">90491421</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.694.0.0.0.0.0.0" contextRef="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">84351420</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.695.0.0.0.0.0.0" contextRef="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">91929445</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.696.0.0.0.0.0.0" contextRef="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0" unitRef="UShares" decimals="0">85585777</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="UShares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>ISO4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Entity">
    <xbrli:measure>plx:Entity</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Installment">
    <xbrli:measure>plx:Installment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Month">
    <xbrli:measure>plx:Month</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>ISO4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2012-10-01-to-2012-11-30.1877.0.21244.3555.21242.5007.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:OptionExerciseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-10-01</xbrli:startDate>
      <xbrli:endDate>2012-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.3865.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-09-30.695.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-07-31.707.0.22155.344.22161.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-07-01-to-2012-07-31.707.0.22155.344.1817.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-04-01-to-2012-06-30.1772.0.3865.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-02-01-to-2012-02-29.709.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>
      <xbrli:endDate>2012-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.20907.3555.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeAndNonemployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.20883.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.20882.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-09-30.693.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.696.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.4381.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.26237.560.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockOptionsAndRestrictedSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.26156.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:CostOfRevenuesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.2354.1063.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.694.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-12-01-to-2012-09-30.704.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-12-01</xbrli:startDate>
      <xbrli:endDate>2012-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-11-04.690.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-11-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.20891.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.20890.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-09-30.691.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-07-16.706.0.22155.344.1817.1319.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-07-16.706.0.22155.344.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:StockCompensationPlanAndRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-02-22.710.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-02-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.692.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.698.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.697.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.693.0.0.0.0.0.0" xlink:label="CostOfRevenue.693.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.693.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.693.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.693.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.694.0.0.0.0.0.0" xlink:label="CostOfRevenue.694.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.694.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.694.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.694.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.695.0.0.0.0.0.0" xlink:label="CostOfRevenue.695.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.695.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.695.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.695.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#CostOfRevenue.696.0.0.0.0.0.0" xlink:label="CostOfRevenue.696.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="CostOfRevenue.696.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 220 0 220 0</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="CostOfRevenue.696.0.0.0.0.0.0_loc" xlink:to="CostOfRevenue.696.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>

  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.693.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.693.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.694.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.694.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.695.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.695.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#ResearchAndDevelopmentExpense.696.0.0.0.0.0.0" xlink:label="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 1,247 92 3,690 348</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_loc" xlink:to="ResearchAndDevelopmentExpense.696.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>

  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.693.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.693.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.694.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.694.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.695.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.695.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#GeneralAndAdministrativeExpense.696.0.0.0.0.0.0" xlink:label="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes share-based compensation 840 117 2,155 382 </link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_loc" xlink:to="GeneralAndAdministrativeExpense.696.0.0.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.691.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.691.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.691.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.691.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.691.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesNewIssues.693.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.692.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.692.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.692.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.692.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.692.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>

  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.697.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.697.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.697.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.697.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.697.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesNewIssues.694.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised.694.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised.693.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>

  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_loc" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices.693.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>


  <link:footnoteLink xlink:title="0" xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#SharesOutstanding.698.1033.4957.0.0.0.0" xlink:label="SharesOutstanding.698.1033.4957.0.0.0.0_loc" />
    <link:footnote xlink:type="resource" xlink:label="SharesOutstanding.698.1033.4957.0.0.0.0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="SharesOutstanding.698.1033.4957.0.0.0.0_loc" xlink:to="SharesOutstanding.698.1033.4957.0.0.0.0_lbl" order="1.0" />
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20120930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.21 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-11-05 @ 12:38 PM-->
<xsd:schema targetNamespace="http://www.protalix.com/20120930" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20120930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="plx-20120930_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="plx-20120930_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="plx-20120930_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="plx-20120930_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" id="plx-ccbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" id="plx-cccf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" id="plx-ccse" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" id="plx-ccsep" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" id="plx-ccso" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="plx-ccsop" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="plx-dein" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesDetails" id="plx-invd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Inventories" id="plx-invt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="plx-invtt" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" id="plx-sapd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40101 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="plx-sapo" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" id="plx-sapp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicesScheduleOfWeightedAverageNumberOfSharesOutstandingUsedToCalculateEarningsLossPerShareDetails" id="plx-sapt1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40102 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted Average Number of Shares Outstanding used to Calculate Earnings (Loss) per Share) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" id="plx-sapt2" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactionsDetails" id="plx-sttd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40301 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactions" id="plx-sttr" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SubsequentEvents" id="plx-suev" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>104 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SubsequentEventsDetails" id="plx-suevd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40401 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="CostOfRevenuesMember" id="plx_CostOfRevenuesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="EmployeeAndNonemployeeMember" id="plx_EmployeeAndNonemployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EmployeeMember" id="plx_EmployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EmployeesMember" id="plx_EmployeesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="OptionExerciseMember" id="plx_OptionExerciseMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="StockCompensationPlanAndRestrictedStockMember" id="plx_StockCompensationPlanAndRestrictedStockMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" id="plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20120930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.21 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-11-05 @ 12:38 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20120930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20120930.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesDetails" xlink:href="plx-20120930.xsd#plx-invd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEventsDetails" xlink:href="plx-20120930.xsd#plx-suevd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicesScheduleOfWeightedAverageNumberOfSharesOutstandingUsedToCalculateEarningsLossPerShareDetails" xlink:href="plx-20120930.xsd#plx-sapt1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20120930.xsd#plx-sttd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20120930.xsd#plx-sapo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20120930.xsd#plx-invt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20120930.xsd#plx-sttr" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEvents" xlink:href="plx-20120930.xsd#plx-suev" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20120930.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:href="plx-20120930.xsd#plx-sapt2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20120930.xsd#plx-invtt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20120930.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20120930.xsd#plx-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20120930.xsd#plx-ccse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20120930.xsd#plx-ccsep" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20120930.xsd#plx-cccf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20120930.xsd#plx-dein" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20120930.xsd#plx-ccsop" xlink:type="simple" />
  <link:calculationLink xlink:title="40201 - Disclosure - INVENTORIES (Details)" xlink:role="http://www.protalix.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryNet.11417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryRawMaterialsNetOfReserves.11392.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryWorkInProcessNetOfReserves.11424.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryFinishedGoodsNetOfReserves.11388.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40102 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted Average Number of Shares Outstanding used to Calculate Earnings (Loss) per Share) (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicesScheduleOfWeightedAverageNumberOfSharesOutstandingUsedToCalculateEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.14.6" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.14.6" xlink:to="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AssetsCurrent.5874.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_AccountsReceivableNetCurrent.5451.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_OtherReceivablesNetCurrent.13172.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryNet.11417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_InventoryNet.11417.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Assets.5880.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_AssetsCurrent.5874.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_AccountsPayableTradeCurrent.5457.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_AccountsPayableOtherCurrent.5442.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_DeferredRevenueCurrent.7671.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_DeferredRevenueNoncurrent.7662.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_LongTermDebtNoncurrent.12289.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.11702.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.11702.14.6" xlink:to="loc_LiabilitiesNoncurrent.11699.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.11702.14.6" xlink:to="loc_LiabilitiesCurrent.11668.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_StockholdersEquity.16667.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_Liabilities.11702.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_StockholdersEquity.16667.14.6" xlink:to="loc_CommitmentsAndContingencies.6842.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_GrossProfit.10358.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.15575.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_Revenues.15575.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherGainsLosses.20964.14.6" xlink:href="plx-20120930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_OtherGainsLosses.20964.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenue.7176.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_CostOfRevenue.7176.14.6" order="3.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.12771.14.6" xlink:to="loc_OperatingIncomeLoss.13080.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.12771.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_GrossProfit.10358.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" xlink:href="plx-20120930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" order="2.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_GeneralAndAdministrativeExpense.10284.14.6" order="3.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.15293.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.14.6" xlink:href="plx-20120930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.14.6" order="2.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" order="3.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" order="4.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.14.6" order="1.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.14.6" order="3.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.14.6" xlink:href="plx-20120930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.14.6" order="2.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_ShareBasedCompensation.16244.14.6" order="6.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.14.6" xlink:href="plx-20120930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.21078.14.6" order="7.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.13882.14.6" order="8.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.10853.14.6" order="9.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInInventories.10936.14.6" order="10.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.14.6" order="11.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.14.6" order="3.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.13875.14.6" order="4.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.10850.14.6" order="5.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_NetIncomeLoss.12771.14.6" order="1.00" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.14.6" order="2.00" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20120930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.21 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-11-05 @ 12:38 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20120930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20120930.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesDetails" xlink:href="plx-20120930.xsd#plx-invd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEventsDetails" xlink:href="plx-20120930.xsd#plx-suevd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicesScheduleOfWeightedAverageNumberOfSharesOutstandingUsedToCalculateEarningsLossPerShareDetails" xlink:href="plx-20120930.xsd#plx-sapt1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20120930.xsd#plx-sttd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20120930.xsd#plx-sapo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20120930.xsd#plx-invt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20120930.xsd#plx-sttr" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEvents" xlink:href="plx-20120930.xsd#plx-suev" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20120930.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:href="plx-20120930.xsd#plx-sapt2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20120930.xsd#plx-invtt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20120930.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20120930.xsd#plx-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20120930.xsd#plx-ccse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20120930.xsd#plx-ccsep" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20120930.xsd#plx-cccf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20120930.xsd#plx-dein" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20120930.xsd#plx-ccsop" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="40101 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.7.6" xlink:href="plx-20120930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.7.6" xlink:to="loc_StockOptionsAndRestrictedSharesMember.26237.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.6.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.8.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.7.6" xlink:href="plx-20120930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.20890.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.7.6" xlink:href="plx-20120930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_PfizerIncorporationMember.20891.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.7.6" xlink:href="plx-20120930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioTwoMember.20882.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioOneMember.20883.7.6" xlink:href="plx-20120930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioOneMember.20883.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:to="loc_StatementScenarioAxis.4951.5.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.5.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.9.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.9.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.9.6" xlink:to="loc_SignificantAccountingPoliciesTable.20885.9.6" order="1.00" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.7.6" xlink:href="plx-20120930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_NumberOfSubsidiaries.20893.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_ProceedsFromCollaborators.14370.7.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.20894.7.6" xlink:href="plx-20120930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_MilestonePayment.20894.7.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.7.6" xlink:href="plx-20120930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.20895.7.6" order="5.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.7.6" order="6.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.7.6" order="7.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40401 - Disclosure - SUBSEQUENT EVENTS (Details)" xlink:role="http://www.protalix.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeMember.21244.7.6" xlink:href="plx-20120930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:to="loc_EmployeeMember.21244.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionExerciseMember.21242.7.6" xlink:href="plx-20120930.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTypeDomain.5005.7.6" xlink:to="loc_OptionExerciseMember.21242.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTable.5008.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventLineItems.5006.9.6" xlink:to="loc_SubsequentEventTable.5008.9.6" order="1.00" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventLineItems.5006.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="8.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventLineItems.5006.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.7.6" order="9.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTypeAxis.5007.6.6" xlink:to="loc_SubsequentEventTypeDomain.5005.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTypeAxis.5007.8.6" xlink:to="loc_SubsequentEventTypeDomain.5005.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTable.5008.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTable.5008.5.6" xlink:to="loc_SubsequentEventTypeAxis.5007.5.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SubsequentEventTable.5008.5.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" order="4.25" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40301 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.6.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AwardTypeAxis.344.8.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.9.6" xlink:to="loc_ScheduleOfStockByClassTable.4702.9.6" order="1.00" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_CommonStockSharesIssued.6875.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_SaleOfStockPricePerShare.15652.7.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStock.14449.7.6" order="5.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_PaymentsOfStockIssuanceCosts.13770.7.6" order="6.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="7.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.7.6" order="8.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.7.6" order="9.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensation.16244.7.6" order="10.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.7.6" order="11.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.7.6" order="12.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.7.6" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.7.6" order="13.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.7.6" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.7.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.7.6" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.7.6" order="14.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.7.6" order="7.50" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.6.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.8.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.7.6" xlink:href="plx-20120930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:to="loc_EmployeeAndNonemployeeMember.20907.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfStockByClassTable.4702.5.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AwardTypeAxis.344.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfStockByClassTable.4702.5.6" xlink:to="loc_AwardTypeAxis.344.5.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfStockByClassTable.4702.5.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.5.6" order="2.50" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_PerformanceSharesMember.3865.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:to="loc_PerformanceSharesMember.3865.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockCompensationPlanAndRestrictedStockMember.22155.7.6" xlink:href="plx-20120930.xsd#plx_StockCompensationPlanAndRestrictedStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.7.6" xlink:to="loc_StockCompensationPlanAndRestrictedStockMember.22155.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ExecutiveOfficerMember.1817.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_ExecutiveOfficerMember.1817.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeesMember.22161.7.6" xlink:href="plx-20120930.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.7.6" xlink:to="loc_EmployeesMember.22161.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1773.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1033.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_CommonStockMember.1033.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_AdditionalPaidInCapitalMember.461.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_RetainedEarningsMember.4458.7.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementTable.4950.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.4950.5.6" xlink:to="loc_StatementEquityComponentsAxis.4957.5.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.4950.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.9.6" xlink:to="loc_StatementTable.4950.9.6" order="1.00" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockholdersEquity.16667.7.6" order="2.50" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_SharesOutstanding.16423.7.6" order="2.75" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.16603.7.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.16628.7.6" order="4.50" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.7.6" order="5.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.7.6" order="7.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="7.50" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_NetIncomeLoss.12771.7.6" order="8.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.7.6" order="7.75" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.7.6" order="7.88" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.4957.6.6" xlink:to="loc_EquityComponentDomain.1773.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.4957.8.6" xlink:to="loc_EquityComponentDomain.1773.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.6.6" xlink:to="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.6.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.8.6" xlink:to="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.8.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.7.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4381.7.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.7.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2354.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenuesMember.26156.7.6" xlink:href="plx-20120930.xsd#plx_CostOfRevenuesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.7.6" xlink:to="loc_CostOfRevenuesMember.26156.7.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementTable.4950.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.4950.5.6" xlink:to="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.5.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.4950.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.9.6" xlink:to="loc_StatementTable.4950.9.6" order="1.00" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5724.7.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20120930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.21 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-11-05 @ 12:38 PM-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2012" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#changeLabel2012" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentDocumentation" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#fragmentDocumentation" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentLabel" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#fragmentLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.385.11.6" xlink:to="lab_AccountingPoliciesAbstract.137967" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.137967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.137967">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.7" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.11.6" xlink:to="lab_AntidilutiveSecuritiesNameDomain.1007" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesNameDomain.1007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesNameDomain.1007">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.11.6" xlink:href="plx-20120930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.20895.11.6" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138005" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138005">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.11.7" xlink:href="plx-20120930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.20895.11.7" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138010" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138010">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.11.12" xlink:href="plx-20120930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.20895.11.12" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138007" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138007">Collaborative arrangement profit sharing percentage.</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare7.134365" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare7.134365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare7.134365">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_MilestonePayment.20894.11.6" xlink:href="plx-20120930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.20894.11.6" xlink:to="lab_MilestonePayment.138000" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138000">Milestone Payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.20894.11.7" xlink:href="plx-20120930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.20894.11.7" xlink:to="lab_MilestonePayment.138002" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138002">Milestone payment triggered</link:label>
    <link:loc xlink:label="loc_MilestonePayment.20894.11.12" xlink:href="plx-20120930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.20894.11.12" xlink:to="lab_MilestonePayment.138001" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138001">Milestone payment.</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.11.6" xlink:href="plx-20120930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.20893.11.6" xlink:to="lab_NumberOfSubsidiaries.137996" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137996">Number Of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.11.7" xlink:href="plx-20120930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.20893.11.7" xlink:to="lab_NumberOfSubsidiaries.137998" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137998">Number of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.11.12" xlink:href="plx-20120930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.20893.11.12" xlink:to="lab_NumberOfSubsidiaries.137997" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137997" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137997">Number of subsidiaries.</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.11.6" xlink:href="plx-20120930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.20891.11.6" xlink:to="lab_PfizerIncorporationMember.137992" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137992">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.11.7" xlink:href="plx-20120930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.20891.11.7" xlink:to="lab_PfizerIncorporationMember.137994" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137994">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.11.12" xlink:href="plx-20120930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.20891.11.12" xlink:to="lab_PfizerIncorporationMember.137993" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137993" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137993">Pfizer Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14370.11.6" xlink:to="lab_ProceedsFromCollaborators.14422" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.14422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.14422">Proceeds from Collaborators</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14370.11.7" xlink:to="lab_ProceedsFromCollaborators.137999" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.137999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.137999">Pfizer Agreement, upfront payment received</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.6" xlink:href="plx-20120930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.6" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137989" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137989">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.7" xlink:href="plx-20120930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.7" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137991" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137991">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.12" xlink:href="plx-20120930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.12" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137990" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137990" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137990">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.20883.11.6" xlink:href="plx-20120930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.20883.11.6" xlink:to="lab_ScenarioOneMember.137972" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137972">Scenario One [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.20883.11.7" xlink:href="plx-20120930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.20883.11.7" xlink:to="lab_ScenarioOneMember.137974" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137974">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.20883.11.12" xlink:href="plx-20120930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.20883.11.12" xlink:to="lab_ScenarioOneMember.137973" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137973" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137973">Scenario One [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.11.6" xlink:href="plx-20120930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.20882.11.6" xlink:to="lab_ScenarioTwoMember.137969" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137969">Scenario Two [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.11.7" xlink:href="plx-20120930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.20882.11.7" xlink:to="lab_ScenarioTwoMember.137971" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137971">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.11.12" xlink:href="plx-20120930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.20882.11.12" xlink:to="lab_ScenarioTwoMember.137970" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137970">Scenario Two [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.11.6" xlink:to="lab_ScenarioUnspecifiedDomain.16504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioUnspecifiedDomain.16504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioUnspecifiedDomain.16504">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.11.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.11.6" xlink:to="lab_SignificantAccountingPoliciesLineItems.137995" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesLineItems.137995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesLineItems.137995">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.11.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.11.6" xlink:to="lab_SignificantAccountingPoliciesTable.137976" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137976">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.11.12" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.11.12" xlink:to="lab_SignificantAccountingPoliciesTable.137977" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137977" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137977">Significant Accounting Policies [Table].</link:label>
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementScenarioAxis.4951.11.6" xlink:to="lab_StatementScenarioAxis.17868" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementScenarioAxis.17868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementScenarioAxis.17868">Scenario [Axis]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.11.6" xlink:href="plx-20120930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.26237.11.6" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168199" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168199">Stock Options And Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.11.7" xlink:href="plx-20120930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.26237.11.7" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168201" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168201">Options and Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.11.12" xlink:href="plx-20120930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.26237.11.12" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168200" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168200" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168200">Stock Options And Restricted Shares [Member].</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureAbstract.2789.11.6" xlink:to="lab_InventoryDisclosureAbstract.138059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureAbstract.138059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureAbstract.138059">INVENTORIES [Abstract]</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoodsNetOfReserves.11388.11.6" xlink:to="lab_InventoryFinishedGoodsNetOfReserves.9609" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoodsNetOfReserves.9609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoodsNetOfReserves.9609">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoodsNetOfReserves.11388.11.7" xlink:to="lab_InventoryFinishedGoodsNetOfReserves.134479" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoodsNetOfReserves.134479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoodsNetOfReserves.134479">Finished goods</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.9" xlink:to="lab_InventoryNet.138062" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138062" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138062">Total inventory</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterialsNetOfReserves.11392.11.6" xlink:to="lab_InventoryRawMaterialsNetOfReserves.9617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterialsNetOfReserves.9617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterialsNetOfReserves.9617">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterialsNetOfReserves.11392.11.7" xlink:to="lab_InventoryRawMaterialsNetOfReserves7.134480" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterialsNetOfReserves7.134480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterialsNetOfReserves7.134480">Raw materials</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcessNetOfReserves.11424.11.6" xlink:to="lab_InventoryWorkInProcessNetOfReserves.9665" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcessNetOfReserves.9665" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcessNetOfReserves.9665">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcessNetOfReserves.11424.11.7" xlink:to="lab_InventoryWorkInProcessNetOfReserves.134478" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcessNetOfReserves.134478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcessNetOfReserves.134478">Work in process</link:label>
    <link:loc xlink:label="loc_EmployeeMember.21244.11.6" xlink:href="plx-20120930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.21244.11.6" xlink:to="lab_EmployeeMember.140096" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140096">Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.21244.11.7" xlink:href="plx-20120930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.21244.11.7" xlink:to="lab_EmployeeMember.140327" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140327">Certain Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.21244.11.12" xlink:href="plx-20120930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.21244.11.12" xlink:to="lab_EmployeeMember.140097" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140097">Employee [Member].</link:label>
    <link:loc xlink:label="loc_OptionExerciseMember.21242.11.6" xlink:href="plx-20120930.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionExerciseMember.21242.11.6" xlink:to="lab_OptionExerciseMember.140092" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionExerciseMember.140092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionExerciseMember.140092">Option Exercise [Member]</link:label>
    <link:loc xlink:label="loc_OptionExerciseMember.21242.11.12" xlink:href="plx-20120930.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionExerciseMember.21242.11.12" xlink:to="lab_OptionExerciseMember.140093" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionExerciseMember.140093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OptionExerciseMember.140093">Option Exercise [Member].</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.8" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.140109" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.140109" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.140109">Common Stock issued in connection with exercise of options</link:label>
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventLineItems.5006.11.6" xlink:to="lab_SubsequentEventLineItems.18100" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventLineItems.18100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventLineItems.18100">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:label="loc_SubsequentEventTable.5008.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventTable.5008.11.6" xlink:to="lab_SubsequentEventTable.18108" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventTable.18108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventTable.18108">Subsequent Event [Table]</link:label>
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventTypeAxis.5007.11.6" xlink:to="lab_SubsequentEventTypeAxis.18104" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventTypeAxis.18104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventTypeAxis.18104">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventTypeDomain.5005.11.6" xlink:to="lab_SubsequentEventTypeDomain.18097" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventTypeDomain.18097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventTypeDomain.18097">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.11.6" xlink:to="lab_WeightedAverageNumberDilutedSharesOutstandingAdjustment.19249" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberDilutedSharesOutstandingAdjustment.19249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberDilutedSharesOutstandingAdjustment.19249">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.11.7" xlink:to="lab_WeightedAverageNumberDilutedSharesOutstandingAdjustment.138056" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberDilutedSharesOutstandingAdjustment.138056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberDilutedSharesOutstandingAdjustment.138056">Weighted average dilutive effect of stock options</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.11.6" xlink:to="lab_WeightedAverageNumberOfDilutedSharesOutstanding.19226" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfDilutedSharesOutstanding.19226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfDilutedSharesOutstanding.19226">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.11.8" xlink:to="lab_WeightedAverageNumberOfDilutedSharesOutstanding8.140304" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfDilutedSharesOutstanding8.140304" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfDilutedSharesOutstanding8.140304">Weighted average common shares outstanding for diluted calculation</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.11.6" xlink:to="lab_WeightedAverageNumberOfSharesOutstandingBasic.19218" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic.19218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfSharesOutstandingBasic.19218">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.11.8" xlink:to="lab_WeightedAverageNumberOfSharesOutstandingBasic8.140302" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfSharesOutstandingBasic8.140302" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfSharesOutstandingBasic8.140302">Weighted-average common shares outstanding for basic calculation</link:label>
    <link:loc xlink:label="loc_AwardTypeAxis.344.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AwardTypeAxis.344.11.6" xlink:to="lab_AwardTypeAxis.250" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AwardTypeAxis.250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AwardTypeAxis.250">Award Type [Axis]</link:label>
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfStockLineItems.966.11.6" xlink:to="lab_ClassOfStockLineItems.2526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfStockLineItems.2526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfStockLineItems.2526">Class of Stock [Line Items]</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.6875.11.6" xlink:to="lab_CommonStockSharesIssued.2734" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.2734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.2734">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesIssued.6875.11.8" xlink:to="lab_CommonStockSharesIssued.138093" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesIssued.138093" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesIssued.138093">Underwritten public offering, common stock issued and sold</link:label>
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.11.6" xlink:to="lab_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.3763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.3763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.3763">Deferred Bonus and Profit Sharing Plan by Title of Individual [Axis]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.11.6" xlink:href="plx-20120930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.20907.11.6" xlink:to="lab_EmployeeAndNonemployeeMember.138111" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138111">Employee And Nonemployee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.11.7" xlink:href="plx-20120930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.20907.11.7" xlink:to="lab_EmployeeAndNonemployeeMember.138113" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138113">Certain Employees and Non-employees [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.11.12" xlink:href="plx-20120930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.20907.11.12" xlink:to="lab_EmployeeAndNonemployeeMember.138112" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138112" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138112">Employee And Nonemployee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeesMember.22161.11.6" xlink:href="plx-20120930.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeesMember.22161.11.6" xlink:to="lab_EmployeesMember.145751" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeesMember.145751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeesMember.145751">Employees [Member]</link:label>
    <link:loc xlink:label="loc_EmployeesMember.22161.11.12" xlink:href="plx-20120930.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeesMember.22161.11.12" xlink:to="lab_EmployeesMember.145753" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeesMember.145753" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeesMember.145753">Employees [Member].</link:label>
    <link:loc xlink:label="loc_ExecutiveOfficerMember.1817.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ExecutiveOfficerMember.1817.11.6" xlink:to="lab_ExecutiveOfficerMember.5919" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ExecutiveOfficerMember.5919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ExecutiveOfficerMember.5919">Executive Officer [Member]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.11.6" xlink:to="lab_OptionIndexedToIssuersEquityEquityAxis.12418" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityEquityAxis.12418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityEquityAxis.12418">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.11.6" xlink:to="lab_OptionIndexedToIssuersEquityTypeDomain.12421" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityTypeDomain.12421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityTypeDomain.12421">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsOfStockIssuanceCosts.13770.11.6" xlink:to="lab_PaymentsOfStockIssuanceCosts.13507" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsOfStockIssuanceCosts.13507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsOfStockIssuanceCosts.13507">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsOfStockIssuanceCosts.13770.11.7" xlink:to="lab_PaymentsOfStockIssuanceCosts.138105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsOfStockIssuanceCosts.138105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsOfStockIssuanceCosts.138105">Underwritten public offering, commissions and issuance costs</link:label>
    <link:loc xlink:label="loc_PerformanceSharesMember.3865.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PerformanceSharesMember.3865.11.6" xlink:to="lab_PerformanceSharesMember.13718" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PerformanceSharesMember.13718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PerformanceSharesMember.13718">Performance Shares [Member]</link:label>
    <link:loc xlink:label="loc_PerformanceSharesMember.3865.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PerformanceSharesMember.3865.11.7" xlink:to="lab_PerformanceSharesMember.138084" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PerformanceSharesMember.138084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PerformanceSharesMember.138084">Performance-based Awards [Member]</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStock.14449.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStock.14546" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStock.14546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStock.14546">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStock.14449.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStock.138102" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStock.138102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStock.138102">Underwritten public offering, net proceeds from issuance</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.7" xlink:to="lab_ProceedsFromStockOptionsExercised.138107" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.138107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.138107">Cash proceeds from exercise of options</link:label>
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockPricePerShare.15652.11.6" xlink:to="lab_SaleOfStockPricePerShare.16436" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockPricePerShare.16436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockPricePerShare.16436">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SaleOfStockPricePerShare.15652.11.7" xlink:to="lab_SaleOfStockPricePerShare.138095" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SaleOfStockPricePerShare.138095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SaleOfStockPricePerShare.138095">Underwritten public offering, common stock price per share</link:label>
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfStockByClassTable.4702.11.6" xlink:to="lab_ScheduleOfStockByClassTable.16952" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfStockByClassTable.16952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfStockByClassTable.16952">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.17443" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.17443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.17443">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.11.8" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.140102" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.140102" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.140102">Shares of common stock issued, vesting period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.17481">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.140098" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.140098" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.140098">Shares of common stock issued</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.11.6" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145782" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145782">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.11.7" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145785" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145785">Fair value of common stock at grant date</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.11.12" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145784" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145784" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.145784">Share based compensation arrangement by share based payment award grant date fair value.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.11.6" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145774" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145774" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145774">Share Based Compensation Arrangement By Share Based Payment Award Granted Contractual Term</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.11.7" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145779" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145779">Shares of common stock issued, lock up period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.11.12" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145778" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145778" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.145778">Share based compensation arrangement by share based payment award granted contractual term.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.11.6" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145760" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145760">Share Based Compensation Arrangement By Share Based Payment Award Number Of Installments For Vesting Period</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.11.7" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145767" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145767" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145767">Number of installments for vesting of stock</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.11.12" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.11.12" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145764" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145764" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.145764">Share based compensation arrangement by share based payment award number of installments for vesting period.</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.6" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.17523">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.11.7" xlink:to="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.140091" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.140091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.140091">Shares of common stock approved for grant</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.11.6" xlink:to="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.17586" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.17586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.17586">Award Type [Domain]</link:label>
    <link:loc xlink:label="loc_StockCompensationPlanAndRestrictedStockMember.22155.11.6" xlink:href="plx-20120930.xsd#plx_StockCompensationPlanAndRestrictedStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockCompensationPlanAndRestrictedStockMember.22155.11.6" xlink:to="lab_StockCompensationPlanAndRestrictedStockMember.145727" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockCompensationPlanAndRestrictedStockMember.145727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockCompensationPlanAndRestrictedStockMember.145727">Stock Compensation Plan And Restricted Stock [Member]</link:label>
    <link:loc xlink:label="loc_StockCompensationPlanAndRestrictedStockMember.22155.11.7" xlink:href="plx-20120930.xsd#plx_StockCompensationPlanAndRestrictedStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockCompensationPlanAndRestrictedStockMember.22155.11.7" xlink:to="lab_StockCompensationPlanAndRestrictedStockMember.145733" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockCompensationPlanAndRestrictedStockMember.145733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockCompensationPlanAndRestrictedStockMember.145733">Stock Compensation Plan and Restricted Stock [Member]</link:label>
    <link:loc xlink:label="loc_StockCompensationPlanAndRestrictedStockMember.22155.11.12" xlink:href="plx-20120930.xsd#plx_StockCompensationPlanAndRestrictedStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockCompensationPlanAndRestrictedStockMember.22155.11.12" xlink:to="lab_StockCompensationPlanAndRestrictedStockMember.145731" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockCompensationPlanAndRestrictedStockMember.145731" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockCompensationPlanAndRestrictedStockMember.145731">Stock Compensation Plan And Restricted Stock [Member].</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.4988.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteAbstract.4988.11.6" xlink:to="lab_StockholdersEquityNoteAbstract.138077" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteAbstract.138077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteAbstract.138077">STOCK TRANSACTIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511">Common stock issued in connection with exercise of options</link:label>
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.11.6" xlink:to="lab_TitleOfIndividualWithRelationshipToEntityDomain.18500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TitleOfIndividualWithRelationshipToEntityDomain.18500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TitleOfIndividualWithRelationshipToEntityDomain.18500">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.6" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.7" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11399.11.6" xlink:to="lab_InventoryDisclosureTextBlock.9626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock.9626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock.9626">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11399.11.7" xlink:to="lab_InventoryDisclosureTextBlock7.138804" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock7.138804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock7.138804">INVENTORIES</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.18039" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.18039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.18039">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.138805" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.138805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.138805">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:label="loc_SubsequentEventsAbstract.5004.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsAbstract.5004.11.6" xlink:to="lab_SubsequentEventsAbstract.138807" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsAbstract.138807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsAbstract.138807">SUBSEQUENT EVENTS [Abstract]</link:label>
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.16697.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsTextBlock.16697.11.6" xlink:to="lab_SubsequentEventsTextBlock.18084" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsTextBlock.18084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsTextBlock.18084">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.16697.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SubsequentEventsTextBlock.16697.11.7" xlink:to="lab_SubsequentEventsTextBlock.138806" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SubsequentEventsTextBlock.138806" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SubsequentEventsTextBlock.138806">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.6" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock.1458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock.1458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock.1458">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.7" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441">Basis of Presentation</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.8704.11.6" xlink:to="lab_EarningsPerSharePolicyTextBlock.5427" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.5427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.5427">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.8704.11.7" xlink:to="lab_EarningsPerSharePolicyTextBlock.138811" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.138811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.138811">Earnings (loss) per share</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.11.6" xlink:href="plx-20120930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.21035.11.6" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138808" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138808">Nature Of Operations [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.11.7" xlink:href="plx-20120930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.21035.11.7" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138810">General</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.11.12" xlink:href="plx-20120930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.21035.11.12" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138809" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138809" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138809">The accounting policy related to the nature of operations of the entity.</link:label>
    <link:loc xlink:label="loc_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.15839.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.15839.11.6" xlink:to="lab_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.16705" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.16705" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.16705">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.15839.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.15839.11.7" xlink:to="lab_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.138815" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.138815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.138815">Weighted Average Number of Shares Outstanding Used to Calculate Earnings or Loss Per Share</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.6" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock.16610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock.16610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock.16610">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.7" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817">Inventory</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.6" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.7" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145">Accounts payable and accruals:</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.6" xlink:to="lab_AccountsPayableOtherCurrent.376" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.376">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.7" xlink:to="lab_AccountsPayableOtherCurrent.138148" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.138148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.138148">Other</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5457.11.6" xlink:to="lab_AccountsPayableTradeCurrent.402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.402">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5457.11.7" xlink:to="lab_AccountsPayableTradeCurrent.138147" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.138147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.138147">Trade</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5451.11.6" xlink:to="lab_AccountsReceivableNetCurrent.390" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.390">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5451.11.7" xlink:to="lab_AccountsReceivableNetCurrent.138137" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.138137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.138137">Trade</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrentAbstract.395.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrentAbstract.395.11.6" xlink:to="lab_AccountsReceivableNetCurrentAbstract.369" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrentAbstract.369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrentAbstract.369">Accounts Receivable, Net, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrentAbstract.395.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrentAbstract.395.11.7" xlink:to="lab_AccountsReceivableNetCurrentAbstract.138136" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrentAbstract.138136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrentAbstract.138136">Accounts receivable:</link:label>
    <link:loc xlink:label="loc_Assets.5880.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.5880.11.6" xlink:to="lab_Assets.1134" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.1134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.1134">Assets</link:label>
    <link:loc xlink:label="loc_Assets.5880.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.5880.11.9" xlink:to="lab_Assets.138141" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.138141" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.138141">Total assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.595.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.595.11.6" xlink:to="lab_AssetsAbstract.1105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.1105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.1105">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.595.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.595.11.7" xlink:to="lab_AssetsAbstract.138133" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.138133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.138133">ASSETS</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.5874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.5874.11.6" xlink:to="lab_AssetsCurrent.1123" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.1123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.1123">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.5874.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.5874.11.9" xlink:to="lab_AssetsCurrent.138142" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.138142" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.138142">Total current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.592.11.6" xlink:to="lab_AssetsCurrentAbstract.1099" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.1099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.1099">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.592.11.7" xlink:to="lab_AssetsCurrentAbstract.138132" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.138132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.138132">CURRENT ASSETS:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.2187" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.2187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.2187">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.138135" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.138135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.138135">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.6842.11.6" xlink:to="lab_CommitmentsAndContingencies.2677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.2677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.2677">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.6842.11.7" xlink:to="lab_CommitmentsAndContingencies.138162" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.138162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.138162">COMMITMENTS</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7671.11.6" xlink:to="lab_DeferredRevenueCurrent.3980" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.3980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.3980">Deferred Revenue, Current</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7671.11.7" xlink:to="lab_DeferredRevenueCurrent.138149" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.138149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.138149">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7662.11.6" xlink:to="lab_DeferredRevenueNoncurrent.3963" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.3963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.3963">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7662.11.7" xlink:to="lab_DeferredRevenueNoncurrent.138153" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.138153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.138153">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.6" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.7" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.6" xlink:to="lab_InventoryNet.9655" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.9655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.9655">Inventory, Net</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.7" xlink:to="lab_InventoryNet.138139" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138139">Inventories</link:label>
    <link:loc xlink:label="loc_Liabilities.11702.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.11702.11.6" xlink:to="lab_Liabilities.10148" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.10148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.10148">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.11702.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.11702.11.9" xlink:to="lab_Liabilities.138159" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.138159" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.138159">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.10196" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.10196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.10196">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.11.9" xlink:to="lab_LiabilitiesAndStockholdersEquity.138166" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.138166" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.138166">Total liabilities and shareholders' equity (net of capital deficiency)</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.10173" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.10173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.10173">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.138143" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.138143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.138143">LIABILITIES AND SHAREHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.11668.11.6" xlink:to="lab_LiabilitiesCurrent.10094" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.10094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.10094">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.11668.11.9" xlink:to="lab_LiabilitiesCurrent.138151" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.138151" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.138151">Total current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.10147" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.10147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.10147">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.138144" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.138144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.138144">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.11699.11.6" xlink:to="lab_LiabilitiesNoncurrent.10143" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.10143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.10143">Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.11699.11.9" xlink:to="lab_LiabilitiesNoncurrent.138158" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.138158" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.138158">Total long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.11.6" xlink:to="lab_LiabilitiesNoncurrentAbstract.10151" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.10151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.10151">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.11.7" xlink:to="lab_LiabilitiesNoncurrentAbstract.138152" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.138152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.138152">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12289.11.6" xlink:to="lab_LongTermDebtNoncurrent.11025" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.11025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.11025">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12289.11.7" xlink:to="lab_LongTermDebtNoncurrent.138155" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.138155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.138155">Long term liability</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.6" xlink:to="lab_OtherReceivablesNetCurrent.12515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.12515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.12515">Other Receivables, Net, Current</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.7" xlink:to="lab_OtherReceivablesNetCurrent.138138" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.138138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.138138">Other</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.6" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.7" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.14913" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14913">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.134116" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.134116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.134116">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.138129" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.138129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.138129">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.6" xlink:to="lab_StockholdersEquity.18029" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.18029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.18029">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.7" xlink:to="lab_StockholdersEquity.138164" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138164">SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7176.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7176.11.6" xlink:to="lab_CostOfRevenue.3224" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.3224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.3224">Cost of Revenue</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7176.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7176.11.42" xlink:to="lab_CostOfRevenue.138492" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.138492" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.138492">COST OF REVENUES</link:label>
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1670.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareAbstract.1670.11.6" xlink:to="lab_EarningsPerShareAbstract.5433" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareAbstract.5433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareAbstract.5433">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1670.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareAbstract.1670.11.7" xlink:to="lab_EarningsPerShareAbstract.138524" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareAbstract.138524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareAbstract.138524">LOSS PER SHARE OF COMMON STOCK:</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.8698.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.5415" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.5415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.5415">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.8698.11.7" xlink:to="lab_EarningsPerShareBasicAndDiluted.167675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.167675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.167675">BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.7" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517">FINANCIAL INCOME (EXPENSES) - NET</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10284.11.6" xlink:to="lab_GeneralAndAdministrativeExpense.7870" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.7870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.7870">General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10284.11.42" xlink:to="lab_GeneralAndAdministrativeExpense42.138509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense42.138509" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense42.138509">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.6" xlink:href="plx-20120930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.6" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138496" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138496">Grants And Reimbursements Received Or Receivable</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.7" xlink:href="plx-20120930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.7" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138500">less - grants and reimbursements</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.12" xlink:href="plx-20120930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.12" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138498" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138498">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:loc xlink:label="loc_GrossProfit.10358.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10358.11.6" xlink:to="lab_GrossProfit.7981" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.7981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.7981">Gross Profit</link:label>
    <link:loc xlink:label="loc_GrossProfit.10358.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10358.11.9" xlink:to="lab_GrossProfit.138487" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.138487" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.138487">GROSS PROFIT</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.2519.11.6" xlink:to="lab_IncomeStatementAbstract.138470" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.138470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.138470">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.9" xlink:to="lab_NetIncomeLoss.138521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138521" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138521">NET LOSS FOR THE PERIOD</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13080.11.6" xlink:to="lab_OperatingIncomeLoss.12364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.12364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.12364">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13080.11.9" xlink:to="lab_OperatingIncomeLoss.138511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.138511" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.138511">OPERATING LOSS</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.20964.11.6" xlink:href="plx-20120930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.20964.11.6" xlink:to="lab_OtherGainsLosses.138475" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138475">Other Gains Losses</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.20964.11.7" xlink:href="plx-20120930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.20964.11.7" xlink:to="lab_OtherGainsLosses.138484" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138484">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.20964.11.12" xlink:href="plx-20120930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.20964.11.12" xlink:to="lab_OtherGainsLosses.138482" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138482" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138482">The Company's share in collaboration agreement.</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15293.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.15873" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.15873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.15873">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15293.11.42" xlink:to="lab_ResearchAndDevelopmentExpense42.140375" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense42.140375" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense42.140375">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.6" xlink:href="plx-20120930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.6" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504">Research Development And Engineering Expense Net</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.45" xlink:href="plx-20120930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.45" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.12" xlink:href="plx-20120930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.12" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505">Research and development expenses, net.</link:label>
    <link:loc xlink:label="loc_Revenues.15575.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.15575.11.6" xlink:to="lab_Revenues.16307" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.16307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.16307">Revenues</link:label>
    <link:loc xlink:label="loc_Revenues.15575.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.15575.11.7" xlink:to="lab_Revenues.134146" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.134146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.134146">REVENUES</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.11.6" xlink:href="plx-20120930.xsd#plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.11.6" xlink:to="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138536" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138536">Weighted Average Number Basic And Diluted Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.11.7" xlink:href="plx-20120930.xsd#plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.11.7" xlink:to="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138538" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138538">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.11.12" xlink:href="plx-20120930.xsd#plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.11.12" xlink:to="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138537" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138537" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.138537">Weighted Average Number Basic And Diluted Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.6" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.7" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681">BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.461.11.6" xlink:to="lab_AdditionalPaidInCapitalMember.681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.681">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747">Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695">Share-based compensation related to stock options</link:label>
    <link:loc xlink:label="loc_CommonStockMember.1033.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockMember.1033.11.6" xlink:to="lab_CommonStockMember.2694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockMember.2694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockMember.2694">Common Stock [Member]</link:label>
    <link:loc xlink:label="loc_EquityComponentDomain.1773.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityComponentDomain.1773.11.6" xlink:to="lab_EquityComponentDomain.5824" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityComponentDomain.5824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityComponentDomain.5824">Equity Component [Domain]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.8" xlink:to="lab_NetIncomeLoss.138697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138697" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138697">Net loss for the period</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4458.11.6" xlink:to="lab_RetainedEarningsMember.16154" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.16154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.16154">Retained Earnings [Member]</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4458.11.7" xlink:to="lab_RetainedEarningsMember.138685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.138685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.138685">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.6" xlink:to="lab_SharesOutstanding.17653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.17653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.17653">Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.10" xlink:to="lab_SharesOutstanding.138690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138690" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138690">Beginning Balance (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.11" xlink:to="lab_SharesOutstanding.138702" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138702" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138702">Ending Balance (in shares)</link:label>
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementEquityComponentsAxis.4957.11.6" xlink:to="lab_StatementEquityComponentsAxis.17875" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementEquityComponentsAxis.17875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementEquityComponentsAxis.17875">Equity Components [Axis]</link:label>
    <link:loc xlink:label="loc_StatementLineItems.4952.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.4952.11.6" xlink:to="lab_StatementLineItems.17869" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementLineItems.17869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementLineItems.17869">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.11.6" xlink:to="lab_StatementOfStockholdersEquityAbstract.138674" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfStockholdersEquityAbstract.138674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfStockholdersEquityAbstract.138674">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Abstract]</link:label>
    <link:loc xlink:label="loc_StatementTable.4950.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementTable.4950.11.6" xlink:to="lab_StatementTable.17867" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementTable.17867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementTable.17867">Statement [Table]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.10" xlink:to="lab_StockholdersEquity.138688" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138688" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138688">Beginning Balance</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.11" xlink:to="lab_StockholdersEquity.138700" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138700" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138700">Ending Balance</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599">Share-based compensation related to restricted stock award (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.17977" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.17977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.17977">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.138692" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.138692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.138692">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106">Exercise of options granted to employees and non-employees (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.6" xlink:to="lab_StockIssuedDuringPeriodValueIssuedForServices.17948" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueIssuedForServices.17948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueIssuedForServices.17948">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.7" xlink:to="lab_StockIssuedDuringPeriodValueIssuedForServices.145592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueIssuedForServices.145592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueIssuedForServices.145592">Share-based compensation related to restricted stock award</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.17939" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.17939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.17939">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.7" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.138694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.138694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.138694">Common stock issued for cash (net of issuance costs)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.6" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.7" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696">Exercise of options granted to employees and non-employees</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770">Common stock issued for cash, issuance costs</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.2741" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.2741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.2741">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.8" xlink:to="lab_CommonStockParOrStatedValuePerShare.138774" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.138774" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.138774">Common Stock, par value</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.6879.11.6" xlink:to="lab_CommonStockSharesAuthorized.2742" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.2742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.2742">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.6879.11.8" xlink:to="lab_CommonStockSharesAuthorized.138777" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.138777" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.138777">Common Stock, Authorized</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020">Adjustments required to reconcile net loss to net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.10" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139058" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139058" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139058">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.11" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139059" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139059">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.9" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.6" xlink:to="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.2287">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.11.7" xlink:to="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.139064" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.139064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.139064">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.11.6" xlink:href="plx-20120930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.22141.11.6" xlink:to="lab_CashlessExerciseOfStockOptions.145608" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145608">Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.11.7" xlink:href="plx-20120930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.22141.11.7" xlink:to="lab_CashlessExerciseOfStockOptions.145611" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145611">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.11.12" xlink:href="plx-20120930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.22141.11.12" xlink:to="lab_CashlessExerciseOfStockOptions.145610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145610">Cashless exercise of stock options.</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.11.6" xlink:href="plx-20120930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.21078.11.6" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139023" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139023">Depreciation Amortization And Asset Impairment</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.11.7" xlink:href="plx-20120930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.21078.11.7" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139027" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139027">Depreciation and write down of fixed assets</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.11.12" xlink:href="plx-20120930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.21078.11.12" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139026" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139026">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.6" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.7" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.7370" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.7370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.7370">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.42" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.139028" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.139028" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.139028">Financial income, net (mainly exchange differences)</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.6" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment.7730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment.7730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment.7730">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.42" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198">Loss on sale of fixed assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038">Increase in accounts payable and accruals (including long term)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.10853.11.6" xlink:to="lab_IncreaseDecreaseInAccountsReceivable.8785" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable.8785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable.8785">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.10853.11.42" xlink:to="lab_IncreaseDecreaseInAccountsReceivable42.139035" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable42.139035" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable42.139035">Decrease (increase) in accounts receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.10850.11.6" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.8782" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.8782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.8782">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.10850.11.7" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.139034" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.139034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.139034">Decrease in deferred revenues (including non-current portion)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.10936.11.6" xlink:to="lab_IncreaseDecreaseInInventories.8903" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories.8903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories.8903">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.10936.11.42" xlink:to="lab_IncreaseDecreaseInInventories42.139036" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories42.139036" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories42.139036">Decrease (increase) in inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.6" xlink:href="plx-20120930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.6" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.7" xlink:href="plx-20120930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.7" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.12" xlink:href="plx-20120930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.12" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067">Increase in liabilities for property, plant and equipment.</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.11796" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.11796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.11796">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.9" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.139054" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.139054" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.139054">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.11776" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.11776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.11776">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.9" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.139044" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.139044" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.139044">Net cash used in investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.11871" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.11871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.11871">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.9" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.139039" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.139039" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.139039">Net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.6" xlink:to="lab_NetIncomeLoss.11860" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.11860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.11860">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.7" xlink:to="lab_NetIncomeLoss.138997" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138997">Net loss</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.6" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.13356" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.13356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.13356">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.42" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.139042" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.139042" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.139042">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.6" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.42" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.13663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.13663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.13663">Pension and Other Postretirement Benefit Contributions</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.42" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.139032" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.139032" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.139032">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.13676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.13676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.13676">Pension and Other Postretirement Benefit Expense</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.7" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.139030" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.139030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.139030">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.6" xlink:href="plx-20120930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047">Proceeds From Issuance Of Common Stock Net Of Expenses</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.7" xlink:href="plx-20120930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050">Issuance of shares, net of issuance cost</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.12" xlink:href="plx-20120930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.12" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048">Proceeds from issuance of common stock net of expenses.</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.6" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.7" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.6" xlink:to="lab_ProceedsFromStockOptionsExercised.14691" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.14691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.14691">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.8" xlink:to="lab_ProceedsFromStockOptionsExercised.139052" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.139052" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.139052">Exercise of options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16244.11.6" xlink:to="lab_ShareBasedCompensation.17402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.17402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.17402">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16244.11.7" xlink:to="lab_ShareBasedCompensation7.138110" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.138110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.138110">Share based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.138995" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.138995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.138995">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.6" xlink:href="plx-20120930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.6" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139071" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139071">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.7" xlink:href="plx-20120930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.7" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139074" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139074">Issuance cost not yet paid and accruals - other</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.12" xlink:href="plx-20120930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.12" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139073" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139073" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139073">Supplemental offering and stock issuance costs.</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.144.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.144.11.6" xlink:to="lab_AmendmentFlag.8" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.155.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.20908.11.6" xlink:href="plx-20120930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.138116" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.138116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.138116">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.208.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.208.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.207.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.207.11.6" xlink:to="lab_DocumentFiscalYearFocus.122" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.161.11.6" xlink:to="lab_DocumentPeriodEndDate.30" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.212.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.212.11.6" xlink:to="lab_DocumentType.32" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.188.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.188.11.6" xlink:to="lab_EntityCentralIndexKey.101" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.192.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.192.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.185.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.185.11.6" xlink:to="lab_EntityFilerCategory.98" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.187.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.187.11.6" xlink:to="lab_EntityRegistrantName.100" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_TradingSymbol.177.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TradingSymbol.177.11.6" xlink:to="lab_TradingSymbol.60" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TradingSymbol.60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TradingSymbol.60">Trading Symbol</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5724.11.6" xlink:to="lab_AllocatedShareBasedCompensationExpense.852" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense.852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense.852">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5724.11.7" xlink:to="lab_AllocatedShareBasedCompensationExpense7.138668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense7.138668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense7.138668">Share-based compensation</link:label>
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.11.6" xlink:to="lab_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.2801" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.2801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.2801">Component of Other Operating Cost and Expense [Axis]</link:label>
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.11.6" xlink:to="lab_ComponentOfOtherOperatingCostAndExpenseNameDomain.2810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ComponentOfOtherOperatingCostAndExpenseNameDomain.2810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ComponentOfOtherOperatingCostAndExpenseNameDomain.2810">Component of Other Operating Cost and Expense, Name [Domain]</link:label>
    <link:loc xlink:label="loc_CostOfRevenuesMember.26156.11.6" xlink:href="plx-20120930.xsd#plx_CostOfRevenuesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenuesMember.26156.11.6" xlink:to="lab_CostOfRevenuesMember.167685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenuesMember.167685" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenuesMember.167685">Cost of Revenues [Member]</link:label>
    <link:loc xlink:label="loc_CostOfRevenuesMember.26156.11.12" xlink:href="plx-20120930.xsd#plx_CostOfRevenuesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenuesMember.26156.11.12" xlink:to="lab_CostOfRevenuesMember.167690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenuesMember.167690" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenuesMember.167690">Cost Of Revenues [Member].</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2354.11.6" xlink:to="lab_GeneralAndAdministrativeExpenseMember.7876" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember.7876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember.7876">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4381.11.6" xlink:to="lab_ResearchAndDevelopmentExpenseMember.15885" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember.15885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember.15885">Research and Development Expense [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20120930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--P3XBRL-->
<!--version 4.1.21 -->
<!--http://www.p3xbrl.com-->
<!--produced on 2012-11-05 @ 12:39 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20120930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20120930.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesDetails" xlink:href="plx-20120930.xsd#plx-invd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEventsDetails" xlink:href="plx-20120930.xsd#plx-suevd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicesScheduleOfWeightedAverageNumberOfSharesOutstandingUsedToCalculateEarningsLossPerShareDetails" xlink:href="plx-20120930.xsd#plx-sapt1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20120930.xsd#plx-sttd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20120930.xsd#plx-sapo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20120930.xsd#plx-invt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20120930.xsd#plx-sttr" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SubsequentEvents" xlink:href="plx-20120930.xsd#plx-suev" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20120930.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:href="plx-20120930.xsd#plx-sapt2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20120930.xsd#plx-invtt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20120930.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20120930.xsd#plx-ccso" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:href="plx-20120930.xsd#plx-ccse" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:href="plx-20120930.xsd#plx-ccsep" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20120930.xsd#plx-cccf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20120930.xsd#plx-dein" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20120930.xsd#plx-ccsop" xlink:type="simple" />
  <link:presentationLink xlink:title="40101 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.6" xlink:to="loc_SignificantAccountingPoliciesTable.20885.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.12.7" xlink:href="plx-20120930.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.12.7" xlink:to="loc_StockOptionsAndRestrictedSharesMember.26237.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.12.7" xlink:href="plx-20120930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.20890.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.12.7" xlink:href="plx-20120930.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_PfizerIncorporationMember.20891.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.12.7" xlink:href="plx-20120930.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioTwoMember.20882.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioOneMember.20883.12.7" xlink:href="plx-20120930.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioOneMember.20883.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.4951.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_StatementScenarioAxis.4951.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.12.6" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_SignificantAccountingPoliciesLineItems.20892.12.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:href="plx-20120930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.12.7" xlink:href="plx-20120930.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_NumberOfSubsidiaries.20893.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_ProceedsFromCollaborators.14370.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MilestonePayment.20894.12.7" xlink:href="plx-20120930.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_MilestonePayment.20894.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.12.7" xlink:href="plx-20120930.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.20895.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40201 - Disclosure - INVENTORIES (Details)" xlink:role="http://www.protalix.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterialsNetOfReserves.11392.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryRawMaterialsNetOfReserves.11392.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryWorkInProcessNetOfReserves.11424.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryWorkInProcessNetOfReserves.11424.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryFinishedGoodsNetOfReserves.11388.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryFinishedGoodsNetOfReserves.11388.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryNet.11417.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.9" xlink:to="loc_InventoryNet.11417.12.9" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40401 - Disclosure - SUBSEQUENT EVENTS (Details)" xlink:role="http://www.protalix.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeMember.21244.12.7" xlink:href="plx-20120930.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:to="loc_EmployeeMember.21244.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsequentEventsAbstract.5004.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventTable.5008.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventsAbstract.5004.12.6" xlink:to="loc_SubsequentEventTable.5008.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventTypeDomain.5005.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionExerciseMember.21242.12.6" xlink:href="plx-20120930.xsd#plx_OptionExerciseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventTypeDomain.5005.12.6" xlink:to="loc_OptionExerciseMember.21242.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventLineItems.5006.12.8" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.8" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventLineItems.5006.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.7" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SubsequentEventTypeAxis.5007.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventTypeAxis.5007.12.6" xlink:to="loc_SubsequentEventTypeDomain.5005.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SubsequentEventTable.5008.12.6" xlink:to="loc_SubsequentEventTypeAxis.5007.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SubsequentEventLineItems.5006.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventTable.5008.12.6" xlink:to="loc_SubsequentEventLineItems.5006.12.6" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SubsequentEventTable.5008.12.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" order="4.25" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40102 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted Average Number of Shares Outstanding used to Calculate Earnings (Loss) per Share) (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicesScheduleOfWeightedAverageNumberOfSharesOutstandingUsedToCalculateEarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.8" xlink:to="loc_WeightedAverageNumberOfSharesOutstandingBasic.17377.12.8" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_WeightedAverageNumberDilutedSharesOutstandingAdjustment.17401.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.8" xlink:to="loc_WeightedAverageNumberOfDilutedSharesOutstanding.17383.12.8" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40301 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AwardTypeAxis.344.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AwardTypeAxis.344.12.6" xlink:to="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockSharesIssued.6875.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.8" xlink:to="loc_CommonStockSharesIssued.6875.12.8" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SaleOfStockPricePerShare.15652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_SaleOfStockPricePerShare.15652.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStock.14449.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStock.14449.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PaymentsOfStockIssuanceCosts.13770.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_PaymentsOfStockIssuanceCosts.13770.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.8" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1.16272.12.8" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ShareBasedCompensation.16244.12.7" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized.16337.12.7" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.16300.12.7" order="11.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.12.7" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod.22164.12.7" order="12.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.12.7" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm.22167.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.12.7" xlink:href="plx-20120930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue.22169.12.7" order="13.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.12.7" order="7.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" xlink:to="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.12.7" xlink:href="plx-20120930.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:to="loc_EmployeeAndNonemployeeMember.20907.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:to="loc_AwardTypeAxis.344.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:to="loc_ClassOfStockLineItems.966.12.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:to="loc_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAxis.1319.12.6" order="2.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_PerformanceSharesMember.3865.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.7" xlink:to="loc_PerformanceSharesMember.3865.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockCompensationPlanAndRestrictedStockMember.22155.12.7" xlink:href="plx-20120930.xsd#plx_StockCompensationPlanAndRestrictedStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain.4874.12.7" xlink:to="loc_StockCompensationPlanAndRestrictedStockMember.22155.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.4988.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.4988.12.6" xlink:to="loc_ScheduleOfStockByClassTable.4702.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ExecutiveOfficerMember.1817.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ExecutiveOfficerMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_ExecutiveOfficerMember.1817.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeesMember.22161.12.6" xlink:href="plx-20120930.xsd#plx_EmployeesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_TitleOfIndividualWithRelationshipToEntityDomain.5117.12.6" xlink:to="loc_EmployeesMember.22161.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - INVENTORIES" xlink:role="http://www.protalix.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryDisclosureTextBlock.11399.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - STOCK TRANSACTIONS" xlink:role="http://www.protalix.com/role/StockTransactions" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.4988.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.4988.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.16673.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="104 - Disclosure - SUBSEQUENT EVENTS" xlink:role="http://www.protalix.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:label="loc_SubsequentEventsAbstract.5004.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SubsequentEventsTextBlock.16697.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SubsequentEventsAbstract.5004.12.7" xlink:to="loc_SubsequentEventsTextBlock.16697.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.12.7" xlink:href="plx-20120930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_NatureOfOperationsPolicyTextBlock.21035.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_EarningsPerSharePolicyTextBlock.8704.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="301 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.15839.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock.15839.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="302 - Disclosure - INVENTORIES (Tables)" xlink:role="http://www.protalix.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:to="loc_AccountsPayableTradeCurrent.5457.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:to="loc_AccountsPayableOtherCurrent.5442.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrentAbstract.395.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsReceivableNetCurrentAbstract.395.12.7" xlink:to="loc_AccountsReceivableNetCurrent.5451.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsReceivableNetCurrentAbstract.395.12.7" xlink:to="loc_OtherReceivablesNetCurrent.13172.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_AccountsReceivableNetCurrentAbstract.395.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryNet.11417.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_InventoryNet.11417.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.595.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_AssetsCurrentAbstract.592.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.12.7" order="2.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.595.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.5880.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.9" xlink:to="loc_Assets.5880.12.9" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_AssetsCurrent.5874.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.9" xlink:to="loc_AssetsCurrent.5874.12.9" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:to="loc_DeferredRevenueCurrent.7671.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.9" xlink:to="loc_LiabilitiesCurrent.11668.12.9" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_DeferredRevenueNoncurrent.7662.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_LongTermDebtNoncurrent.12289.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.2935.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_LiabilitiesNoncurrentAbstract.2937.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_LiabilitiesNoncurrent.11699.12.9" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_Liabilities.11702.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_Liabilities.11702.12.9" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_CommitmentsAndContingencies.6842.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_StockholdersEquity.16667.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_LiabilitiesAndStockholdersEquity.11731.12.9" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_AssetsAbstract.595.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_EarningsPerShareAbstract.1670.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EarningsPerShareAbstract.1670.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.8698.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.15575.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_Revenues.15575.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherGainsLosses.20964.12.7" xlink:href="plx-20120930.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_OtherGainsLosses.20964.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfRevenue.7176.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_CostOfRevenue.7176.12.42" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GrossProfit.10358.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_GrossProfit.10358.12.9" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_ResearchAndDevelopmentExpense.15293.12.42" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.12.7" xlink:href="plx-20120930.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.12.7" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.45" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.12.45" xlink:href="plx-20120930.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.45" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.12.45" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_GeneralAndAdministrativeExpense.10284.12.42" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_OperatingIncomeLoss.13080.12.9" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.12.7" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_NetIncomeLoss.12771.12.9" order="11.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_EarningsPerShareAbstract.1670.12.7" order="12.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.12.7" xlink:href="plx-20120930.xsd#plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.12.7" order="13.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract.20976.12.7" xlink:to="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1773.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1033.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.6" xlink:to="loc_CommonStockMember.1033.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.6" xlink:to="loc_AdditionalPaidInCapitalMember.461.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.7" xlink:to="loc_RetainedEarningsMember.4458.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementTable.4950.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementEquityComponentsAxis.4957.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementLineItems.4952.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.10" xlink:to="loc_StockholdersEquity.16667.12.10" order="2.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.10" xlink:to="loc_SharesOutstanding.16423.12.10" order="2.75" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.16628.12.7" order="4.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.16603.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="7.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.8" xlink:to="loc_NetIncomeLoss.12771.12.8" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.11" xlink:to="loc_StockholdersEquity.16667.12.11" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.11" xlink:to="loc_SharesOutstanding.16423.12.11" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.12.7" order="7.75" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.12.7" order="7.88" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.6" xlink:to="loc_StatementTable.4950.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_StatementEquityComponentsAxis.4957.12.6" xlink:to="loc_EquityComponentDomain.1773.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  (CAPITAL DEFICIENCY) (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.8" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.12.8" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.8" xlink:to="loc_CommonStockSharesAuthorized.6879.12.8" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_ShareBasedCompensation.16244.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.12.7" xlink:href="plx-20120930.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.21078.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.12.42" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.13882.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.13875.12.42" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.12.42" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.12.7" xlink:href="plx-20120930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:to="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.12.7" xlink:href="plx-20120930.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:to="loc_SupplementalOfferingAndStockIssuanceCosts.21083.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.12.7" xlink:href="plx-20120930.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" xlink:to="loc_CashlessExerciseOfStockOptions.22141.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.10850.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.10853.12.42" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:to="loc_IncreaseDecreaseInInventories.10936.12.42" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.12.7" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.12.7" xlink:href="plx-20120930.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.8" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.8" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.12.42" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.12.42" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.12.7" order="1.50" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:to="loc_NetIncomeLoss.12771.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.12778.12.9" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.12731.12.9" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.12740.12.9" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.12.7" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.12.9" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.10" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.10" order="11.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.11" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.11" order="12.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract.893.12.7" order="13.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:href="plx-20120930.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.212.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentType.212.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AmendmentFlag.144.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_AmendmentFlag.144.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentPeriodEndDate.161.12.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.207.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentFiscalYearFocus.207.12.6" order="4.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.208.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentFiscalPeriodFocus.208.12.6" order="5.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TradingSymbol.177.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_TradingSymbol.177.12.6" order="6.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityRegistrantName.187.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityRegistrantName.187.12.6" order="7.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.188.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityCentralIndexKey.188.12.6" order="8.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_CurrentFiscalYearEndDate.155.12.6" order="9.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityFilerCategory.185.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityFilerCategory.185.12.6" order="10.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.192.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityCommonStockSharesOutstanding.192.12.6" order="11.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseGeneralAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ComponentOfOtherOperatingCostAndExpenseNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.12.6" xlink:to="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.12.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4381.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.12.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2354.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenuesMember.26156.12.6" xlink:href="plx-20120930.xsd#plx_CostOfRevenuesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ComponentOfOtherOperatingCostAndExpenseNameDomain.1072.12.6" xlink:to="loc_CostOfRevenuesMember.26156.12.6" order="3.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.4950.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.6" xlink:to="loc_StatementTable.4950.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_ComponentOfOtherOperatingCostAndExpenseGeneralAxis.1063.12.6" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementLineItems.4952.12.6" order="2.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_AllocatedShareBasedCompensationExpense.5724.12.7" order="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001144204-12-060041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-060041-xbrl.zip
M4$L#!!0````(`-.`9T&"Q#TA;S@``$J)`@`0`!P`<&QX+3(P,3(P.3,P+GAM
M;%54"0`#7LV:4%[-FE!U>`L``00E#@``!#D!``#L7>MSVDBV_[Y5^S_TL(]*
MJ@`CGK8SF;WXE7C7,:Q-,IFZ=3\T4@,]$9)&+=EF_OI[SFD]0<(08\:;3>U.
M!5`_SOF=]VE)_O$?#W.;W0E?2==Y6S'JC0H3CNE:TIF^K7R\K?5O3R\O*TP%
MW+&X[3KB;<5Q*__XZ<]_^O&'6NV3=`(^%>Q"VC!!L:%[+WQAL9,%&[8^G]Q<
ML5D0>,<'!_?W]W6O]3#V[;KISFNU:'ZT,6O7C7K38,GOGN]:H0D+P;5FPVC6
M#*/6Z+#_84;SN-5CPP]Z)*['@`%''</^7]Y6,KO17JX_/6@V&JT#O#SF2E2B
MX9[]D!L-&P;<E@](W0'NV#AJ->+!N)1<L[AT$!XS6?QA%LSMW/C[%HTVCHZ.
M#NAJ,G2%[MQ0O!H/M41*`^VOA%F?NG<'<(%(KC6,6LN(AX>J-N7<2Z9,N!K3
MRM&%@BF7MX-VT^BMXU2Y."*>X(3SXL%6X!\$"T\<P`CA2S.:L`F&(%?&?D3&
MCY4Y$W-^(R:,@#C&%=]6E)Q[-F)-O\U\,7E;`7'68JG5'Y1580=Z'<#FN#\7
MC@7_!1<VGS)IO:WD?JEWCUKU1OJ_"C-=)Q`/P0VN//%!76.HX/^!&WT[JL%6
M2U-A\D\3;BOQX\'*QBD]IZ'OXX]2F=S^17#_W+'.>""(M+*+.Z:R5H.K+4/3
M6;9G2O*9:X;S9,@01.I:%_";(II+K^Z8Z'^W-+VE^Y41C#R5D9M<VS&Q>+6(
MW&2_56(U)UEM*+SR#(3JJWER<WNN$CL"8\S1B#_LF#2C4?MWGBC<)*7EW`ED
ML#B%WWUN7SJ6>/B76!!1A5=V3%VCT3`:C6[S,#*CPCU7B'7G<]>Y#5SSR^V,
M^T(-PH""*\3/+.5KA@$MC7(VN*JYDUH2--O+HW%\Z$@]^*->O,(L8<HY>*ZW
M%6#LJ-7N=HSN48ZM-00M\PC9@/!/06NFKI\51^[W'0NC;YH"5H?%+4;[9(G/
M;;Q,[8V82@4B<X)K/A<9<O,7=DSO\&8PZE]=?F8GEX/1^_.;_O#\X^CR]+;*
M+J]/ZUGB\V2DU(]\CN#?+N9CUR:R<[_LFMZKSYJHW"::&HB^QZ=<S6RAU/F#
M\$VIQ&!"NC+P`LCOM-]=/V2W]&95_"RKWK56Y:<>9!S@[!XG>[?LM1]GS\BQ
M9R3LM;=AS_@*]ES;YF,7S$?>B;X/RC85%`-\=R(#,G@(!Z;0V3YQN\T,X`#R
M^\8A>")(:Q_U6S'74(T4S4IY'X:^R')O@%.NMR/6MR%P_T@87X6$L142W2<A
M<28\'];CJ"K]N>L'\G?]V;'Z2HG@<NYQZ>-".@W8>/@>+;W9R]CZYA3N!X1]
M^8-F]^CP22"\P^"C8,2-D/-QZ"M2'W4C3`$:90U\_8F/;6T16XS?HRYTNIU.
M`L,6).X+AWVI`V1VK9>,0V<C?>@5Z4-G&QR,HY>-0W<C?>@5Z4-W*QS:S>;3
M<+AT3%]P)2Z=*\G'TI:!%.K"]2'`>,(/%D,;%H4USW\+I9?XRJUG[=%7'#:-
M!)*MZ?PC@-E;;MGN]7:!S`>HR%3@.F+(%PGCRS^2U"#M.6S5VT<=X^OE7K1&
M*9<=B)@8*!(VE\E*N;CF`>1=@\G`P\H34^JA:TMS,0+B3FQ(M(FM1T?MN%3[
MNQV\^:%6.QN<CGX9GC-L-[/AQY.KRU-6J1T<_-PZ/3@X&YVQS^]''ZX80,*@
MIG.41-*X?7!P?EUA!1WIT8UN71LX.?I8"S(SZU9@55BM]O=I\.;/?T(J+'F'
M7UCF<T3<;<#]X,+G4P143Z%1`3E+%2QL`?K0OWEW>5T;#8;'K.'!B(O!]>B8
M&?"9C>1<*'8M[MF-.^=.5?]09;?"EY,W+)IZ,AB-!A]H-H`J;%MYW*2CC8;^
M[G'+BK_?2RN80>K<:/RMDA+DQ]1\.K^!`KU_58.R_=WU,0M<+S/,BH?]?'DV
M>@\[UCO2J<0<0_WN.E/\QNOX_2#]@;X&5F:EU4GOA`.J8S\R\R#P,Y\1R.2K
M%U,W.O\\JEU>GYTCD#6P#*`R1HM@@O\>Z%\#+VP*N&:4S[TWSEAYFC+O6Q1J
M+Y%JGMF<`%=F-8MUP=A,%Q*_\62!-W8G;%8J[>??>A@=UK$3Z8YF`(XGPD":
M,`@B4IV],J'@%296N_8"%""8,1DHIL*QDI;DOL3E@IE@4+I#M>,L*J^KC#L6
MC;J?P>1%S;UWA)5.65333:\"JP[C?<'&TO6@>IYSD_;G-OAM7!`V8!-L\>L#
M3-S*$D",JV,\;@4#Y]B2@15U_<7<"8/"S)V/I0-1$R?%?#$\G!3240Q/,),E
M(^))#G]I';U1.,X#[L"U+I#<4S"%\P=2N=!+=-874RVQZ,=X=28>H#)4=!RK
M%BH0<_:JDJQ2>5T'<$$('EP8"Y]!RGBT!`KP#(6C!?RY2'T9E!!Y+;B*+-C\
M7B'C^/E:X"3(&"R56?>D_@G`!NH@(CHH4Z".)(I3SD-,-+C#/@A+@@<`V/M3
MX9@+H/S\0[_RFG'/@TBK`08^3>`/%\M-_NC`U3H;%4(:W+LYQ2&Y^V(B?#SF
M#ER6TS5@`)'D2JO7;69BO;)W,_D#+70`,N$+9E3I]%Y;V\?Z;9U=N*Y%!G#F
MAU/6M^;2H>8V2>@5$C>!U"='W^BF?WU[,;@!CQ]ZX`I-/,;'732B.!Z_79SU
MGS*==,5W[U"JH'E3.S3!`)5@W)YPU&S0FU^U`E9+S&\B?16DRUC(H;Z1(:BB
M3H"N">=W2"%!@3P;G`9Y`VWHH+(0B5[31F09$!%J@?#G+(`4.Z"18"C<"NV`
M>0`75F7:$CC:QD22Z8&R31U726U5>$)GL'<\--$<+:DP60=-7^4/)O"L^ZCF
M?!':-2Z(D\"&?#'V80\+9[]Z=WKV&BCF01:4V-T!1:'"@ZW$CQ3N?H_@V,I-
ML1LO:+E+Y7-A2_9!:\D"B7@ON`U<OR(+2P8,WH.UR[R#,IIEO.)<+2T/2Q1*
M&FK:N3[B@W,D"F[.8O<%ZD=ZG2-[\+Y>9GI[L_$=;50,Y%B@=.?<_R+PX"UR
MK>!1\1OD^`$LF[K[L8\(.7C*=GYU?O7+[8#(!_.WQ!L$=#B1O\-8'<6?8LUZ
MH2?Y@S(K7XW<'I0RD)^3C:-R2"N%0CR8-IC`'5BT-(6#T#D8#"$N+1B?^D([
M`>`=?Q^+X%X(9RFLXI4(&=+ZIP,#83+:^4D0Y8(FXN6[X72VG"EI[5"QR!$9
M;2#?C&WDQ37%%II(1(9>/U:"*KMW?=N"FB35!\@A(F^YDAB*HE"4FM.R+*ML
M'`;@P`(N,>,*9B[,\>5T%J@,Z%F9L1EZ7IQ/N0QGRA.FG("[X[;M1GG3HTH)
M&27WZ?X%I`IR2,]UE(S[04E(PYZ&=$*,4IED6$S@>A"-6N$6J`5XP(WDK)'(
M]J.6)`(<>A,?E=B+FDG@D__:;=0;;"YM&WDH22#%@S##./LN@E1;ZPPHM"DB
M02R>!%JH6&/JO@?[:R>SE6E#L,):(,-ES1<VW9DPCUM),:EY<61YRJ[?S&ZP
MLD89=Y@1I7Y+!RY8#5DM<.8%KAO4=28AQ-UKN%T?'1M]OA,@2&:%?BQUCVX6
MPE7T%!G$LX@AS6;J[R(WJ58S!X7'D9J'2!AXU1$T9X(5&BB*[2I<6V,*BKMQ
MA57`.%S@K-WX&TWJPK^0!TA5)3V.$_LJFC!D%IJNZ$J\<4P7SD?"1(ZT53)B
MC<^8Y+(7/AU<#6Z.V1B2Q"_D8J#T`I4R0U@V1CP+2>H3>.H,2%VI7@%VT2?$
MEAZ"?8+[F1.86NQ\[H:84)(XYI"YCQ%0S%QA/#8@P:LAYHK;D47':T+5B&Y,
M19BK@%+/*:3Y,-JUK5S$^&8\?M9H)>8$KN[1@&QRJNLR=TPPZ2"(UQ,[+/9X
MJ!89TS=1+KKP!'Q_!8-34.KJ.TI8=-\FZF=F_1`<OQ\K6Z8`5N`V(0\9HR^?
M@`^QB((3G_\N;5I=5^W)CMIFDS(9;P"3NCT`_Z`;Y]G?SB!PT`<HCG7.CWI5
M1E8Y[\6E.6!LQ1O(J)*RW.AT*G;>I>V`C!<DBH-`""(A&@@X#W6=IG7[?3C'
MS;&\.7W_8?B:_3,$;XL%!7,]Z6@NR;#U;7M\RO'VY;4<%SJ?.OMY!I+0#A!V
M8E.4$%1B+O;4[S!ZJR^UL7`$F#EX7K`S11P7XU>E#E9"FMX8W;`N;<`<L4D1
MF;SK>S,>*V:2HLA@D20PH+V?AC>7GQ[K((%ES"2X&<\V,T@OE9UI'5MGESHX
M.&Z0[V@I/A&!SH3!28+:F@OMX@"B8OR>U\SWYD[VMM%EZEPH?!6H4)!W;9"P
M?D%M+NAC@DCB**!=AQ<;T7+1_ZW`EW&X20^&&L%4!I.&@S;K!*PDTTCS`9UH
ME"1>:`.X,E@B>"@OSB;&(MFE=#6=5,19:STK\[5D3VUW#&G_(JGC2NK?.+^%
M(,%M'9?B?$<%H47==>J#4V#`.]E#15D2^)4Y7*,:`^9SD]JQ2<8"E[`U8,4T
MZB114>1*PU.\#FBBDE-'PP(92.B+*)F,_8SFD=]Q:=/Y$XR+?5*"@L1$"`JD
MJ/N.NQ)N?"HHCTE[@LFJ=6QN_C,$G(P6M3<;>9OAC@,1U*0"+,IM+T!I3,P;
MIYC`X3W146P(L)2Q$H<+[K@?PG6IM.L>B;GG^AQ]JY5(X&,`A54TX%5_]/%U
M%3/B:"@LW5\)M!#(JF41-R[.<EW&E8YA'P@;?8P[9QD^YL*$("+5G-%A1]2V
MB_B-.G5):$4AWFH7'[7I021S_@5R6=>IY?JF*B^WK+PN?'Q,",H,@08`ZX02
M2Z%P#'D.F^DM'4QSQ8-4@8JR!R0?:]I[5:@$T:*P552Q9``I,^>Q`/`>27%T
M>8#L(WBQG$O2G/A6B!)18=%+R9N"HI5.'R([G0)LOJ,+GZ1L5\C,S%6>A*4`
MA?^]=@/D)'G6@"@XS1AVDF!A7`Z29FPFJ]DDI4F8^Y@S"_CB3H4^%DH3Y"JB
MXOG"X\EIBNX1X.>H25:P!166OX72URKGS18*G"1WLH40"CP^\4%`80[VU/%?
M2<*(>5E1VP(SQ6SX_U:"YTJG$Q5<:U*U$!EPGG$`B7QOTBXL<DZ:F5)WB69?
MZC!!"IG,/HG0:7+_K83D`?K,:0C9-SIB[8ZCZ@L@H8=1I:-[6^C8]9G*2O\U
MZ9D4G#3`IPA*+_152`<#;M3FR#O^I"-&A58JVU55B-1'KRNQ9%G==ZUKCI6D
MSL[2)HPOYI",H=+`2(0B.9'0AQV_A=P/DJO&<MQ*R,?H;5-#G[)R#19,2O([
M2]C@(WURSZG)K0$X(5/OFS0.XYZ2HYTS.6'D6_<9?!&$OE;FHO[6:A==F!QS
MC4>A1>\A5!#'Z(1M1\F8F>P172;1O:.<1[=)*'$0#Q[%YX2]9DXD`51&UA+P
M3>P@:=JSG12]-!9&"?YU=J-;;55J]V!"4@Y3%8-A]`04M6P>A2'7UTN.7ZJ)
MUF3:DGH,W49!#3I81(7D+(D^DA%X*!BFHW,L(]2&N#?D:-^IRIJMI3[I^TU+
M+^BFI>9F-RU=20C0EHS*^0L\4*4P=B.4&_H0RK[F9J;_M.!4D#'0.?':5GP5
M+0MC_22T8U>0.:)8K<BR-7E2'L7W,Z4W:"(%CNO/<=_D3E1&G35/@!.'V=09
MUAW+V(%AC@MU5BXKBLC/9&&8KH$.TXY)E)`8?QVN.YEQ)?I$'U%==DS1><D?
M=D8"Q1'=(!1@I8YI&G72:0%0!^JE8R4<5PNYB&O.)(@.;[VP482Z"(W\*;<`
M6RR>HTP80BNAFXH.DF>(!Y3SKWALNIL"6_,H!UA!.I!YYNBDOCV`#95$:8`M
MD'DNIX[O?\A(G9E87EB4#J?'0]+/'*=D]147I),C+*L3O2MHEB\?O""3*UN2
M,H,^FIA@IUI=>K^<OF>=RE!ZIT1\/PX$6^01J^D,!)`O>'F5CWK[%`@32@OO
M@2A)PG/G""9V#O#\EBLPF+&-#&)_6I/DA@'X`A'9!6HD@JE+DV\EE_^ZC3K=
M>F^;D*SW.HD;SZB\45D&(E"D93I")<>(,HCZ4UD3&T,.3-:+1YW@=K`W%_<K
M,`TGU<@NCK<:.4NGWZD0$Q,&_ZB/T*E*3QQ#SEZIH`W@(E>QPCX`XDTVA_IY
MANU#2.^H-^"X>&P0ZO8&:!A2.04C='0.&]..BD=-D\S1TP0R>[1KZ?K:"6&]
M`SB"'Y]D#A=#1_L9*K3T\R#D4'0RJET3S]SG=R?2,T.7_(+@/AJ0LW1C0#0H
MCSKZ4T?$$4=\R1&LDPQ`+7,PG4=FV51^J-7.'2O_'`(-R3ZY$'_13X,\^C1'
MYO&0$.]$&TRR]X'J)T(*+CS7TTWZ)0)+;WAH1KP4T)&2/T`AO\.CK2M]K(VD
M+_^XQX>RNKWT,=9E,K:G>E]/3-5:O79GAW3O[?'(;K>[0[+W]31CK=G:!.TA
MIC'"4A>P]Z7"KHX)-IUYR<FU"`:3\]A1(5/;3=GG0^Z=5C.UC.W(W"\B>WOB
MO='M-)Z,R$T4FL[2J(0/,SI3"1$(`TPT!:83'%N,WZ=V`!CI\[U;T+@O(/:F
M%.`8#E\R$/OR[-U6YL'W%XC#OD)%[\AXHC[0NU.HDL#\%"[K5VFDKU@Y6:1#
MHN.]_CWW+7K,'M^K=L&E_XG;H7Y!P`[7J_<:W7JS:70Z]5:[78QF]D4SO9K1
MI3F-HEEKGY7O'*:^=H<<[`IFG(6O9#.#D-LC/)UX.M0K:P)TO0QPQJ'1JQLM
MXV@+4^[56@8MTRA?*)'#!RQGEI/Z]BYDL,+:#N00UQF7^))/VZ9J^L+U/PF%
M79YA=._P4Z2RR0[[EE&&EB5)&=TG2FH3=K]5N<&GKK$3P2VOM(GDFON5'!X3
M"MTI'4PF%(@@+%'6&J>RIW33-4EAT]&KZ>>#DL>.M-]6`C\4.\U&H_<<*UGT
MEF-(3(V#SQ^N;NE-O[7T1<H'^\!@7YEG-Q,?-R5/\Q^]J_FX;U+36($F88^1
MZMKH9D3]0N/RZ]';XTKX+'G7W.9=`J/=;A-W&Y"Z2YZ:&_!DZ)<<+X]^-"_L
MM!L[80E?E2G6L)2]_KQB:K>;O74L92G9)4O/**5.H]5\&DOIJZP@J2_BJ6C`
M,\NIT>P4,E5$RFZY>D91&:U>L8_8@"OKUU#IXY>1VT]Z_4,NK4OGE-/=C<6Q
M^'SNV>Y""'*MPQ!*.Q@QU,?C-WB(IV0@;H5_)TVAPRY0XTX=?59.@/TQ>U-(
M;4-BTC[J]!YM!Y2&Y-45UBI>TUAR$'\,\]^EC[G%9M)?EYML)_U>J_%=^"]#
M^/MJ"W\W^)<C\WW5(?^Y9AZ71\):K?B>LL`>#<[H'7X%^B5TORP(]_?R4>/9
M(-0/S@BK1-]U\U^#M=%0G<6U#HVZT>BVOEZ_"I98!U&K>[0$T4;4/C\8[4W!
M6)O5;`E&^_!%8M'90C%*C_NVQ,)HMGLO$HSN%HI1>N:W)1A'S1<)1:O>;'7:
M3W08!4NL/14W.IT7"49[4S#6.8PMP6@=ODS%Z&RA&*4.8TLL#I>;H"\$B^X6
M>E'J+[;$PEBNE5X(%N`PND:G^U2/4;#&(W<4O4@TVANCL=9E;(G&"P2BLXU:
ME/N+;T0MNMNH1;G'V+-:.(&TI!WB_?*W^+P_/21PCF_IL82%=S+B$F%`*PPF
MY]S')V<4U-JT25\_A40X[6*ER-<T6[UZI_N$:KE@B4?^%F'/@(JFU<F@N0M^
M7CK8[4W!7N_)M@:[?738:';_R\#N;*'9:[SEUF!W&H?-=N._#.SN%IJ]QAEO
MK]E-R.V-YP4;_WY:U%"CC\][5MSKM7I+_0W:]7&BGO-4WCAL=#8D*G<XG?WE
M>7'K''66.['9S;>E]!G!;#7;1\:FE)[@^[\&D^AH'>\EH\?2BOX@T69#O_]5
MHF_Q71`E;W48?\V?)2(]PH=3A_@4IZ-]Y0[^2-'NGO+=YQ/%](9CT]0/JN+C
MIZ'#0XN>`L?W&F".3Y\4F)FEW]*2O!5#X6/BT5N=<J]YR+RS-7E/5L&K5GAB
MROC`+JSIX8MAHD=P\1TY)KZ^N.P-_4]ZU?Z[?G_XM#^\H?^X1@!(SC.02`?_
M[`2I5)WUB5]@SZ;WS(L%L_Z_O:MM;AM'TG^%Y9NMFJF2%+Z3FMFDRK&=K&\R
MEB]V9NH^7=$297-7)KTDY<3[ZP\-D.*+^`:*A$@;'V+')`!V/^@&&D"CV\.7
MEA&O,&'C(`@1<JF*^%(Q*F9G`X8!R>0.M>MNDXO#F7[`T2KPQ?LHXBMJ'76\
M=1^%H<!1%Y+C)^%G",X3Q]?PP:#`5Y!=?%OXEUUL(41`$EP`DR"L+<=//AQS
M`2&"-F$2/3T&*`J7`-(`*H?:2R0D`F,U$Q:[<,35[>`;W.3R-R'*0<+BN"L<
M,OC9SA.3#@^]N_4=M[S>(DA>;,NGBD<P"KT.[);*'#QXVPWD=8"P#JLHSL8_
MMVXNT$:JZ9H&(_T])8+[U<9Q05!3GR!%BR1.?]]U!_0$1$E&+9VCSL4Y4122
MD`?])`&@H\!W\5BSHR<QB+$&(:OX`?S:4_&>2>@*/-A%E_KOK`T>CX('&R(%
MAOM?32(8(D7`85MV8:IB``IYQE$TT0^`Y<`+_'3&4J&!E9[KP'/;N7<A8P)D
MNLRVAM`K-+M:-<"-L5H5IQY#,K;,U>+V0I"$J7"#S*C+3\BDNKH53L_.%M^N
M;B^O/@O7"P3.Y<5-D7G3(&09CUC6+G<F3<`RGG#S%4H"3[@Y@'1^/.%F<0`Q
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MXA)[0C)FI@9=72@&2O226Q09XT#1T2<I#8H(Z`*+8MG&HH"$I-BY\`E.86#7
MLR]SHI4,M!UWVGT,S*LE,=,A$):]RD$C_'SRY?H&+G7Y1!5Q&:33*[3$P8L9
M-X8S4O3O-NR?PZH#3A*00KLXVQW>6<91N<HWO)8X'3/BTEO^"]P8?.$9IT7]
M:2:*4IJF,+I'"*5Q;'>X3(A6TKN3S]TN!IF"Z&:+$73;S0Y)]"OT'3Q)I@'9
MK3P3S#.O\>G.!IN0:=R\I\PNW6[0MJ,I/)[]XSEBY[!*C)=8AI#(9`YM[/4:
M]G>^QQ,5[%5-X\AKP^V<5JM"X3P%PLJS@XP-:4S4N3D191UWD#&1]/E$5+26
MW43\<G8"4-)(/%N[X$1!ELS1I)U<W%+$:/Z$)LGUP:QS-"%7E<T)>AO]I8GH
M+U5D0GSXX-MMJ>\V8$BKV!W9,")G5O"`JL*O"[1D0*,<&"&GX9GE^X!7D@VZ
M4<F>8^6)LJ1G(M`U(JIOCGN,N0=Y$J7A<6PTX%C<<6S0<*QH.&7(T#@V&_5Q
M+-4F%<>JIJO]<$R2'5U&^Z9HB8)_5S!>7(%A7B)9D26M`1C%A++%A%6BH:FD
M*$V&O4:8).<-T`#VA0/O2%C\8@C*W^^/[15IFNF'^H,R,W?#GDS/7N-QO3/V
M/)>D.;/\A8]W-%=X.(A#`>_8K"G7Y4P=MYD67`@Z#XNEE-#6$]4GMYV-X/US
M2]94IXGW:([+_/M.K:ZB>-5X2,[-RN7D=,E7=_-N[WR1K&[%/)%W,T,2F_63
M/)7E?.D&_&B2H55S0PC)<Q*$BW7D!QC1GWK"</;7YWINHDL30DLULT2`DI*7
MH0.HUAIA71KYG\+2THWNJ-8;85T:0K\YU7)CJ,^C,$W1RW34].)7/2=3SUOY
MQ40<SD./RU%=DJ5#>;CRW&4Y&\G;GGO#4.?S*E820KKBIL\\!^)<5EIR`\%"
M/I([O]<;RR4Q_3]Y/OP1/0_VN:2KU6]?HO%W3[/HZ#L6*#V*A"2J>Q)Q""CY
ME"/XN`:MH>(]9H"@IDQOAD2112ZC=3,J)B<`U%#7![O]6"`E"Q!@5U&.RF\_
MMDM%]^I'9;<?HZ>(70FS*W7$;5$6EIHR/.+WZ_.`X-X,W)N!>S-P;P;NS<"]
M&8[IS5!C>N1L&2SRBW7LI?G5"NV%6WP@1@P;B@H,MSJG9-<PA0(%G6PA87?.
M:8@=0?*)W"DE^U%(EL`$M+`;\F?+<;^@:?4COBUY:_W`B%"49WD8GMLQI*"2
M)1RLY$,SQH`&J_U[4QH#&JS.!::2:++"XYOKVS@^\ZHA($D%IA,,[>"1D,D6
M$7;SBZ9W!$G\?N'>H.D'/#'AUGSX`CNI(<Q*Y)(I@-&LZ+Y@5'B?'"@GG;BB
M]($`,T&0,V+0C+X<^^2R(;)#3C.7CR_(M6+"=W49AF.!H6A98[.&M#YX968E
M*+F![PB\,CO#SQ^''X%75C.\I,GZ`;Q"0/%K',"<\)7\S=*@-U0IUV$)'30$
MLW-M4>==T,M*(10Q=P[>DEY60JT;1C-R\UZ]EVYTQ2.XMEY@ZQS48+E$IL+J
MBV/MDF\`9^VJ,M0*1<_*6#N"CX\7*Z54%=-D"-A7'`(+'WI5PY,49#FDBO.F
MTI/0UR_K[,Q8,S>;=,%[SG.HA/%<*9;K6G6>V_JHI:XOEIEU]'S>,<>7+BH&
ML;]+Q[Q4"8:=*QE&G3:G".N:2V;]:>AR>R[)BY=S)UAN/(A$GW7DJ"K`O3AJ
M#R@[R-LN"U/A\NK/BZO;Q=?F.=J[.RAE>2B[DS:(6[)W<"B37*][H5%P?"`<
M'3DZ$%][$'78<>]_/2(\&<>>R$?&U/[VF_!Q\?7\XNOT;/'ER^GUS<6O..NO
M]138+=Q]OEQ\NMU%S*WS]VG@XG/GA:'W6.3E@V/$1*66.%(Y(7?ZU\7EYW_<
M0M4-4B/7^^Y;3^]/R.]"B`I#HC1KJDE+#0E%H".H7/#]*_I21OA8D#TT`-)J
MUA_5::>M`4KE]>GY^>75YYU7G13[M'34?C04Q,WCG'GP$0%'LOI-Z*8K8>@\
M'H^O!D.)-8_C4X[68Q9])Z9Z3"_\[,\X1?P*YE8_BOWF;0-D002_],E3<:=]
M/#W[_?/7Q;>K\VF4']._O_M9%M6)K&D3]/N7WX1V';NQU^A]9%\8*G'D_6I]
M%QXM"%:(5@GU<<C^UFINR7PY:N.G9E5Q'N&D;N1^+$WDN=K^VS21UP;"L6S,
M^^"WJ0Q^?W!"^Q#!PV7^\OQ_@7[A4/YV4"!O;;%NU4D8:8+NW.SP6T=B8MK9
MEXXS,A6-J%#Q$YRQ/4#J/DBW2S<B]S&K[`#LW.A(^E)0=9U&WP_A_57A1J$$
M;5!C-E[N$R?/XCLSMUZ((S='.R#->S9IHG4/X":0K;2]V]AEW5LQT5&VF>I8
M>2)J%(-T%7YME&+4T-'9#FU8;W&E:LC!J)E^:Y.-ZAZ-(+A_<8GK.%4%;58?
MR)?N;M?6,B1Y(TC>^CB+;6%BY.1FT-+".37!!?$WP;<@,<:$),L@S>""43*+
M%4E;69/Q`D,9QZ.?"<3)'F):6[O[2?4II"`*]Q_6BT!V=.5L%HV$Y@!'CB]B
MWPH";^E493#NZ'9)U7E(R=%*;.E\!D/GRL8!1@+;?]X=(]66ZSEX12Y*3@."
M^N1T\&'3=FS`%=4,7^A!OUTEH]FRN*_0I^FH[#7,:/[4M9;(K];W/^+]B@K!
M*2W6<T@0>:X6<U1*4']\'J/C:-F$+8%+]YJD7JO@L[Q<SWHT+U&C<H+ZY'3P
M0U[>J2WKJ=9C1QFR+F9GIU*7LVH:>]0:PS!-F9I&B+`-5V<?O,W*]@.X&!"^
MY`DO+-0SXH9BF&7<%-+3#XM]QK>23%'KAL5T"+7]QWT;`ZI2RD9A[#0:POL,
M)F7J<Z4MX;DX685O^L5=DR5#*B._+.`5/0=]*L!<,N?4''CN_:WM/Y[;=V&>
MA<)7/4N_D;/)BHDXG(<^`R!JN:57$QZ0\0"7U9$I\>RL[-7'EV]HJ7[I?HKS
M29XF63J!K^;%V5Y%E[.]UYQ,=FBP<N"4Q7DN>D/':(`5&H2-T2@HSO2F\3SG
MA]Z<3'9H,'/NU?)!4CM&8Y?ML!D:!<79ACDQ]29H%)#)#@UV-]#U>6X_Z``X
M+EW(UPTWEV..DR=,NYC<:LSPE%!"2S:[VS.&+NV)9GNZ65UQG&IJ;M/G(+*9
M!>@PS5QL^H/(5F:JJIDS=:X9M9B7BGA!$TP%O2$+5>).RP*5T.\&H1PG!<]9
MCC>RF-L,**#G$$98CD"&TB<G[,8D'%FE/T;8C5)&+BM"/2-P))M<KX2MXO16
M3?GK?E?;BIR[)5E.2'?\]+CR5DS%:,7/M?6"\SU!G'/8S+=7P2<D,KAZV<*"
ML@[#P2^W#4=)Z#&081:J0I:[AV:QQEO+D#4'CEG.L.M"&H>B`C-#G#<2!SDC
M#O)4GN>KUM^7-<5"KHOH*F;QUCM=_GOK^'8F[-&IN\H&<6I>G.5U85,R"MFO
MIY(=&,P"'^53A;8&PW8#DE$6*\LUDAW?#E%]*(J>P@/[\6GCX>93"26"\CWS
MCMOLV7O`S!VH=4S]&.'N\W3)R.5@.Q[<45N0&-)W[K8DH'(MH$6U6.[-J\W1
M*R+U6/BPLPQ8XY..H$91GJ7,2!0C7)9*EG"PBW.F=01'RM0\@YN,=QY:/GI^
MI"5E;Y'=5\\JXDR2]WL^5[625>WD@[Z7\K*4JFY8`\F41=.489]*:B_;16U4
M,:IUP&=L/R_6J4R:>_P6EF*T"A"1+FOY@&"UQ)5S7!`"==_\;5Y^?T@;>%S;
M?K%@=T!=)@XU-%:``7*S(#DF+G[8_M()HG#/M:58K@C%N5[.>Q%Q?7',K*MU
M91@,PR@_%XV9HFE:^YXN:J,F^:,Q!/[1FM&8R9*LJH1X^*\\0W.0486#)*9Q
M0"*`<,`MB55MU;A*'HI'\<@0WTJH*M#SLES7<PDQJFCIEJU>G2OEG'=B<[:^
M1I>](/-?<M4K;6]7EF"YX#",W%Y=)65=L\EL-#;U7&<R99-9\A$E%XR;*9>L
M3@/G.*]P6RYQ(,X@8HC\P5#?%$7/79F)B6A&)RN%T<7<]A4=F<P"BQL'D<DL
M2+ZDR`W()(L`;`U<^\[2CC.O8;++7L[0P-9L<D=K6#E?.DMY24I?9.IH">UE
MA.1X00NZU19*[JYN1>?`MW`NG`V.VK0P#Y2:A"C@43%Y5$P>%;--/)K!2.6K
MB>C(HV+RJ)@\*B:/BIEM9V`Q(GE4S([XY5$Q>53,H8Q,/"HFCXK)HV+RJ)@\
M*B:/BDD3J;)EU,*F&Y6YO5#8'OUH!?8*0C':;F#!/B#9^2Q\Q?!`0A?UK(]=
M,46',\3JY`)?W6/`CS933!W]4-7:7BH]Y]AOH?*P8RZR8$TR#+DY;VJ&-QU[
M2D`#1V3NU/<M]Y[XA+XD1:)[%Z??+7^%?_Q)+AM=H^'"6TD5D+1K<&:(QDR6
M)8V@`)=B9I(BS2E$Q0"_!0/[EY0U].%:_=\ZT-K1/UZHT?]TJ1.L<RU]N%8X
MV'V-?1Q<`+>WT7?P\)((@9=N$/I;<ED2?/QO'RPW<HW[C)H(@TN7?/8PZ"D_
MQF8L3T^00'60\RB7I$9S9/?LO[T>[FT*J>MC==Q=?+6%4]W%FO!VN@T?/!^"
MY!_6EV6M(K#U9FJ9]H,QII*.:QZ@B5I7W53&6D%_!(MM"-<CP.$BP3/]%+ON
M2J*B5(2O*7'W+:A5@\%<475)4:4<"&EZVC(A-V8BZ]Q+SX2IZ8HH:48/3!B-
MF1!W3!CMF)!DU50-N0<F3(J>B,7);-D3VMS4)(J>*`Z)S#K.LXKLK>Q04!/U
MF(;N'OW;I[(N&D9OE!L-*,_*?7/*P9U2Z8URLQ'F:6&GH-Q0M/XH[V?LKPMV
MTZV\]S'P[_O)ZSW*?1^C_CX'4H_RW\>0S[(/I!FR3.C58+]238P?9=[?^"DW
MY2&K")0\J)HIJ3WJ0D,>LJI`R8.LBFI_/)C-^R&M#-3]H,M:G_I0'=*R3"&H
M`W$J1BZ`1<<JT9"-G$Y0LR'->[6,FK*14PM:-A1-5?OK#9.B-S*:0<L&6J#I
MA^KWE1?:!8GF2K@K*<UOGW1_/H_:"D+?<^_ASZO%[86@"%/AYG9Q]KMP^_7T
MZN;T[/9R<76#C^.3DKG3_*>,8\+EU?D%$#&5I9FL@:]T43I*0YS-J=-1EOH3
M9*[C1+=G;A?7^),M+M[$;A0B.`C7W+L1OCNK\.']";((_];D$D[H/14Y$T7>
MG^I\IM-XK435(JA/XLY)NBI*&)GKN\*V]G)[+ESADWWG;RW_19#EHIR63A!L
M(<&FNP(?KY6@321#FZ#10@CP[@&DR20!5H0H2(R+"J,1!VG[=]\)0]L5GK9W
M&V>)2JYMG`G3"@5+>(*K;7%:T5T)X2>X"R<\V3YI?R;<HM>N'8)[*K[/'U>)
M"<2)0''2SA\.^$QO7H2?9&VBF":F\F>HB]K=$412<3X^(L9P%"_@S(EBQ40Y
M.E'Q7(/2Q#!%:.^761LG&ZXUK+4F+>D[Q^MR';JKUZ'X:66NW'.2ZA7DTW5<
M6T!J$3X$@HV$;R5D[J15J!J"(L3Y9S$1<<9:09I(FCZ13+4^96^Y:J()U86T
MM^@923_[`%ET240,+/>'?]PCIQ_"W0L2"3^TT%>1YB-E]XFRD0B&MKW+NAOQ
M3U0]!L/'$8X!COM[W[Y'>B@LK>`A&0;L?V\1G6@PR*EJAFY$MF+@<:"6[`)P
M<+KA&)U@EFF9#P.O<!A8=C0,?/(V&^\[C`20+SNC2%3II6L_E!U``C`FD<H@
MW?'N7><_T527.*61Z0U).D["#4^0_J"Y=NWYCS#_3>\LG$T;SLW01/N`)FH\
MO=[#22:<,:;-!;1\@NI4.CX!'VRD5!"&6O">T5"(!IP'W[:G+[;E`REP+`W3
MLXW31PG;)R"R*O%X%MY]2&LQG`FI43M`T+G$W`D?''\EH%$&8>H#'_LC-@#M
MK[!Y%*<9)S?5T*<?O:T;%I@2RF0N8E-"6$-:=51TN7W<0G<\VS$`L-3!KU8P
M[J$V<`?P`>C5#T"K9@,0,MO_>XN$2=(+[(B4FGSTD"*#_)P[2%1QS$JB.?8*
MU\!B!>^EB18)96(ZH%\ALM%![S-6!-)Y!QO)*7W?#0+@`I%H_TQ8K,DLFFJ,
M?&$")D7TS6B,B#Z-1YS(%LK:^BG.7.L1O49S\W*+%2=##1Y=$#623JR$2:S%
M"#+'79)HID$\_JR]K9\>?B:%XT]&$R?X,Q`X)-C>_1,AB^T005:GV.`38#-C
MNGVJ;!!U!%KR8+V(@O+C;R#,+E'AE4.&"_R=;8AT(42%-Y@!8K2!=SRQV,X>
MP`<"7N#PO1[BUPH([(CG1X2EL++7R!Q=Q97W\91%48_Z]]*%&[H`*L3APFTA
ML,&"1?_?;'*]52$HV3XL[3'4$&H5,)A$XZZ=`S`N`]PX+@)FDL8]ECW[Q](F
MIB>Q)%$WH\>`J]I8MG.REQ/GW&26E36YB:SMS74-A"UK%X.HP%1"<%I;CB^@
M>7!KQ[2E%0VS5-0D\':WMVHV)QI9Y-*L<=O>\VBZ)UBP\7B)^X=,VL2WBC@R
MD.>?/!]-%L](MH)D][%Q%;R/6',\UV0CDMX]8]_CB8IP"IS0[(I?-<!G5_1X
MN&B247!P4TMP_WBH3?&HNG5#CX>:#^_<.1Y5-UKHZ[&*D%KLSZOIDJDVQ*K1
MA9C*!DKCJ-)7.^)`1`=:?6A5EI@=22DAO;VJC1&R(\7O+031E,TQ0CB>`:XU
M:G^"B4EE7Q778#.J%41';S!A%E/,'IYJ=YA&^5WI?&-,M<`78[CX=.8@4(=*
M@6M']Z@T,CZS)8^D1(VL\"RE?</`8+;?=T<?'@SLQPQ(O5+@I'QL(-2&0%1F
MEJ8#0M2*_&R/#02SZ/9[*7@&P3Z[=#/:O-%BO"W[U'9J>:W!FUX'6J?=0G6,
MF66D4!W!8I64YF/NH+`ZP@25CSXT%JB8&?KY1$JC08A=IJUNM6U[%]C_WD("
M$3C##'+.XF5ON7,X"^=P%9S#OWV\N?B?;Q=7M\+%G^AG*]]PT7&+'4O$F0:O
M.@HS5P9%]"FCQ;<B;Z#%,O3`5Q,.>:^\9^*XV<!I4U`FIFQ6>$?7N6#&_I/@
MFK7UEP_@R%39YMT+]C^*3JD+O2K+G"@;D`-_QR3AX_&?M(ED&K..XOV5J7MV
MS/C+AL")]NKTV49?L#,Q'5+WUS]:@;.$)$7.9AM&(VN[JOU-0(61'D1U+JER
M*M)#.ZJ/#UI/<U)A/`-5T1!HXOA!ZRF94Z&D27-YKJ:/JL8*6D^II4HB9YB:
M81C=@/;CSM\XO\(G,0#Q)_'+W>M'VP(WF`_D+S+P__U=]AUN[5W27$GSYR5-
M7]XLT)!C_(I*M&OY&A6M)!M-7W:KIB_<T`E?2MI^VOSXE11HU38$;+(V&YBE
M*CZ0*M7J*W^`'V!%^_A]2]CC'&+9UM'4ZJSLZ%FF&I).&R?\WKVDE05<XUU5
MBZG/G=NNA]WTJCY8)]?Y+^XW&K]-\5V&730V8/@./,/.8FYC,<R#@,A!S]<.
MW&&#K-MV)B]W8"]G]][SN[/+WT\^H'65)(JZ;$HQ[4GE?+.!?;_+5)UZL4)D
M_`!74B?\@QBI*V32NG"Y[?U)/%Z1%=FENT*6W>K6PXNWV/&._#S]X02[5.*X
MV1W5\&><2UQ_1UZ>$#6,;$[RX;^_*Z2G%<$YN_#VY<EN12%A/%Z)-J,S[HHL
MX/'33)]'7?.41'A+=Q@LW\Z1T?TAD;==V[MWN4HVFBV2*B"4R8=7J0KQT]2G
MXT>1N-=K0+E)H2HFQ+K1=X;L6`4?5D&>BVHOUC@\W^()!BXT-9]Y`4XQ3&YM
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M@?4ITT,-W/<(=7-?W9&JZTV($,/;]/@`;+?<I-\BVPT`JU7DY7=M.:M+]\QZ
M<D)K<UPEE@:WKBF7K+W(Q5RT=@=,$./&7L7;O%RFFLH4/\FD%+3!GF2.2.KX
M*=1;.X4:E7#R4ZC&0C>D4Z@QR1@_A:*:=@=]"C4FN=N/H3-2P>O991-)VA62
M:RH'3BY?2+Y,$]_IEL8N7[LUZLW2=BV$53N;+*J\<+D,T<B0S&5H3X9NOWM<
MAAK*T'YHB;&+4&=;9>1N+,61)!>GT1^?#`SJJHN'?$/R=6Q(2O2'[-+QI(YO
M2+ZI#<FQ"2??D&PL=(/9D!R9C/$-2:II=[@;DN.2NU%;UH.$NGE@O)%J^%MP
M3)+HUVS'E"SNF#0"QZ21R13?!W@M^P`CDCJ^#_#6]@%&)9Q\'V"4^P!CDC&^
M#_!Z]@%&)'?\P';@![;C$J>Q;RL-"VK4MI2]6HBA-L2Q0QTS-H"S<2N8>NM=
MK$V$K#X71XBN`X%AT9B3,+)K/'K3(5"QQDM\=W/HNYL9N<@H4-]RP?<FA[DW
M>32)D$43_9[/YV.7B#-OL['N/++@2`7^"(CS^K+D-4[48BW)=DR;I?7UVOF/
M[5^B#_A/N'G/?4.B(W+1.4!T?$@#X_SXZ'BW:%%N/=G;T%D&;U&6^(IW>"O>
MHPG#J,W\WH$RII*.5IO83XE''N.1Q\84>2RK*2#)S#5EY//+@'1DG$(A3V5Y
M9DBCWT["C/0&E`1;@8J$)F29;R>-:#LIZC=6<L&WDP:_G<16(O@Z;M#K.+;"
M,.+YM7^@X@6OR>?74<VO_:[O<W+!Y]<1S*\L)8+/KP.?7UD*PZCGUWZ!$G>&
MB,'GUQ'-KV+/=E=.+OC\.OCYE:U$\/EUT/,K6V$8\?S:"5`;Q_W7KVO/"UTO
MM+^@/X0?^%$(IU'O3\23^.^7)_0GJF:[*WL5/_6]31:`M'@I[^#U.RBX@Q;7
MVGC+3*OH;\CC'C?ZX-OK]R?_E;G/D@]+%9?=6'?VYOU)9=G_0^V?".\R),0<
M9^CP[<#;^DN;KO&[#0T:\8>Q>J(ON/<(57?Z[>;DPZ6+[ZH%0@#'AM,[.#<4
MEJF#'$&614$D/__^+L-'(7.G?A9GRU_&I*+_UE`;E7BWMI;A-$4U^8+O/39"
M/?J\UPA%SU_9_OL3";KW722R>_(Y-K%5*<16[5-L52ZVQ6);@'JYV!:@^"K%
M5J,06ZU/L=6XV!:+;0'JY6);@.*K%%N=0FSU/L56YV);++8%J)>+;0&*S<5V
MX*);&;^BQMZEJGNH:%-^C*&H2Q-9-82Y+"@3?2X*BFH.0>);=$ZB`2W`?A4#
M>1W?568T5=V^M>%X9O8XM:'2^FX!]IO0ABKKG*INW]IP/.M]G-I0:=2W`/M-
M:$.5T4]5MV]M.-ZB8)S:4+E6:`'VJUD[U`3AJ5D]4-8^5"NH/\=0+TQ5%"3)
M$.2)I&F"8LIYB3B*7K3JH$0S6@'^*F:*>LZKUA&4M?O7B^.M)<:J%Y6KB5:`
MOQ&]J%I14-;N7R^.MZH8JUY4KBM:`?Y&]*)J;4%9NW^].-[Z8JQZ4;G":`7X
MJ]`+$J=XL0W!I0ANLN.H#?N.<UD!;5CK4#UH_)G.Y)^XQ0G8+VXB_(0:%R7A
MR?*%9VNSM7\33K?A@^<[_T%:,16L0/#6PHW]%!+'/46<"'";5T#$[C^64`U)
M$R>BB/\1#0MF0]`>JNY,M(:J>UZ'MH!<X'S,J_.MCSB^QDYW!(@K^SM^%>!E
M5ZT*'=#4P7IUT+>YLAVF;`=W?$H##^[(UZ&6!0.1W&H2*ZC5QR16^!FN5YU/
M8J7=63V)E7;/J]E6+N+::*4Q!;7ZT)C"SW"-Z5QC2KNS6F-*N^=US"]-IUFU
M.[.OH"EF9E_AM[FRL3'[2CN^A=E7VI&O7RW3F9DN?MC^T@GLU>$J2M%LK^I*
M10=7W?Y4EUH@&JHQ=0>_794^<+.%HMFCJ#3?A!F(2A^Z(4/=P<U5>O@+SBI@
MR/-/GG]C^\_.LHL=U(9-]JK0C6G@RMR?,E,)0D-%INI8NCVCP>MQP>+?;+5Q
M5%"KCXVCPL]PA>M\XZBT.ZLWCDJ[IZG:D%@7Z#__#U!+`P04````"`#3@&=!
MQ:``VE<+``!*?@``%``<`'!L>"TR,#$R,#DS,%]C86PN>&UL550)``->S9I0
M7LV:4'5X"P`!!"4.```$.0$``-5=6W/B.!9^WZK]#][,R_0#%W.GJ[.S!$B&
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M]\;JW6ZWXOWU,)3CJ(%P4[WRY]?'N;E&&Z.$B4#01/`MCC]S[^(C-0W'@SWT
M];!4]<I!W=@1XE,I&%82ETJ`8%TOOW(K$/%$F>A);@!E3=OCS*B-9FBEB9_?
M9J-XD,6`RAP_$;S"ID&<GFE2ESA`GRFUL8D1'R#'P#8'8;P[KQE:W=Z`X4J!
M?82HOX@+W-A:P3!GMP6J<;S9V@!:);5H(_*,B$-9(D$P><Y<D+F[Y.@O%X09
M"HF2P.(B!>+$F@QQP5G+M=%D]1WAI[6#K!ZL;.,)C=W-$K'):KXV&.(3U_'<
M`GSQ&T?6@O8-VW1MPT%#@Q&XRA\IYU/$O.&):.#HF>OK4//'@AF$&Z98=$GP
M=YPKP@]$E<.(*EPJ<FO$46XD.>LPU6M5<I%>E23>SYT<5;97E6QA+&U9$CLU
MA2R6%D1P.7,R]RFQ$`''"+]P@,8"QVC=&;9(`^9KA*1H99I+?A7!Y@[\NQ%D
MGZPF6_#VLNO/-'GFGNB\A)-5?VV0)\1'Q(LL:VI;D'@._W*QL^L;6PQW&Z"5
MX"*16B&@`LJS"E,809PU<F#!V9+Z9+[D+[*F;_#UO4U?Y$ACKK(6<$!-5XC2
M(]80_)&S&Y$591N/R!(B60B3#UQI*6Q,)6QL^BD93/$(GX/QV+'A"XTJW%8K
M:0/,39MRER'X,!K_,1PO)K/1<*[]ZB=)GX*)A%:I$^Z]E.C508"*M:\V`CEM
M:OJC;&.)[-L;N/#?X%:[,7+*NM[0VV6]46X=HQ.NYE8&7WIUC<M+3X:Q]4K`
M"K(='ESQ@"Q5=;]"^L6_?#35L;RVJ-(H"V"5$WAFO'P%*S-LV!SN.%G-$$?L
M&7%0H]ZMJ5<C5@`IY4*LZ;%`SQ6C&RF[.#05&I2!"_1:$%"QOWB%1_!IRS`0
MRMG=WL`'EX/@="N$^[E2#&:></.XRO5'5+B[V?N$$H9E>`P'C$EFY^^4_1B1
M*:-0-9VHUJ@UU!LZ7H*/L+0D'KZI:T4R]3TFF$-=_$"I=<KB3D>]J>,E^`A3
M2^+AF[J>#U-_J41%1?EXJ5=K;^.E-A\]C$?WHWYOO-!Z_?[DVW@Q&C]HT\GC
MJ.\%T:"=HM&5%C14-+^CHNU;*N)/^Z:*%NJJ"%`LS:':H;&B!9T5[5?16_FD
M0?ZP_^*G5,'ZH[M`B5."&%$&V'9%:O56HK+>KG?JRI9F0FG2)Q:R%K@S.#:%
MTFUUJ5(B6;+P3.^W>>"\TL-8H.0D4LDXL'K6_USNB&H$U`7_=EW67):J`/Q)
M"&V^<I_W!<2J%PX/!2W\WI^,!\/Q?#@0O\TA!`YZ"_APUWOLC?M#;?[[<+B8
M)PA0\DVTQ*&DQSE\O>\R47B7FYVVNFS]:*KT44!T6'K$$C]$I^C9L$47H>?T
M#<9VP+@_#-M%Y5:SV5*FB90(62S:"]8)5F1B2`KDR/V,C,^0B4"SI8T@S3X@
MTFBJ<];G9KZB<64!R)=+/6O3B;-&[*<^/*207M?;ZCI#\1-?T:"2VN>K9BQL
MBS(;F\5JZ%NI40`K[54%'3M5Q3$^.\.<2GMPBW&&*U!L$P^W"&1RB,`OSA3R
MN;U6]Y2)#_YU/J;$]/5L=YOJUE9B<:YAYW=A5*"8.&5TBYBS$TIY3^\@D=N*
M>L+S.(U65YW=STU]#1-+JUZ@D/B(C26VL8/1P4?I>JNEKD%^.F'Z$BM(.:?&
M3F0H"V98*)1QJF/BF8FS(**44=[FW1=`*%"X>:.1EX?^U*BA+NT^,_%'FS4.
MA`)%#HB0".2W9@AR5/?`T7:KK:XVCI[SZL:\K'HQ0T8HFP'EN]UK1(V$:9T,
M%<-)6:NESK_$3ILQ(<^:)8:3T1@4*&H\4O*T0&PS0$LG#$"MUE'(R\A)/\*<
M$NH7*%9,$1%GDR#)]@+?E'*'(0<SY.\9%!?09FO3G;@0*KIX#&[U3J>IKC#)
M5MJ/H(]*P(L9VP"L=E5=+`C-E+&](P0_.(F+K,BGP\]:^:B,K4#>,:0)+$WO
M',[1GG0!0EU=4GUI^O1Y690JK59+72&?4GAY/LK:)R#I!02*OCR3PA&WL@NT
M6/MTL\'>SA*A?9]ZN_80$6>ORJV.PF[&F8FS(+G46CT\^9<#(5_T?N]VF[K<
M=IOY`GY\'8X7<VURKTVFPUEO,8(![]UX<_Z06.(=.`],[`QE%/*^LEZM-]6U
MB$,SI0\E?ED+;J/9;*M+_8-ILEA1YQ$.EE*D8OE:.)<W53P8F'A;C4&/6K7;
MBMK-%762ZN3;U\/]K-R%BD?<V_[OL:C<UML*]Y^%I[J>I6(UC"Q$2_DTTQ@Y
M(P(.'@FVE?5:6V&7_&BN]"[7#S+D*2QXO:IP&T?$C%G0[!+V!Y=P0>$">>5[
MRD`^LB^,S5WHM0["Y0G-[M`*QBR,5UAYU:JZ[;<))+FFK=,"E,_(<`$4N94<
M0!/GE0M$?W$:#L:N!Q`T;+H]G$Q_P@0A!D`,7[<BP18[/2#N1_KBR'PEP8VS
M8',RPZ75.I+3.8VC#X@`)#;HU;,VXA2D(P!Z1KYJ0-A:1YTSNS#[]4V>!(XB
MI4L!E4&Q$)L/6C5K774'"\_.G86)W^>=WJ[VRQ`5R'$_0!SV>DHSA#=+E_%]
MQV._;1U9D]`&=J]@B^I:1#KN!#?.CXG3HI$SA_[>QEL[3>.MWYO_KMT_3KYG
MVG@[><].XKY;]*&I*9""6N#R&3(X&J#]SW*KJ7"S0Q))TE>1P]4*F5"_#U]-
M[ZU+,P!S0J+G+G?:NKK@G422+'S`^RP=^("T^!7(Z8N32*`(E!S/&!;1W4Z\
MRV!$Q.$7+C*A'M1ES_Y#HYK*)Z'R@N2''RG!RV<=FX0>AT3Y6,.VN@<9\H+D
MGAZ7P"O0'I\8#>\Q,8AYHF%#7?=27I#<T^,2>`4Z?C@UO"UN?$%[)N#$4.RQ
M'RBSVVUUZ9:\(!GU0=/'U,,NPG381:8>.6TT!"J*<WWBS6G(XO<`HO=T,!*L
MNLK]2PFER1U1TJ!8I+946+FY(5[/=69%-)I5I8<G927)#TM2HE>@7#6LXHAS
M5[PJ9[(2VZ4H\798>2_K\YL_O%S3JY$1)[*%E>S>"JTNEUI%63TA)`6J88^X
M+;2:>.+PX2MB)@;8!*.;"L\L7)H_EWRXC%2!UK[W$K([P^L>;@2;O1N6]5:M
MH:ZI%3VI0F/+E=V'_<^7,?$MW"J`A0=HRY")]Y!M*'/PW_O?B>6];&"TV1J8
M>?%+N#'IAQ/R]\V-85-"X1N[70!CGSU"Y9^8.CQMJW<ZZG9^)Y`D-_Q(BYY/
MD$X!"/*VRS(BI^],*^O53E/=HVH9$7)#B<1X^5SH%J$R/%4N]'\Q@%;=NKI]
MN6?GSK'YXQ`*TOYJ,0W_YE4?(B*:)G.1=73ZJ=I1N`,XG5`YIDIB3`,.%:%V
MO+P7]1L!'&S\-Q1'W6Y+G2=)(DENV)(6OD(U'B72*7$,C^&EZU73(JE2>$XJ
ML3RY8<O[D(Q\\)53SIQZT3?OB/&2+77/0R_.GQM.)$/*YT"S`)$EWZ>.KF':
M>`0*U%P.XMB$1#PV"3TSJ>I==;F!G!"Y,7P*S(JR;=;_@_A'_-?A<.7_4$L#
M!!0````(`-.`9T&$4J51M!```';F```4`!P`<&QX+3(P,3(P.3,P7V1E9BYX
M;6Q55`D``U[-FE!>S9I0=7@+``$$)0X```0Y`0``[5U;=^JX%7[O6OT/-//0
M]@&"N7/6I"V'D#.LY@`3R%R>NAQ;!'>,1"TYE_GUE>0+$&PC&\DH9_*2!,=(
M^_+MK:VM+>G[?[ZLW<H3\+"#X-6%4:M?5`"TD.W`QZN+^WEU,!^.QQ<53$QH
MFRZ"X.H"HHM__N//?_K^+]7JK/G+Y[O;:C7\&+93:=6,6L.HQ,]7A&P^75X^
M/S_7-LV7!\^M66@=_W?C(=NW@%VAWVS4C4;5,*KU=N5?%:/QJ=FKS+X&;[H.
M_.T3^_%@8E"A9$/\:>.^7%WLMNXA8KK."VO_DK55[S<I1\'+K&.;Q.]S.I#W
M2-^KMR^#?\:OLG[V6GYN\G>-?K]_R?\;OXJ=I!=IH\;E+U]OY]8*K,VJ`YD$
M+4"_A9U/F#^\199)N-AWOKY+5?,R9C?U#?:I&KU698^J5()-H_:"[8C$`V:2
M.[F@4JY4`CE[R`5W8%EAO^_OQNE"9B]<SIU'Z"P=RX1D8%G(AX3"9X9<QW(`
MO@;$=%Q,B>$MKSRPO+J@BJM&^F&D?L<>8'-C1Z^1UPV%&G;6&Y<*[;(P:6/X
M!"!!7BY"'/@DG9"Y_X#!_WQ*S(A1E$<L/E!`3JK*`&:8M7T73)<_`^=Q18`]
MH)9M/H*)OWX`WG0Y7YD>P%.?<+=`OWB/@;U`0].U?-<D8&1ZD#[%MPCC&?#X
MZ[E@0`SI_!)D_;;P3(A-BQE='OD34J+X*5#%9(04FHJ8C1#E2A+3CJ?:5@6-
MM%20\-^O8E#9E$K9PGQP14%,&@I1+$P(P[)T,`\1M`&DCI'^@:EH;.H8[<^F
MR\*`^0H`(5A9U@,NA;`YH3_7#.S3Y71#O;VH_5D6ENZ)LBF<+H<K$SX"/(9\
M9%DAUZ:!Y^A_OD->A^;&H:U=@R7#(A2R$,H"T)F%&7T#DA4@U.!<07ZDF_Q1
MU`Q-O+IQT;,8:*RE;`*OD>4S4@;0'E%_1%['<(F\-0>R`$DV<.`9+:V`CI&`
MCDW/BD@._]RE.IX'.)!<VL[Z,GSGTG3?T)`R>8CF36SBT>:T[7Q3.E40D4%A
MPO:_+)VV%6W0L_P'4*5/J<X/0"=,:$9+TJF.>ZC::&TZ14E.:T8^O;SYZAJP
M>4A18I/:4"E9L#1]EYPNVOUVTBFF+SK085[EEGZ,7G>(2]]OU8VZ4:E6KAUL
MN0C['J`?*O/QE\GX9CP<3!:5P7`XO9\LQI,OE=GT=CP<C^:5OX63I;]'G3,6
M)>8$`E[`"P'47]I!'B+BQD56^)9K/@#WZH(^^,^`MF8[KD^<)S`'EN]1=@&>
MF&MPS;5;:[?[M6ZMDRAT+O"EB1^XU'U<?33-#<\670*7X.@)][G5NA$F4[X+
M'Q_M>Y\IER5YD!=I*),K/OV9;OAX0$>Q.X")YUALR.#S[:\<L;5&I]'L'C*7
M-$J(M2A$\!94`R\B?>FA=3%]$%208^31.(GG*>L7E8WGT#B?O%Y=T`\^IL0C
MWM1V``VML:!C"01"7Q'27K(,1B^6ZU-0WU!9#=%ZXQ,^WD^748XDRH]\?DUN
M8/#BX%J[4Z]URH2S%+*+6X(0GDH52$[[+F(N2J`269JX1)696&:0H(N5]3ZL
M;!\3I0KD75E9KZ"5]7:LK*'0RI+B15$S&R*7?D)L<OH$!I['DA5\SDI'Z0F"
M5LJ_=W.WX>#=[[=416+2B"QN0K,P[OWLH,6*SN4W@.K>PF/:N;=!P=P^BF+J
MO7Y=,&X3;U:"G2C3=605Q82D<:@W6SJ_`R^-?D-4R6FMO`N=BHA`F9,[7842
M!,0'@GY?62`JB<3BSDTNB/25DDY6EP2JR.84Z$/O8%^F/!7%L=^8D>HK)2V-
M-&$*H$`?FL\5YA:`)J7J'N(-L)RE`^QPMM-JMYNJ@O_47D_(OX9-+I[1-I;I
M-41SK6^_+0&KXJ*-,ZI9/&@<4D=T3R'8H3L!/9FRC[]]5MDG\J!Q+!RO2$<,
M</_6ZK<-54%;8H^G&VZ*JE0Q<9('.@(^(96\!5X6_WI'>AG\*@I)RH6@*B;.
M`\&$L$>$?]WCF*-%C=R?MVMML3'I:'.GK!2GZN:`N'.;RQ&4%1#Z=O4X6PJJ
M7-[1"AU=%K,48>'<BUGJ$%6*0E2Y06FPE#E#5@3!,M,NZN`F7=`AM)K:0BM3
M6K<.!&/JT3%?0VC4^J>/LW&3)XRUH@J60*YX6'`"*#/$'(^LN7C>&V>#`L9/
MK+H0V%<7Q//!]B&"!+R0D<MA?'6!P2/[0RI4#PJ0E4!3,"VA&)KQ?CS_`=-A
MQV2;7CB!HGF3I`;*AE]"(N487QKG4F8>L@"P<1`K1/X;>;AFM)K=A/5_.>-A
M:K<::%-()*I&+@DJ_>JX`!,$P<Q\9>Z*<YI0U))H86^_K($^LO@)U=#24`UI
MP1*%U](A//ZF<3B="1+SD0]/_;:@CG*UK($""TLBU&Y;2^VNUPCR>O"9Z4T]
M/K>W?S)='T2SJUJGU^VIJR4[VK\6FL\CI5#='0W5?>)$>[!FLJNU>T:GW&T>
M.2G4`#*R)1V"JGL>4'U_^49D5`*_">]]:AWN?9K??YZ/?KP?31:5T4_T9\'-
M3MF'>^3>WQ1LB1G3MU_8P1ICC/UX>W#PD\_[F^UV6]7JEA@)Q><N6>TO:&OA
MZ@%EL7,.%K<D2+#A@NJ,3#BWJ/1>Z\LC#47K9CJ!^PPLG@W<"0N'N46E^2IB
M'GX4A2X259_(XFB]<=$KB(M<C$9+=#J\_U7%Z,L0=X2^=%9TKI7:CS9VV&RS
M;>.J"N[2>CW538Y>Z&35P;LZ$$VP)C4@(^86%O"^%TOG1..,Y1MFMU,*RFOG
M<%%#"9@DY,+?ZHPO4E`6>B6Q(&WI1E0=\5I--N/?R.),IE3*\7@R0,HR-WR,
MLJ_I3)Q.Y`$5;GC:P>YA")$GL6M&I]-4MH,R/SW*$9YV2D1AJ84&T-/0]>ZN
MC*3PT6)A<PF+1MHH.Y=,0MWV-=1M0@P1E`'5ZUUE%<G)?<H;5-\$0N6Q(:^J
M55`M::-KD@3T3K=D<JRJ+KED();'1CE`3"JP%I"`YJF1]$A55=%RT1`]OR&5
MQ$$>0\J'OT1E9(#O#>O:UUKG25,J4J;$K+-$W>863%PCTFB?3=6GK0,V$]8!
M%]/AORN+N\%D/A@NQM-)P87`(\?,YS_I\-GT[-C>FBUEYRCL=72"D^1U\"8_
M\W:]H5HT`Y!N:YL_OV[?"2N0>-];`J`]<TVX<VI2J]=5QK<*@B68<*;>8[>L
M5MAZQ[6'$E)U5)GNEJ$J^GTOEI$4+:L5MN:!]M`U,9XN^6"TS;CT.\K2^8D=
MGF`J\04TO,7/K[S]((QI=>L).T-D;:=-[5<"<(6TLMU/*R*";R.YGRX85<6>
M<N&Z4Y49Y*2#7#6KQ%26NTWI4RE,LPM24UC7>>73C.UKYCG6MH36:'?:"4O0
MDIQ,2J]EJTZ$>XVW`^RN$S#0L6MUILL=/-:,5JNE[!3XH]V7K<Y<\M!X(T`8
MBT5\1ZP,$2:X9C2["O=09?1<NC8%I:!QB?_'6G=NCRQCG?M,A?E_]'7NPKY:
M=(U;Q_J%H[/LS$GV3P"3&.0&A7*CJR[HDDAIZ6Y!D91U+IY(9)D1GU1IK!(B
M>BA[E_-HSE]_-WH3@.K^S<(#GZPH5[_S`:Z9=-O1F;U"&KEZH$62O".@:5D"
M7Y3Q8$5S##'Q_"#")BO@+58F#,?@+[0)@L<P<)A,'G5E,XZRN'@WL#Q!.Q%:
MM4PTG6JF3"*FZW*1W"!O;TRO-1I&1W3_C5)*W@W,\HHUPI:.IY,4%@(W)7XU
M+?%,B_BFNP#>FK,M?+V@W+[?#7Z.BT[CXVQ.X_K:).#&=#Q^Y@3G."'%J@`L
M>_V^+Z"DBBQR*SJFU[-S46F3E(ZA;OMA?H+TRM\=E5F<P&MKAX9KL`2>EPK_
MGQVR&D/;>7)LZ@N#LT4H^P<VP<ZUG"$:W`'B>('A`$CESZHQ%JPXCPW)43.\
MO,-H&LKN5SH74\47F@^:8S3>`3>X0G[E;!9H!`E%3509;AC*]IKDI$6"+6H#
MPLC>BZM#[\JZ\PI:437;'\3:%4GOCV;M"26%Q=6A>;7@QV%3'X=-?1PV]7'8
MU+<&[H_#IKZEPZ:"*Q'`F_.:ZOVZ:+(RJR'%R,QQ$-4Q-G4^ENI8R;JJ/;(G
M5NV?/&Z\^^VB.11WZJY1?3<('^XK4G5]4N[]9/+5E\*L]E<3G7=6J`@06J<F
MY&-/`QW&.)><:I=W3Y*R_8OG*F51M5DTN>`8>$ODK5G)?+#Z$@92S5Y'795Q
M<I\RC*P,,,2UR4=%IW,(RIS0KI`8TY3W.T#]A&,18/,WHK"Z8205G2>O7N=I
M^;WIO+#8--[<5RA=J\@UJ,B>)T^67X#%;WJ8+I>.!;Q08T9/'6_)74JP@%,5
M&,^LC\E$8W\6907PUO0Z1LY\A[QQ2)I&TKDZKT,YY52A>KW-CA&*KB2F?P^G
MD^O19#ZZ9G_-I[?CZ\&"?I@OZ*^O[,*1Z4UE^,-@\F4TKXPGE?D/@[O1#]/;
MZ]'=_*^5T8_WX\6OE;\-![/Q8G!;N1[=C(?CT63X:Y[CB(:(3M`A'T0@1JYC
MF]R7AS1.E\,5&T[P&/*A9(5<.Y[$#\V-0UNCP3J[:09:K_M2RW&$4=@>'5X0
MI+V&X#"ZW81;"B7YI*0>BWO5G4VTD?.H-Y41?]";!,L54T'"IOX#?C5VE@/;
M=H+>9Z9CCV&(X)"%5I+CE)30R>JX=.T)BD'CT.V.G9D&@1W=1161WFHKN_XM
MN<O2=7>4<YWKBJ-A)<S^]-O*+J#?[ZJX8X_;>:.EX%9MRH&Z<SVS>I8Q?<Q6
MQG;B)R8`[9/W,2.W<9$NI5[=05$'W4D`X8ZJ5),M[;**XV(_@-I;-K^-,ZS2
M)*&L&EXF`&F@MQ?[LZKTI$U`$BOY]_I3B,2T;%<JOZJ6!F3MW,%3GV!B0K8F
M0NEN-91-1`ZZ*UE-6=S&6NK*/8-8W<X9OOMG`I[Y?S!#7%V=YD1(.(/1Y9&*
MQD>/9>[SV6.FH6S"(D:#%CK.D$NL9/V<[<#^KX\)7VE9H)0Y=?(B393>#([6
M\SUK1=^8>>C1,]=W@`XXV"%@#KRGX-`]*J$[8*''0`6U=D=EHN(L/)6+PO,K
M3N/3];+<<-H)8^V^LE,4<Y.CA4,3DY;&Y[%]',TG<6`3/YA/OT%N`L@86F@-
M;A&F`W.CVU4V]NQU5:[Z4KG4^6B]#-<3/+Y!7C@6!7&SVOFZ*"E:&.9Q*<4V
M^6[FC[O':^\SU>Z5K?H46K30O8"<8N7W>OHI_VA"7M4].">O2.1=_%?$2/'%
M?T%H"JDFKG4YPK_>NR<%>%9U^4SI<%3$R!GAF+`!\AC_Y]_O>%H-5BMG#=:<
M%6%-9Z.[07CGVXR.'I"L`'$LTY57:H6GR^D&>$&EW%X?A<NJ8B72IMDIB6'[
M\)$=$C^`]NB%)3;`%P#I\W`#1+VCS.WF)^>D@BR1OG8JGXUZMW%FSJ5>@B5!
M^3O57H6%J??H551(BD:"=V`AY^5<"PM)&#1/$>;Y!U05.%%7^JH`)RDUAAA0
M(:UHJ]?@";AHPV.IH(.H[*[94Y8.$^B_/"/(4.^V,C&/O#2N$HX,'MH#>TU%
MAPF3R!/89Z71;"O+=@M1H)7R\\I,X]IBQOMT>4<A#/WM!I2.D71`2N*VFJ0&
MM%+6,0X_2HAEEA`7#3,4L:4HQI12;'R2J#XJD#\JD#\JD+_1"N2!R]\&=DI=
M3N`8:NUN0UE0)D9"R95,><6BY^[9\#G[\4!YH$_^#U!+`P04````"`#3@&=!
MQ+"ENH)'```%_0,`%``<`'!L>"TR,#$R,#DS,%]L86(N>&UL550)``->S9I0
M7LV:4'5X"P`!!"4.```$.0$``.U]:W/;.+KF]ZW:_X#-?NCN*L<1==?4&9Y5
M9#FM.H[D8RGIZ4IM;=$29/.,3&I(RHGGUR\`7B42)``2$)0Y55/3CHC+\Y+/
M>P'P`OBW?__QL@.OT/-MU_GK.^.Z]0Y`9^UN;.?IK^^^+-^/EY/9[!WP`\O9
M6#O7@7]]Y[CO_MW\G__CW_[7^_?WG;]]?+A[_S[Z9]0.Z%X;UVT#)+\_!\'^
M+Q\^?/_^_7K?^?'H[:[7[DOR=.^YF\,:;@"JV6X9[?>&\;[5`_\'&.V_=(;@
M_G-8<F<[?_\+_K]'RX<`P7;\O^"V-L%?WT4=D*9=[^E#N]7J?0@?OHN+XJI)
M20SE>X>4-4:CT0?R-"GJVT4%4:/&A[]]OENNG^&+]=YV\$M90U3+M__BDQ_O
MW+45D#>9J9Y%U?F02$`M@?_U/B[V'O_T'KV4CG']P]_$$'/"%'?R#KTX`,)7
MY[D[^`"W`/_WR\,LJ;VU_$=2\^"_?[*L_0=<X,/.>H2[#]8/V[^!6^NPP^^1
M-//LP>WQ"\\U@#_B![@+?/P+;LU_3[YKRXBD^-\%[09O>\0MWW[9[]`K_5`3
M^/K9<I[@'?X;=]TH>$K;S0JP]:RG%^@$-^[Z@/]+:-6H&*4]R!&&O#,I0ARU
MS`_^5(-&(?H-W'L0:33<T)$?5=UYWFE-K,`CK,!&GR"FM"D!\PWZ/QFX<^TV
MAMV!3R(O.ZIVBKBHM::AWD//=C=3IV',Q<W*`;\,+*]$,\7AYQMN6H"5&UB[
M9J'GFVP:]!PV_+9/&VS\+:.HCMN05+SE7),-@A9XO4$>)^L[)1[N#OT5E<0M
MED1FH5<,@\U,R_!'`)T-W(0!6]*VNXY*D5[^^@[]\/_&Z[5[<`(4H-^[.WMM
M0W_\Z`>>M0ZN.\/>M6%<]T5=+/[EU,-&/Y=T>RS)#H?`KA>_I*/7-/9B>;:>
M^\(M3N"B*M9C616C,QCU!^^`ZVV@A\8S[\`>F2+/#M[^^@X-;0X^0NCN<:1C
M)=_6\M85'RTJ\6'MHGA_'[S?Y:F!BA2*?/+]V-!S,"F/Q(.^>_#(N.1EASK&
M`SGHO/^R?`?L#2L$<SG[-)_=SB;C^0J,)Y/%E_EJ-O\$[A=WL\ELN@3?XAK_
M]]\^I!(RL!=UN[%WA\!^A4NX/J!/@[J?_ECO#HC^MX@6$_=E?PBCT<5V:GD.
M@NDCC[)\MCPX?L'`KWM#I*?2F-X$Q)I*(><M)0K42/,&&F3KK6D-BBE=)9O#
M:F;;`FEC(&X-8**!3'O`W8*X18":!*3-*Q"V>DX%'_RW@O.\I885O#-LM4?_
M"BH>"<JNY`$E@%6GZ2%D<T'>OP\"%^Q1Q\]X9G'MOKP@I?8#=_UWX+@!L)U(
M\6T'D*[1GW?W2_"(!O3H*X+@&0*XW<)U`+Z[A]T&/0`6@OD^QJG4!'Q\*VY@
M_,/VKWO]EJZ.OPSW6:T%UPMMR(24]FFTC-;/;%88A-<\GJB6@!IE?,-E&AD5
MS*T7>..^6+9SW>N-%*M]VKD,W2T1K5P!,Q51L*?Y2)=-@O.HPBD,&I^O`"X)
MOH5E.7D]<7?H7ZYGX4;'GH<7CO!RQ;WG;NV`:!K2N#5>?7F"U^W6<%0T@;/?
M_2#<;8TZ+<)<]`-?T_4H7%>*F-%\[>`(1_,!IIA`LODNA,H\J@4RU4!8+QP3
M@K2F$DT8_!2:D!N?\7\BS0,F,8&4C+>$H)GW6_N?T`/C)P^2TE=@>P@.2`$\
M^`J=`XIS+&<#X(\]=-``RD>MH/`)[-5JQVEBPX6J1R:'0MQ3Z!T*B0G$KA\;
M>A*''(\Q./485L9C[$./D=>*ZV;4PA\[FSGZ+)3'*_27;ZW)Q`@9L(Q&\D8/
M#6&4HWAU7U25/O*VW^ZWNQ>IIV*"GBO2$T)+CP!#7X<:?+^F%Q$9]C>`_S-\
M>80>(FY79PT/49Y=QRDOJT$MCWIH]XW+],>BHEZ`IF?QUM)UD&U5>&($+U$L
M\0K%O>4MO&6`TX*^6KL#C*<@K_O#P5#:&B`#@+KJ*B!AJHF5E0<H#NMV^KI/
MD'#(H6@TR([(G&06TJ[`WO+`*RZ(`UH2W'*.\C[;.XC:<N"]]885B8R`BOQ6
MX3CNM'8]>C)@B<F8*TH&`'K/1U`QRS;4M([-Y`&(GC3%'98I,E7<R1FRXM?1
MOD#NM!49*%KO&0+MPR<@\.RG)^C!35-48II/4L6E_*Q0\:LQ+I!,AKJY'1J`
M/)\X)V?F!QQ/+K;+PZ-O;VS+LZ%/OEZ'U:,5M5"/38R88D(5%L<9L*.^UJ0J
MQ2W;PY5U;H8/P6(+LH^;)!:+NU--K)S;H[^CX842:ZC(_94AB-GERF,7DP=4
M3:^\)Z2_);VG74IQJ_*(92`R%/.SC_DX%BX>SIRUZ^W)!(KKQ+,OZ)L:K/Z1
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M5QH%!ID3DAE7`:@.R%9J)M05H`W3\$MCVA=9;IZO,M)[S49`&E6VG1.7AMQG
M&_=I3/Z"D2'G=]$[=4)`&F5C1VYHW`K`.;Y<KJ%CH2^X<&#*DR'S"FBN>CTZ
MLZ")29LOBU_90._Q(!VT[+B#VK,9/P'HD:`=+?EN+*&".A;E'#_EM>@](TL'
MK<2-4[LWO^R1)8+6^AG<WHQ)(N[TX+E[:#G@,]S8:QLQ;/P$G?4;L/9[SWVU
M=LTSCLE!JZ-<WMU2WI_>$[!TT*J<)Q5!L043=(2K[V[F"[9Y'6%2O1D^E:$Y
MI5-:EIR!I_?(G`Y:E2/,]9S2"#VJ:98*OAN/(Y3/(JHC/'XM`[T'NG302AUA
MKOO0$=[:.[Q[U-V">^3\K,"SURAH?X5^8#^%0?L]:A:??#7]/&Z><%Q^4#[C
MZ'[PY/7I/;JD@U;M!W,(B@V8H!_\XOA[N+:W-MQ$I\QT>[VB<6$SJSC4;IOA
M(X,TIZS,5S'ZO=9E#`RHV%4Y5QJ`A*)7(%-$<`_>TGYR4/VUY03Y`X'OT%AC
M%L"7,`V1/8YC:K,F*45Q)Q1E:X!,(>F]OXY3$NGTY8)C9HJ#M#R(*X!ON`H@
M=9JD]LIZW)'31PI/2^>G-6E/(J5I>)GH'%8F'D[O/0T<4IR5QD=0JBE,BDMD
M+UN4JA%]"^)8QM>M=VH[AQ3*(EUF2*P\Y@V&\>9JC#\.6\AI(]U1KR@%OJ%`
MN*C+FNQFDR*A<V%Q8S#LZ[WWIQ2W=)-;TGDZ+A,Y8X9L]8].R1X[FP?HXXF$
M`&[(7O_T5(QV9\`<#;`T69=S8JA3$K+4-_I#0_.T.CY!Y-.4`XU)2H/XA'94
M'J05PN,T?=%I*SYZ,,V=:D?J_!PKZ]MO:[XIG$\0-7.Q/)"26P>L\W&:+?#5
MCM0%X2_[F]=\:I=+$&5!,`\J+I/-&0SCI0L',>OMQO;7.]<_>#"Y=:L]&,H[
MH;*DXWK4YY(HIGM9)7PT14_O>(0%ONPHA`&#.9M_G<Y7BX<Z=[4E_=S:CNT_
MP\TGU]WX<Q@LMD@KH/>*]TVC#H?RJ4M'T!"%N43,<;FD]JC?NA!&5PJAC-=5
M2,RDY!6(RP)2^`J@XGC).*X@D?%2MF/IQ?A<",Y4N]/M#BZ?\[$82L)O#D!F
MPO@G7$:0X*AI](&[!@E*1U*9C+IJB++%H'/<),60'^SKG<Q<B)>#;92;JGG8
MENG9)#=?`SM^),BK!^O[9PLI@FWM\D:E<!VY8;91`33$01X!<\RD5Q[I?F(R
MLPS*HH0*(-D@`14%2=FF8@0&)L@-$32@.CU`H%8FQ^MVAWK/9?"(H39`J`9D
M8K:_Q&4$R?V'Z_U]YI#=Y'[NXW?;\D[;9T#0$+VY1,SQNZ3VJ*_YL=SL0B@S
MYE5(LM8<E\57V4:EF[+G+'R0:]"UH#S=I)?5QF,3O=>W><10:]*K`9DQY?=A
M(3Z&3U_V._<-)ENKC':7^=3YX[KU:%B)(V;<24&CVVII?B(O!;%L\UG<K1G_
M++@21_M.+,O(*OB2LU#YU]!IZSV:HB!68G>*^S8GT`LL9&(DD8=IO58%>_(K
ML$5:=&GT::D\0;>X^[S9X5PA#9==IS^@M[;]['=CWGY0U$(]%C%BBJE46)R\
M'[WG(DMQR_9B99U'J28@?BIHE<H_(Y-M4LVMO)VBOR>]][Z7XE9EL\I`4$G&
MG>_LKO\^\_T#W-P<\-6G]Q!]BRC3))N($G>TN3;Z_0YQ2\-C"C:5#<T+J(%D
MJ+HOX"@QBK.Q;LO0?+F]AE3LJO(*O4>W5BJ@$,+XPK0PB\HF3>!1*WIQ#B3W
M!8+O=O`,8*QG[A:$GX-S1(N/[H?_."!C,,5CZ+MD:UFOU>K+VUM`Z;6FSC#+
MDB@&K88Q-'3/$:R`+CO4J.C?3)\#4J#.'L3CKL+]-NB;RLN6*NJQ46Y29*#P
M,MIAA%ZLWA.#9;`5\S';=P$7A383GO2`D)&]->@K%FUXD</$J--FR4B5A,;'
MN`)^OYH?1%".7#4KC[O/$Q,7$-N<E>\H.N\`?=2BW=G2Z-G(:1GLTI10-#[P
M8:C[)%0E]C/0]`@`C:A"IV7\`>VGYP!NQBBVMIY@>$_4C;T[)%L)%H?`#RQG
M@R+F\>:_#GX07K<X0+&Q-"8+HJK'\^9>1:P&PBV.VEV]AWLU)9.M0O7@F7%U
M$-4'T?5I40OQCIE,&R!M1+'^25FZOTS]RRV@";>(=YOHO3);5S0E2W(U0:9Z
M:$5ZN,%U[5<(X'8+UR0[AMQB+S;=4@AOL:4!1$3K%)Z!+5'GZ&@DZ!J7Z*4Z
M5M;2J-V^0-6JEN@L/JT2%M67X=MF<V[L*G9QBA1)RNK`92A2;EV`LZ4AR7#0
M?,`O+).B-0%1?'G/M`Z7"/Q0I=Q,9+AUO=!OH=)K:[<^[,A*7R,:ED/XT?+M
M-2;90-XL&!<6*=K%+':%;M':&;4-O>=VA>0YDX,J!<7KGDA=):JCTC5II#JL
M;JFXG<A`ZIT4)"C1>5U2!;I$C]ZS.:1'7%O<'8V_6]XFF3_O%.9=-Z,Q1SW5
MTXART#'?CTNU>WHO/!>@E6WF\UV:Y"?QY9+)SO)]1'$\DK]+EJY'?7DI#X4]
MUF,7FQ`QRXI+MWN:#XW+8,OF74G?)GE&8@8R&R2>W1!F^I!60HL;)@Q=]X<#
M>>MVE$YK\I%5DH22E`KM04?O068Y<.FT+.O]*'/L*HIHKT!8I%EF2HE7S\+,
M7`A*JX"GB37/$:Z"KBBHK(!A?G'0&_R.WEP`';`_/.Y0<.ANM]`C@ZXXE,RF
M/^(C$GUWQTGB&XC:].`&X=E#QR>1Y]CS$&1R2NX?=O`\0T'JJ[TY6+OIC_7N
M@"-6`AG%NW!S'U[EC4^\NW?]P(.![9&:'Z$#MW;@?WQ;V<$.+K9I,V&*1\>0
M=Q+=N:2JIX;Z?(M8S\^&J#/HZVU&SOQF9/O0\XIGQMV#CZYS"$]_O?=<5(\X
M;')@/+Z1Z_$-D%9PG)FV(S3BB;>4(<!SUX$G6_I:H\(<QM*MA44MU;,/G!A/
M=QT65D/^QC#T/L28";]LA6`!D>Y+Q.>Y9HK5W.%:_KUY-DN?BY/4C=3TUZFW
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MG(RH.+YZ/:SPBP_"PD*3/&48,INZ$#7D+72S89"G`F5RLJA`=O-;N]O6.R[E
M$^2<*I!#4ZT"5W5V&<83M-'R/6[:0B]\XOH!N3=YT)*F`65=U^,]IU`QW2NJ
M]5IZ;X]E@2^;V@P8S+A,FA42%P.DG`P"2]F+=VX"YV93*ZH-C9;>QT0SX5<R
MF\J"A&%MWO;]Y-I".R;Y6H#DT-NZW@NN?G2+7&?8EQ>D4SJMR6Q621).4RH@
M+=`\[JY`+MT4EW9O9A[7NT:SZHO*,;WGX&;>WE)?\;`UU#LUKPJZ&BM;#B++
MT?>/.)T`D'QF8:;BL\SAQK]%7SRVZ(MM)@/KVNAVN_*RD2K[KTE?`?$2)C/4
M[77U3H%FED&ZY64$8L8%`?Z(:12,XN)L=JHTDLNQS-J0/&^NJ^OBR$[OM5QV
M(=28<%8X%=&R`X/PKHE$'>)X69S^M*-#HQE?Z?27<-ZMB'A%]*?4Q9]*\TD.
M9B&4T[\4CCFQ_.<3AM<_E=;"F9.DWWO/7D,4+Y$XZMKH]7ORKCZD=5N/VAS"
M)(?94:OTNQV]@Y4JZ+)CE(K^3?P\F:"[`J0,0(7"L6+3-)5BBL]%TYSAI5?!
MFSSTGI*KQ*[$S%:AX-DFLR=4WB,J^P)47C_#S2$!\_&-[&\,3]'M#EH2;2Z]
MXYI\YI$H871)):,_ZND=0C.@EVY^*R&8<9%TF>3Q#83;:<7.94XV95`V<WQ\
MR^W;(-,MY/^^0C](3N8W$,;V0"+9&X1:4SODOK1$GQKM9M#MZIWM)T-<Z1K;
M/&:35(AF-K.M@DRS6.NSY:*FPYG0J_`_(&H>A.WK8!?DW"[SD]N%_(TTC7:#
M[TS1W#/+D)?=,M2[Q48"=C-:F4,A0,%6[ROP&NG]7J7>AUE',\</O$.X2!X\
M0V_U;#G1Y,<GU$3@SYQ0&$3O3DM>%I$J,<YD+^J_[-JVA!O"H#O4.QU0]:O0
M-C81DZ>)N"7*WLUT#4C?($"=@ZCW*Q#V3^Y>OP@3)V<BZ[]-7/G+5F_B\#6.
M>F<?*7\7:B8"%4M5'H`ILD8$VHT5P%O+]KY:NP,DN_^*$E4*]R$VV/&93`33
M&ZAM!0IZP?L`AS_IF*E$7&T#%CKF4%/!Q_*@Y&,4E$3ECH*2,-@`N'6`FP>D
M?0UTG.5DCY];QYOS]#0":;X*)T%<O?TU';A)=/,5_Y1SRU8`GH@2;U!-#327
MZ9B`GUMU\\<3-,X)O3.M98C+KKOUCD60@#WRT^&DP#KKIZWCR0,_4VX?^6F+
M^.E4Q<$VL06<YS+4DPS7<@+/6@<':[>"W@OA._/1<`UW?DZM9WD3S2A^OB?,
MJ,'/K/QTD?4.T*FXFPK22>VD!X"[T$3]Y<?JEZ+^#<?L%$[I?9J,+)$O(':G
M@J]:T]SA?QSV:M<TJ\BL()"_%+UN.J"G$.4GG5VO$/DR`GLJ_J:">U([]>\!
M[D*1)8BO=<)+!=9N1]8*;EWO*#^#*$/1S4K-F@46*&<R$H)OJ;;%8.H7D[&O
M]^U0:EZ`MJ,$'BD:&#-$-Q<NMB#;(4`]GB=SDD][I`XI?AH;T]QP@YV<>F^5
M5/,"]!Z*\(ABIA><VEDS@6]EC!,MXVOMM304<@<I/XVE:'``PTZOGW2:DNL%
M:#^XX9&F@:&.4VUOPDD0U6.?<(9F?`B>$4W_"4G*74?>>=6-XSVS&6)X?8U9
MGGQ?@U[[)]W]526S]L,="O`F\JESE[.GO6AC//1*CKXXX]'\""??%\YZ_4GW
M;E0*?1DC&1I\VK**M=][[BLR&#BL().K#=L#OW1?&[F.W-G@:_KFUDM\M'5W
M.)!W,;T,Q)*-0B/OD-DLB/2&/-50\Q-U)(I]]LA"'+L93H'6."*>'#Z1Q87[
M0=T]H#&*9Z\#N"$ETGN)"B\.*9Z,X&FZI@[6E"+1+JYV\&"QK?DTH9!`TC5"
M!)49GI-R%$*3"V+Q+7)IS>@X%;%#9`5YQ#2)K[TVY$-0[L_4T7QP*B20FM!1
M!!I5):RSJP3;=+7V.E$PG<S_H30?<PD)I&RZ5P2=F*O@G8C%E9_=W2:YWF?N
M!G#\Z)/,ENON:#B4-PHJ[;L!3>&0ZT@QZ/7P87Z#"PB6JB50$AU5PC"7J\7D
M/\#J83Q?CB>KV6*^!-_B0B(VGEP\M;DY>,EJ2#CI4#Q\N3;Z?4/>]20"B!I@
M?>U7<*0+O*T-1KT+T`\QJ93HC!`T,[VE"GF$L'*4,'053;=?'<W-9]NX`G,8
MX%FY6]?;0CLXH-(*54_.G/M%J5[QH(6[M7;/N(`H35`L=0,8,8#F)+]5`)\*
MA%Z<`]<D>OMN!\_UCU1?V0$^E77F;.Q7>W.P=G^@9A_@CJ#QG^W]RITZ`?KL
MT20;`B=O89P33#T=JRUYK%Z\#1G#7DOO;%U!B61[-#%8)JF&%22M&"I/MBJ^
M9S2L+#AKC%39]A?;>R1'/+)#0ZNE_>386WMM.<%XO78/#DFL<7?VVH;^"OX(
M/N+M/]?]UE!>X%@'63T5:_:=Q/I6JU4\'-9:]QJ03K8>UH=HDB:P3F8;(7-T
MF69`V@Z(&P+?<%.`M'4.#9427UZXAN8"SGH$Z0R'+;TGS1N13TD(V@12<SG[
M-)_=SB;C^0J,)Y/%E_EJ-O\$[A=WL\ELNN33PIGSBI"XWMN-[:]WKH_&AYD>
MC<Y(WGV$95W74R-.H6(]*:TVZK?U3D!@0"_;$U5#,),B("U3PXFP?6DI7N+<
M],V9^;)J@]!ZZ+T-@$T`)8::"8HYFW^=SE>+!VZK6SR!7OBY^_U!1_$J3>.$
MKB-N^>)-81O(2VI^+@>O+.=9T*$#,K,5?HE/T\9UFC'K`H21-].LI7X4SRJS
MM8&ME^8'3G(+HVX&F0=6P1(HIR(<'GWXCP/R15/LD/QDC;77:DE,8:;T6I/E
MS+(DG*;5(*]7[XFC2NS2;7H%`'/YY>-R^I]?4`0#ICB.J;$Z?]+5D;T:2=RY
M1^NW6:*6B4.CZI''U/V(T"KLJJEZ"L!,"X"P1)W8HOKKRHDESD;6?*Q`KX-M
M@][S'-7@U<0"53#R]E5H?OQD1O`M_/^C6=^^[+6J"@R-S'ESRWDRNUU5W^CV
M]#[3C4L.16M*3&#2U:.T^%6X0O0&OD7_K;M,Q$H/F0M".JD!;9&GHCZ>N^IV
MNWIG$O&*HG+IAA54\9(J'_6GEN>@COSXNO%3+@P'$L>`%9W7(SNW9#'+JRKV
MNIIO=V,30+9Y9T)AQJ5PLFF88-J<66=E@!1[K@6W<Q:\JB*.*S7/`64508G%
M9@23TOS7G>O[O^%#C\)3D_@8/;=P<O5BNT#UPSRVTP[;1JO#O#>YLKEZ+!5!
M&Q.UNBX9`ND=;K,+(=L8,R,QPY+X(-&T;'U3S$$%EFW$^A`W9V'9WK2A=S8P
MNQ!*K"PS'/,3=%"1G31R,FWHU8>=^8V[C(9`[[5M=B'8Z5EO@RXS(G/U#(&5
M)KGN0\/JX;QTN,$IZ0$JX(1&F.SP2(PP^A=^!DG*.N\VW?4SW!QP*OT?T'YZ
M1EV-7U'#3_#XS*65];C+KC#VAAUYN7E"F&I.9#?T&I));K'V^@/=U\;KR"5]
M):<&.#.NC+4IK@ZB^OD3!K^11L3#GII\D[-&='%JEU];$FL/QP@_I=Y%@JE9
MDZH#T:Q6N<4A\`/+V6#G^,4/7>+$VJT/V$&"9!SM>N`.C:33:2-1Q4RR,"<'
MST-_Y4@X&+05N,!R&$VI'[>P>8VK:J+?UWQLPRN*.G?&A.?(@R4UKD!4IT&7
MQ4H6R5Y*+\TH\47E3809W8;>*P?\PBCV.8RPTBT@?.2/5M[\>^L--SQV-N@7
M[P`W=[;U:._LP(9^U'.2ZM89R5L@$\!33R&:>`&Q9@BUI?DM$L(RR?8BHL#,
MN"*(:I(=N5%=D*F<\3""&9PUN"7%Q5R2<N7<CDA;R#@:7;T'0'7$4N**:@!,
M56V?434+5[=V_E]J*=,B>(9>U.]UK]N5-V0IZ;A1[2B7B*(&1Y4Z`[V33"NQ
M*_89.0`YWW`%2)G$%31/616&7BUEJRSW425B*?1>TV:!?PY+7`3$)#_68NG*
MLS8P_:8]>1M-2CINE*7E$E%8>E2IVVI?$D7SV!4;UAR``L-*RC1C6`L_L`K#
MJI:R58;UJ!(Q"'K/O;#`/X=A+0)BDA_%6/H`U]!^Q2W/89#YJ(9TRUK4<S,\
M99/IE*B%M3HCO:?/J\&KLJY4!*EY38N0,VIKVM?2KRS5P)Z)N5036U@+VX;.
M9=C84OQ*C6P9DJ:M;&922=[1DRP`Y%&7*B(+@S,3HWKGO[$+<4Y;?(2DVB;7
MGE=FX8-R*ZV>\EQ&^VB.LG,9\V5,<IS=B)\B2A7`2TKSSOGZ/@S\Z]YPV))G
MODD?-=E*P9D0,GQN&!W-%_NR.*5;TDQG9OB/6NP870@[1C1VX)&FWCO13I!R
MF!PWL':")N>H3W.%6P*6,%W2\Y%DAH1'737!'BKL8Q*E-MC0/.&Z$*\:DW/<
M:61ZQ(.QPN\C)^R23JM\*'7RQK!KU_O<:@IB->%18=_F>+F<\AY4$S:5S$_(
MO%O[J*LF6$5%?<RJ9/!OM"^!4L=PU9BJHSXC2R4ZIU?X:20&31()10FACN;L
M-5^Q*P2L,*`ZZ3J*J];1S(1X?'4Z&.R-)&;F%/78(-^H0A32+C7[K9'FLVDE
ML)7:M>.^3^U;S9",\A$E1F;JF$B)TPIG8B[($.:`*XS:*!#,R9>'!WS:8!C$
M<4Y@32S_>>QL\'_PT<:OU@Z?:C@.)I;GO=G.TU=K=X#7_5Y/WFF#3!#J4550
MRIB[;-7;QE#OI38>,61;60XL)BY$$G/)'YGB5\`*0%P#D"HRV2_%,&O'_ISE
M9JM.K)'>,SI\@BBQ[%R04D58XS]@6H&3]>[+BQV\D)Y0WRXY]@(Z^-JIZ_Y0
M8J)Z2<<U&<XC4<+KDDKMON97PE>#EV[!JQ"8F1*A^<Z6:9ZR<LSS.2F;-\4E
ME;"1Z.L=2K/`5V-VJX&8D\7GS[/59_X3O&_@%J)(??,`7Z%S2/(T!_V!O'S*
MXC[K,915CIB<E/*=T5#O],E2W+*M:%GG9OP01$\%)U8K/J04NWD&0N:L):4\
MF5#4>_ZK`KD2&UF.(>6F%S[G=.@GK<_16TL^9U]>!$KMME%FEDE#(6>F2F?4
MUWNUJ0JZ8IMYVG^!V4R+-,U2%<93'4NK3&BF"K8#O4OE:0S^'(8T#Z,!6VH[
M</,1.NB/X!Z!"">,;UT/_R/ZW<]^[Y'$79/<<&JSNJ[T&;9S-M7M:#[D$A5)
M@0T7P65&]4!4`.#"5R#*D-JZ'ODA?NK7LOR"K)+E$2Y#IXH\"&=3),+4?L@H
M*)0JCR,&S[S],K]9@MD</$R7]]/)"BQNP?3S_=WBS^D4/,P^_;Y:@B_W"_Q\
M-7N8XMD1P9O;YQ`G#74->7XHVU4]=:@`G;N)'1<;]7MZKX84H)5M]/-=FIGC
M$M&/37!)BOV5S:6<V3PNAM=_])ZQ*,2KQ-@5]9S0BGNA(7-F%/HN@Y:\J8A,
M3_4850XY)M11J9;N1]H4H)5MG/)=FIF?&F"1E$Q6N2S*I;$>E<*C5[VM4A%<
M#J,DGL):T'&4P+IK@%-C9Y._DQY_M8Z\%::J[AMC'ZMP!92D5&T9([VWT;**
MH-`$EN'(VD6RL!\^E45GV7;SK'0NL["4JGA]^M+Y',F@VA:7HLD;:$)N<B=@
M5.$7DG05O(%?'1C@T][7UM[&E39H0+VVH;-^^ZU9-4BR?=NCKKPMYJPHY&H%
M7596Y<BDZR,%NV@=.17EW+;_!`_%!PCOB.#FAI1AOJ9ZD)L=8/]8>%[O9U&$
M2!8ELPJ\J,R[V?CC[&ZVFDV78#R_`<O?QP_3WQ=W-].'Y2]@^I]?9JL_P:_S
M*9E2G8SO9ZOQ';B9WLXFL^E\\J>XVTAW8/;[0Q4>HI%<'B8!"NB>%&ZU1GH?
M54('K="4'_><-=J"N61EWTUVH"Z=>&7!>#;_J:?W(2@EJ%4'W"?]GVSB;6(N
MY'177'M4>-FV+#(V'A%4RD/G9C9$T_QDW6KPZHWD"8)"8]E$?$O[PK(C6M6,
M+8M:B_:R=B_-G^?0JXY,*3B2'<&9F)1S6W"FDVR6@-$?R;M\N+#/QEA:*D8!
M0[/E6Q<TALKC5FA)<YT?&U'19*R*SR@[[E3$QK+H\S1I]&)6;PN`JXY!\Q#B
MF5[7>0+($K\T$HBFW60]H;STIM*N)1"5+E4I7[-1U>6,F^CXSV)-3T#0K&H3
MT6G)!Y<=H)Z'QF5A:M$7P"9$[YQO-@%4!ZMT*.;=8OX)K*8/G^M$K,B8KY`M
MOX&/0=;BM]M#B2%K8:<U6<LJ2,)72@6CU=8[`[4<N'1#6]:[B9^^)[$!?GX%
MIC_6N\,&'S,3SP1\MH*#)Q(R5'Q?.5;V#$3-&U9*!6P%+I.I$7(UIK04`R'L
M<3#+F9!#+N9+C\WWCRX_,0;R$F'I'=?C)Y=`,4?+*K5[AMXTK08OVZA6(@CO
M?\S<..+7N0:*Y1-+L:?GY&S.KI96&J+_72QI(_1*[&LU#I&[2^^AXZ.W.W8V
MI/*]BT)?&-@>Q(?/H%_Q#_!EOW/?\`^9'5L^=09C*&]]JV&T]71!_JN+%:CY
MGOI#O1<S)$DLV[W(@6U&S9(\MM`_';=,'ARW#;(;D)$/:V2>6QKCI?C`?PUC
MD?.V$GHR>GJOULL268E?EP0^F8-](\<.A"U`"#S[Z3GPP6&/[$G:#Z<=\-P]
M]((WC`)#Q"F'>]P,V>+8[8_DK2J4=5U30_F$2M2MO-K(T'MEE@6^=*]9C<&,
MRUP1AQ8D*=VDG,#>;+:O+<<OG9G">8]16JW3-0R]M_,PX5=CRQF0F/</B_OI
MP^I/DH:-$Z_O\3$5B,-3SK,JEH$5$.N]V-[:CN6L;6N'O(6-/T:RAM$=]>1E
M7;,@J$=I,1EC9C/5Q@ZSK?<^82XY9)MK'C#F9#&_F<Z7TQN`_EHN[F8WXQ7Z
MQ\?QW7@^F8+E[]/I:BF\+ERT6:[?[\L+/YK>B,DD0,KF?.%A2WOJTD#+YRFE
M9S/[Y)=X9]@X"#S[\1#@R340N.#>XA\@EWU.*;&$2C[FX@;:5E6]IY9*4"N)
M$>C]F\5[LFIOQIJ@$>1B&QWO>#TP!A+ORLEV58^*%:C3(^>SQ3KMMM[L*X(K
MVQ`6]&GBW_`&\>C7)@B5WK]W48Q*81=3"BEG=Z1W0E4Q8`9:C4):.?`)A70;
M,7M6V#F*^Y9D)^G#].MT_F7*>47!U/(<VWGR[Z&WQ,<;I&%E?R#OE`%:K_58
MQRY+S#]JC5Y7\ZN#*Y#+-G3EW9OQ8X">`U)`>.!1^5&E1'MG(F@N\*/7Z`Q[
MFCO@2NQ*@L`J%.;=8KD$]].'<)\^V9._^/QY,0?+U6+R'YRYIZ>]?;1\>SUV
M-C?V[H#L_O6P/Y(W1U31>;/<K92,1N'3BKVNYKE4;`*HMKB%*`H,[Q4@)<DT
M?E16#J65V.&S4+K2*I]61.:\/[AL4L<BG,5&4\"8'\?+V81,YM_,[KZLIC=\
M3+YU/6@_.6$NU_IMY5F.CSP!^@R?+-NY<WW_(]RB,BOK!SXFH]659JDYD-2C
M>#V18[[SM#+H=O0.2_B%D6W:N1&940T05P&9.@!7`K_B:K]=@4=2$Z"J"G1%
MB@O06U=ROH&K%12"&GHG_(B(H\1G"``S;V?S\7PR&]^!V1P%^5/PZ_1O]WC-
M;/D;>,^_*OP).M"S=LA1C3<OMF/C@45@O\+ICSUT?(A(TA[*\R$5O=?3!7[1
M8OY7U1P,!WK?Z,$F@&R?P(3"C$J1X/ZX'(@*2F*TG!EH/2B=GZ:NJ(JOZ$46
MIJ7W\C"[$(JFLYD!F9^F\^D#LMHX\A_??)[-9\O5PW@U^SH%L0'GY#GR%N3"
MWP=HOSP>D!,B-P"'>S[@9I'9_7'=;HT*3U/<[WX0'K=&G19A,?J!I^&:;*XE
M04)LCE;(>H/>Z6DBXD@WY/R8S+`.0)7`<2T05P.+[,XY!>0?7#SY<Y$ZYY?I
MM32/6P3$41*I"P`S=]#W44C^%"H"#F^\H\H*&&^T+Y[R1CZ2X;5&>N\8%1&'
MG?,;=WW`[5E81OF&?Y@8_CS?T3\CP^]ZT=\D>PX3!#RYK]!S"-(=L!T_L(,#
MAAPVM'9W"([K$2G`WO("%':%-V0B*2!ZV<^DW`:^PIU+<J@!#$,P'[5&-KML
MKGD5#HV_[SUW:^.#BCH2\Z(S/=55L#+(J?ZDI0:CH=ZG6.7!R@]V3GHTR2\@
M_*D!#DDYX$\NAW*'^1V50HH_U'L&L`@N1]P@?G!?0<?FIP>R6O^PN)UQ7S>Z
M=E]@DE&?'O[5,^2="D7IM![+F"5);Y`LKH!?JN:3<57091NTBOYIFRZ6*_0?
MO-=HB?-)\":D\6J&"@AG0<UA$$+!$]LHKAL,Y%V(==17/:I6P8X9>E(.9^;H
M[5J+`2LQBX5=F_@Z$9+)=+MX`*O?ISBC:;;@7"!?["$.$YVGHPY:0WF)H`4]
MUF,<FPC)>3E%I=L=S?=5E*"6;0_I79O)(Q`^BY:@&V2@%&NGEH$YRU=<>M@S
M]+9_9;"56,$2`&;D;^>?B$44.$<,KR#[N$GHD\F4HD7<PNF@T]HUF52-Y>C@
MKVQ1$J#HG8)&Q2S=B%$ZCDZD(T]`^*@I\K!,GZLB3_&I<:?O0_-CJZB8E4QI
MTWI'XX'/]^/YG[\LHVSRV1P-#.[NQA\7X0@`C#\]3,G(H"EF,4U3JZ)6?L*Y
M^$WIO<F+BEG5U#$-@+EZAF#BONPMY^T7/[R/%MC.R12O]>1!,EKEG+1]B&:#
M<>)M.A><I$?TVJ..M'%`:=_UV,HK5LS<JGI#S:^59<(OV]6R@#`?LLL0F6)B
M.4R,WUM.!M/Y>9S/7BJMB+-LNJV.YJ$BJP@,=&XB<XD1CODP74['#Y/?PRT+
MTZ_3NP4Y@4@P:RGN-M,G/OG(>;(="#TT%HH0X".0D$L.Y]I8ABT<#3?#83$)
M3@G-T@I)*-`[E!411Y7=YL"4FO&L"<<Y3)EJL4GG/T9.B#K=WL6S/Q5!B/[8
M$NF]Q",B#K>=7XG/-`G@JS;\`F?0";&':72HMP+DQY3<QNDR@AL><52-1`6P
M'8?S15E%5\"!_(-3<NH)&@KW>@-YQ]['W=3E.15LRN&X2+_3TCL!Y!2J_-CC
MJ#\S_G==PDC9G2B+,+E)VK1(IVMT]<[#SV%5,BE[VJLI=B+2'Q"?VPTWXU?H
M64]P?GAYA-[)CG2R2]U?'`(_0$8.F<$T"0>YK:)#WPH=;ZVNZC&N:2ECFM9K
M%[N0CM[<;D9`V3:T$91FW`J(F@%A.]&)(N/T1)'PJ!$?9!H33G5JB)DL*VZ7
MKW\Y-]'`A]<[Y;\9`94XI$:@FG],9Y]^QTF%XZ_3A_&G*9A_^?QQ^H`3"\D:
MX_+TR"KP!><CDI7'S_=?DCR(](PKSC.M&J(JTU#T\C4R/UQM@`9Z#Q":$5#5
MD+81M!JYQL66])!I/W=\TJ`SDC=D%@,E05=%7D2ICC(T.&IW]5X%KB?86<)4
M5G14'72W!4I7^QR\NIR3,OUPB<K'%K,R--@?]#7?@5=3LO-%J<P8ZY[)-]YL
M[/`3W5OV9N9,K+T=6+O/$*.X[O:+UK";49W2GNMI")]0L1J4U]*=Z@SH97N3
M:@AF6@3@,N]M!T2EP+>P'&=(-M[\U\$/R![ME4L!$)]I"3<X=P\Z/@E<I]$]
M@>26BGLDVC,J<>^Y3Y[U\@#_<;!].X!+Z+W::W@/T>?>/,"U^^20'JY[?:FJ
M<1:AZBJ=)E\BU>?S`!IT]1XNGO6]R+=!YQ/.S'2.[U4Z,78@-79788#\_A&#
M`%D45R#&`0@0$",!$90KD(`!$1H0P@$9/)=E1*6$YO]M1.M\B7,;4:,S[(_T
MSALY]ZM1,CHYLY!FUDZN,ZT##^YP8AFVLSXQE"$;.+,4$.`7UR$0HS#5:'7D
M;;/(=5?/6C"@3V]Z.BW:[H_TSLNE098=0E#Z-</?([<L-EH);\'#6N(Z2*5N
MW!?+1EP?#.11KK#+>K1CE"*YK:&P>&^H^_4Y);!E4["D;S.ZQ#-Y"+Z%CYLY
MT60H@X/R3S09GI(N=TI'?Z3WJ*P8,#O17J'WZ(IZ^<+.3?0KV.'CP_!9=<$S
M!'OBIGGS``-$3KB)[QB))^&Z$@^E*^ZS;HH@FQQIOF!A>:-O]/2V>^7`95N^
MTM[-^"E([ED2\\,5'U-2IJIR4A8DL1:_7:3P0[T'6Q7(E8R%RC&8X_7Z\'((
M1R4W<&NO[4"0GKGT!\3_;EM>C)CKKQXK6>`G-VOGRP[Z/;W7]*F891M'6L?A
M*-F_RJZW-\8XHW79E$OQEW`.1SQZ;].C@V9G71B_+0/+"\0L(!6$^1$^V0ZV
MBN"CA:JN(?C5=L(3,GC/("O[EL:%<]%@XN*@I?<!+730O%R<.H)'`%`AF-,P
MQZ\^#>-#1T\&X_[XA^U?=T>]@3Q_7-9U37+R2970M+2:,1AJ?H`%$W[I[IL!
M1&YZ!PUQ\&/>"#+NZ@X%K#/T)_FV;?F,3?IKB*8E^'/<3,NB=]G7^S8H.FAE
M+#SMV4R>@&_X&2`/18FWV)*)\F=WA[Z!'[(ZR>)&WU+>Q7Q,$!JB)Y^4.<:6
M5L>AU4#ON2(^090QFP5-Y='A9%O/[^/YI^D2;^8A.W=^7]S=3!^6OX#I?WZ9
MK?X$OT[&][/5^`[<3&]GD]ET/OGS-^'=!0G\%;F3!+%'WKG/QWTUI`P4W#G6
MA^6PT=%[2KX8L#(69WO-VF;R.S>W3O4!#4KZ_8'$`7ZNQ[HL8Y$@Y5J^-)ZF
MTWMO90EJE8-\*HK\*+]!%LH9VJMD87YP7_@F!YI?9%>"6MWPGHKA9'PO0,"9
M[Q_@YN:`C\\)$X_"R83P]UO7BY*2\`$HO:',43X/F`9X6T?P(TIS-#08M2^`
M[=P"R0\"!%"986I2^!B$]:+<X"CAV+^*G^(E_;BZ&AV2LJAZ"3J46X7E;:C;
MZXUTG\T0DDC)JJT8-J;$4]1`X-EK_*\P!]7Z;GF;.E/.)5#G\#MYA)G5;\M+
MGF$#(5&5R@1E4J%,`X/10/<Q)H\@9W4[IVB8W`VJ%)9HTLL4,$2]=SF3*O!Y
MDTP#>*%6\V5%/DG.[SURF.(<\=`;V&FHM;;\9_"K`P-\.`+^G:Q-KET_\'^3
MY"_(PT6X*6+Z`WIKVR?;QOL=F5/OO(`D*@_K"V!2)$IC@Y'F]_2("W567U.&
M["@TR^XX`F//0SV%TZ2/;T=[+.^MM_`\=!RA78&HZ2L0-XZOVHZ<ESH=5.^T
M---!/F=&::PS-%IZGUE90ZKS.[E2?&;\"_9KT0X\\(2T,!HAP6@3H$_._7%<
MYWWZ2]-N[ZNU.\"B<7B_I7P2KQB+%$5C%KM"QVCM#$;="U@UX97G3-ZM%%3I
M@(K4E#=]5\4BE:Y*(^5A=5"T=O!DTD4.NBH$.J=;*H=68^*N.44Z&K>W)&[<
M8,$@3W'*Q&11F*,9I<Y%3G$7RW%.[W(*AL6K-#Q+1R.'<B=R'AW@<AHG<T@7
M.9M`$>3L3B('26A^KCF5H(V&>Z/165R$NMD`+O%9U(8Z0=31?2."H$SG="EE
MP%C<2U@D:B"9<FLPWJI@EG*_HY=B<?DCZG1/?W21DVP,0IW=3Y7"JS'%)N$4
MP%2*6>0E)]A)7O?Z$G<7U4%63^N:?2=<A^K16AUH[N'J"R?;U=5&R'709\8]
MAM-W)+0DC9U!/\]WU*:^^BEVZ"6EU0%)5-;\SM]F!%3B-QN!6CKNNSH9\`F?
M('EO>0N/;-0)W3KR\&0R\KH_',C+UV,`4$_'A"0L.'>26KD]Z.I]MCZ[$+)=
M%S.2H],JKY!;\@!>,B+%PV$9'J2%*1+R""_E-$&M")\[>)"E,K%*>L_T\8C!
M3OI:AQ1R0#IA_QZQ_Q67$V9ZF`HQ/@3/Z#/]$PW.T/>7-V=7TG%CS*Z6J(#1
MN4K(UNB]O%D-7J')+D9P0M;HZJRT5/.DE6V6U9.VS`SG*A$CH?>V`!;XZLTN
M#<H)@T6I>Q3JX\/@G;6]@T=GTZ[<"8K8[SWWU=[`S<>W+SX*^9W%'GI6@*^)
M7`?V*QHA()#)(1Q#>:<HR`#<X'A8UBLL'"8WU=F@K?<TLSRAE4Y[-8G\=#HL
M:1O@$Z3#UL&ON/W?\&/<!8C[P'G:O^)N@.W\!I*>0-J5\'DJ,G5!_C3:3V].
MRF?=FNK,Z(Q:FN]`ERJW^CFZAB4X,BX>OC?&BW/X8BOCQ.?4HU_QWR29XQ#:
M%.`F)L5*^N",J%%S8V>#_X./HD`#27)F7S"Q/.\--4Q&H-?]7J\O[S0=)@PU
MPVQ!,9.(FZD^_JH]O?/)^01A5[#:!_-P`3,_CN_&\\F4'&,V7OY.KH@E?^"S
MR[Z.[Z;SU1*,5^#C]--L/I_-/^&2]].'V8+S"EE.XD@YYT<__<@=!L3Q]?3.
MA.43A%<_A(\,XH+%K!U3]'NC>A&F?2#'Z$'+AS<P_"_BS5#B?"('$AE*PBIS
MN:I06FFWNWHG1`A((WU.DAN2249M.,.(_)&I=15?/QI7!+_&53E39X7(,_H7
M5)A1+84A)E#O218A>3B&.FY@[9KT,N7(S/ET!6;SR<-TO)PB[9B&?_V&CY6E
M.A]^U;G=N=_GZ.VC/V?.*_3)N,K9W-J.A<9)V3'6C>VOT8#IX,%DM#4<2;SU
MLB:X^AK6Z*O)*EVMAMOMH>:K$,U(J,*;U8<9>CC<SA6(6@))4\3S)8UE9R?3
MYH0G*IMBJ)1)R9]#>7.3C;4;QK:]KWD.1U,R*IE$;`JMN?QR?W]'CG`?/_R)
M?.SMXN'S>#5;S`'ZWVS^=;I<X=D.['1O9W,T"B3_FJQF7V>KV70)Y@OLK;\N
M[K[B!\0OW]XM_EC^A5^K=]!/$OJC0^FC-']D<XRN4>!R][L?1!5;HTZ+*"+Z
MH:*M^BK&A3.K0B45C6ZOW])_IH]!`A7^JQJ&&1=+-E"!Q?9X:Y4<@@XNA*"%
M-K[BO1J:)YZR2:#,/E=C8=ZM)(>K1OM"R)H"Y6&KW@N9C!*PLW7CK@]XX8^<
MWR&%L*V,6849YH8;!2+^7O-Q]0;N/;BV">CQB^L%]C_#OYW-V/=A,'O96[:'
MY;IN&ZW"G0&%M&5OMQZ%:^&/V<S1"%GHU?O&5P%I9`<-_)#,;!60K0-0)4!J
M@;2:?-*S!!8ZDSX7</!^$[UG?P2D41*(\.,Z9CZ>ROF.WC0$&_>[@ZW]UOZ!
MHA,+5^:,2T1HPQ2CZ,S[?.S"^TGT7GT0D$953,,/S5P]0V`]/7GPR4*4AS_P
M@6B09$\].3A'&R=)!:C,^N!Y^(3<<!D>_60%P-H1/D$_+.'ZY'R<`"&S'W<P
MTABB4+9S^BL*]L.F_+"M1^C`K1T`S#W\F4E+SW'Q:S#>^2YJ9KT[;.+^GBWO
M"8.W;`?U#"T/7SV%L\#\PX[,RI*V<-%C?8X0Q$]MO,\S3`((MP%A;.'O6_2V
MPM\X@[SI=@O7P6([_8%0.D_P`;VEA5.\.G0]'!CRSMSF05+/5M23.;857*WT
MNIHO[@M((SLRY(=DAE6PZL25`*X%7`=0U_T5Z(N4!0W-]2475'*U0E:<?R*-
MB>51$EB*(#.GM[?3";DL=OJW\+I8\#!>39.K8Q?A&C^?MMRZ'K2?G`EQR>NW
ME6<Y/DY?=IU/R!?B?.HOC@>M'=F$-1KU^]*\"P^2>MI23^986[A:&70T/Z=#
M0!K9WH4?DAE5`7$=D*D$<*UH<]`52*LJT)=N^U]08;JYL1M7,V10H?>BGI`\
M#%HS"K7&(>,HP1QE$6QFM/IM[?#HR'V!5V23RZ\OJ,;N#0WHHH!M8R/WA9OE
MOD\A[GOA+)%S6VSO/;QI)GB[1S($V.?MPP%ERQC)<S1L(.IIC+"@L:XP-C`8
M=/3V*UQRR/8H/&#,C+O`HQ-<`P];XCJ`5`))+;F*(,>#Z*@)>;?!UD*W?6WT
MA\9(;Y?!+8LB=\&+R\2%L5KXD5J(3VR?YC+/G/%Z[1YPKK/U9CWN()YQ7*^]
M`Y+-MA[M'<G*0H1!XUAI/D(,5#U-:>Q%Q(HCV.!PJ/GJ?RVY9/N8.N#,@HTM
M>-(\;@%$39!9LJ@1D&E%K>))F3.[1,7+3:2)-HC"\([>_JNF9$HFU^IA3'40
M*9X5*]X^HW@6KFOMR+5R>`T)+_;L7/1_"/,+YX"(CO4!KJ']BCO%1.O)VS/#
M`D&6?I4*6:U-F>K#P5#OR6@.*<[GHDZA5#JDM(),WLL9_>A&_/S(AZ4^CLFQ
MY;I\]F<D433JX4-EQL6(X4^5(7$27F/*<`.WT//@Y@&^0N<0<D3>X7*5_3>M
M!=7BT37@M"ZR4WJ?"\HJ@GJK7XB#9O+CPB`J+8WBBH85YZ(XPV`A5Q?;'[TW
M`+(+<:8A``5.:M,1Q3<QQ;VPT%&$CZ^[21+7<#J<Z]2.]?'.0P?Q+!Q-CCKR
MUCQ*^VZ:^^5BT7F?K3=$G^?"&)^'K]ZDYS#0S'FFH!06JPK95=.8)4C/5(RC
M1[W3D%E%.%M87@B'%H_;S5$[.34RNOXE/<>A;Z@TUC0<35.>75XZ^ZEM#%$$
M=&%J4"&+>OM>#HAF[-/#CJ-JP@>("%!&43ROC8HP!/C4-HAEN[2XIU*:,X7\
M5;C,"4EG\D_.[DUWFNS2U0'.$SEB,#,GL\)PZWI'R^IC9Y/F/[31`+'H6LO"
M+5O<S3>C!'6D.54&]K;(82N7,;O)+Y0J#\*-+'4E,R>[Q`Q0Y=,<*+RG5S`/
MJ@:U6/;T7HZB4+T&WY?3/,M<7"BE/H0;GGF/6GZVPJV&^U@[L`^!RO6":=/O
MY2A&?@NPH$W3>PN\N%#LFE%O0[`PPJ.,BDQ,1:Y%C97E"NR)+SG2&<Z=LG,8
M%%W]4'"F&V+5H"MO08T=2#VUJB5PK$X\C1B#D=XS6?S"R([`N!&9^"HCL@6V
M^.:BHK-!Y>N)E,.O==:3W,G7/(W@'9MZ+]@)2,,1@HF?>LV/B^@+.4-WG]&7
M;:(EHI?QL"-))A8ZG7Y/`Z?2S-17$_+SZTXZ26,,^GK/A(D+I8_/.4$FXGN$
MYY)K$$S*G/(%*5ANMD#DBR/SV?U9HKF<5$KF"\3QF>EAS^#V8?&Y\'QHSDEG
M"IKT>.NC**<C;_,4.Q`I"L0F<(7F%#9B#`87J3`EPIS)%=$15;F@]**$AH<_
MI;11.?S10D]8AS^%C6`;=Y'#GS)ISCG\*<&5#G_B>TCM]"H1Z1J2B4R&RH<^
M)7A4*0Q=?GZ]R<3BPZ[>ZSCB0NGC;TZ0B?B=IH<^+`13.?314<%8ASZE7QR;
MSI]/PR*ISCGT8<"7&_ID+LII>.A3<.DWCG`*#\*7JD@%0*0H$)O`%9I3V(@Q
M'.A]@0F_,&=R171$52XH3>-L>.A32AN50Q\M](1UZ%/8"$XMU/M2;0%ISCGT
M*<&5'_IDTCBE:T@V,I&W%X`?CRJ%H<O/KS='L;C>VWG%A=+'WYP@$_$[30]]
M6`BF<NBCHX*Q#GU*VAH@VSD<7682#Y-8YQS\L`#,C7X6]].'<>W1SXR<UXH/
MY2-QC-2UG;2OVII0"CO#\FPY8]C7?NB>QZO`^.<Z)78]_#4^R'0<!)[]>`C(
M85:!"^XMCSLWF?+=9%EGR70K,JK9<EAM]4X=+@:LRA#FNR:TVZ$?^&AU;[WA
MG-\HI7@-X<:_11]O$3Q#KWC]H]\?2+-SG&CJ4;.^Z#%Y^5OJ]/0.!@0EDFUO
MQ6"9<362^_YK7)/<'X7B;%RY@05N83K).;3A,E0I?[`#?U.CEN:#5U&1&+2I
MB8,?!.&9XY?P`+;MP=F$$T&HLWUTSU1\#S3P[*=G5.BP=_'SP/8@[HS<<2"F
M7RMWO/['`;53M@5F,!A)=U+50)I1*B&!3]6)J9&>H?<D*K\PJAP2,Z+4%Z%Q
M0%0GV=E[%6[MO2+[L03W]HJP1JX'TE%/Z'ZGNI7H+)RNWBMS0O(H]C@\V!K?
M['L/'3^\695XNGO7#U+_]#&\S'3B.N'(/;Q1OC,<R$NWXL934VL:$#_1'8&V
M^IKO,Q&62;K+$01F1A6)SH2#GN.Z(*H,CFHK4RI)3NABM*K`)0DT-FIU-!\,
M"0NERCF)`@SOKL(*5F-@U+RZ3<,;P3'1"L\Z4J=G$1+Y&D87F4>UTE;ZFF]`
M$9!&!R]U#(G=/T7U%*B*E-45O54EMS+#UPJRA'JO$XJ(HV151P!8]BP]*[J8
M*C[JY8U,=C?K;3*S@S/?/UCH<RRV$_?EQ766@;O^^QR2V[4)1A\?)E0X"U=X
M-!)?VS7UHJX<B6KP-41&LGJO:@I*)-V;",$RDY4>7`_$%<%B"\*J@-0%>.44
M_1975Z,4+`?I78)2Y/T%_[?2_(1B08G4>`TA;&:B"VA$XC];J*/PUFGT3SM^
MM$8>2(TN,!V>=PG*D#\V3\1RZ7T9H:!$[-I0[\`\,7BIJ\`D2'4`Z<,Z=!4^
M<161CL"XNKA^%-SX>[Q4T>VU)";:L"-I3I/X12[2HNI6^AW-EV;XI5$98+%!
M.M&8TXO:&UG*%.&.G"&[UNI2&H(QM-)O7<Z@A%4<Y<$7([`3M8DO<F]D03.+
M!GNK!?EL_O0']-:V#S<80T_B`F95_PVJ!J-XA0I!J=L?79#7*)-!J:\H`7+J
M(4@`%94%26%I'!_^W!P?"G`<#_XT7QUD%H*=Y:_0>W0;,?%E@,SX%VS.P[?(
M.9.TQ./PCQ9J$XU6\/B"#("NC7Z[VY5FM(L[K<=B9D%BZM(J#+HMO>E:#ERV
M(2[MW21/WS_BQR#[O%E22@FWST'*7!!=7(%L*30,O2<LJZ`K"8XK0(3\!"$_
MU^+\#*R`+&4MMGASZ.W._9YNX>V.)(:[93W7I"J73`E?RVJ136)Z7^?$A%^Z
M264`84X6\YOI?#F]`>BOY>)N=C->H7\L5^@_GZ?SU1(L;D%FQ['HIOWE8;_?
M$336;K'=0@_OPW`V)`R)IS8GKA^0">AAAW6IE;G9FBRN@3[A-',;Y$H@O0=P
M_,)(9SLO(C-;`\15R%5DX?`N65<BU:33G64155^ZYT,.ON^A]V&O_,*H"4MX
M8:5KI7A!%#AN`-Y@`/:6O2&S=23QQMKYX#UP<>*.=-(SK9;JR_K\&BGG)]%[
MWP"_,*I61KF1'5M[-[;VF/3A:NA1J@#O8N@8M;O!;=_NK*=KHW*.PX?KZR?W
M]<,&VF&0COXXC<W13\?MUF-W.<28OL>E]%Z\SV&5'6*<=F@F/P#\"Q]E)@</
M'YQR:_MK:_<GM+RIL[E!`?NU43G.8V4/K8MZ1&(&'G.*6J&M]\Q#*6[97"OK
MW(P>@O`IP(\!>@YP`3X6WD16&"_O.0%Z^S-GZWHOQ"BG]Y*W1JVB`V\+G35+
MB_4(*(@YIB-3=3*QH_=&"2XY9-.5!XP9%PZO?2;%0::\\!Q#W&ZH%O?(P[N;
M6_0;"M@*^2MB4ZE]-,/I:NBG-,[7,-IZ1Y45R%51M;C[E)R1<0T+`%*B#AVQ
MD8Z_:%4NG!@9DQZ:I"(==C$1T_)&6^_UKE+<:DEXW'F.@L2_UR!@2.$D3.M7
MG>W(2[^C]ILA7SGD4^H=E]9\TQ8=M"K2Y7I.&1=9NWK!Y`H!NFX;51MT>6F&
MFVV&784`3TE%"FF^`3V'516%X@Y3YN!?^.@21GX35-FS=C-G`W_\!WR[-H9-
MA6J%[=<C$!ODF$F4TBV]EW9*4,MF%[UK,QHF1,\`>0C04R'*I1LHR,*]OS@$
M?F`Y&]MYNC9&3=FMZLX:(2./,"?,+*W:TGN)G54$19RMPI$0.+-9\PJ$94&F
ML`B?;^T=]";(73^Y'K9&3<T?%K3>!&/+X1Y3]+CL2.\):1ID-13,]1M3CCP`
M\1,1@CW`)QO/R#C!W'I!X?BPJ0%L4?--4*P"\#''3@NW]!X_T$&KX5E!SS'3
MTD<`/^.CVLJSL`%<OKT\NKMK8]`4QX[:K4>N<H@QJXY+:7[50!ZL;!;E>C2C
M7T#X$^?*ZXY\1+@I3M&,#QGI#=KR\L[9,-1<OA64,UG89:L_U'Q/!8\8TI>#
MV;&825E`2V47.PF*DQ92,MPUI'\N&XVM/DGH[O?UCC)Y16%7@QJ9:)R@CC9T
MB"?,XRY<AV0XDW.FDNN3<.H/7HH,N_T$'?3[;OS#]E&XTB]*+FY&$_CQU$S%
M:$#^)$N#OZWV4/.I+&&99+L.46!F4A'OS`L/%DSOUL.5PS,*PNK@&Z[)N8C.
M"`W']S?NBV4[B%(#>6=Q<L-1HE%ETG,J5*:I]E#SO5BB(FFB3J>X^+3IBHQI
MP;>P!6ZM\A&X!_@*G0/T/\.71^A=M_M&K^C>U\*\JJ(6ZG*="5/*YX+B1G_0
M'^H]45R*6SXSZ9V;A&&(>?%C\"TLT"BWF#+L59,KGS=/?5$CW4UB"6YV=M7+
MAB\#$;)L4<`RSASW.!AQ-N/-B^V0B;[`?H61>8P_<:<G;Z*%"4(]W@I*&=.8
MK?I@J/DAW#QBR#:A'%C,J"QQV\>ETYA8R,8^0!^BU_>,4-P@/=JYY$RC8PC=
MSE#>K;D,`.H17TC"F/8LE8W>4/-(@4,*V:1GAV+&10GI,X6K&9_]X0[]A7Z,
M?T+_AR=GT"__'U!+`P04````"`#3@&=!AD-#X\,?``"QSP$`%``<`'!L>"TR
M,#$R,#DS,%]P<F4N>&UL550)``->S9I07LV:4'5X"P`!!"4.```$.0$``.Q=
M6W?B.+9^/VO-?^#4/)SNAQ#,G5Y=9PXAI)IU4L`$JGOF:99CB^!I8].V227]
MZT>2+QB0;<F6L.RJEZI<B+3WMR_:6]K:^OEO;SNS\0H<U["MCQ^49NM#`UB:
MK1O6R\</7U8WX]5D-OO0<#W5TE73ML#'#Y;]X6__^Y?_^OF_;VZ6G7_</3W>
MW`3?!N,TNDVEV58:T<^WGK?_Z?;VZ]>OS7WG[=DQFYJ]BWZ[=VS]H`&]`?^R
MW5+:-XIRT^HU_J^AM'_JC!K+S_XG3</Z_2?TS[/J@@8DVW)_VIMO'S_$1W=L
M3S6--S3^+1JK->I`COP/HXEU+_H\IL-V7N#G6KU;_Y?11]$\)R-_[>#/*J/1
MZ!;_-OJH:Y`^"`=5;O_Q^7&E;<%.O3$LA*`&X%^YQD\N_N&CK:D>ACWVYW&J
M.K<1NXF?0-_=A!^[03^Z@0AVE.:;JX<D7C!#GN0#1+G1\'%V;!,\@4T#_?_E
M:98,,OK`[<IXL8R-H:F6-]8T^V!Y4'V6MFEH!G#O@:<:I@N)P2-O';#Y^`$*
M[B:4#R+UK^@'KKK7PX]Y[WNH:JZQVYL0M-O<I,VL5V!YML-$B&&]<B=D=7AV
MP1\'2,P44<0"RP$(("=19,!%.JL?3+#8_`:,EZT']#&T;/4%S`^[9^`L-JNM
MZ@!W<?"P6X!_^,4%^MJ>J*9V,%4/3%7'@C]U'VW770('?YQ)#3R%.[^>K?V^
M=E3+535D="SX>]X5X8>*2H>1+=!4Z&S$$RXD.NDXHFV5TDBOJB3X_W<Z5=E?
ME;*U^FS2*K'7%JC%U(0@7>:NS!/;TH$%'2/\PH70Z-`QZG>JB<*`U18`*K72
MM&?W*H2M//CO#BG[8K/80V]/:W^:YG+W1.D4+C:3K6J]`'=FX95E:YLZ##RG
M?QP,[WVB[@TXVCW8(%VTJ"P$L@!D9F$)/V%Y6^!!@S,I^>%N\IE:,U'=[8-I
M?Z53&FW#F\![6SL@4L:6/H7^R'N?61O;V6%%IB!)!X95HJ7ED+%-(>,]C-/@
MN'B.1_B#\`\,SX1_T6TI+9BF->X-5S-M]^``^$UC-?LTGSW,)N/YNC&>3!9?
MYNO9_%-CN7B<36;35>.'('3Z,9P>\<HQ0_"Y`6\>@.CI?E82\F/:6O`I4WT&
MYL</\`?_NAQQ_.QZ#HPAFIUAKZFTF_U31.,9X$9UGW$N='!O7E1UC]/&6V!Z
M;O@3#/Y-2PFRJK\&/TZ9]I03$^5YMA,*)I65[(6UV6X-B4R1U(1B/"I:XVHT
M=D*Z-XZ]8Y:`9^?BU':@@\0;%#"?WSL&7."]]X\?X#<'%])M[Q%I1\M1'>U"
M*T^SWN`3MWML>#?:UC#/HGSX"2J9C2'INF$>/.,5K(!V@)1!%N;J#MS;.]6P
MFKW>"'$Q$**$&9,74$44C"\PKB[TJ4\`"M30D`/#V=]G@'+!9KO?[@P(W)&U
MD69(/@K)*I-(+9FY+DLS(00;X#A`?_1EEC@>'LR#X07`GRR@T],WS3Q`G_P`
M<9[8N_W!%\!B$R;\8;)_]TX>8/QFN,U>OR7.)XNC.[\ET2KC%1%A=!#YS$V,
MNH26RH"JQ(O'Q#;A=S:*`E_!V'%05H"#0^A\YK:E)?PZODD2^*31J"MLE>%&
M97XC6@8QY9UAK[<P:MX#*'D-)E":[>QM/XH.O7-K.&K1KDGTXW*Q%''R#NTB
M)U"U7,:6&^-/X"2QKE#K2-(P55$)*A@"#6C72@,X@(M7H=%(W!+-B<;\OI6[
M!LH*DUQ62U2LT&9%R$3B.&BE`4N%%'VQW#W0C(T!]"",Z_9Z'6&!3>*T!?+F
M8,CU5_OH9(=MZASY_,^Y:"L#O%$FG,I'+<.%D.6%!6(LD[0O5731GY<M.C(?
MM5SGHUWUD'?L7+NCGB)L/2).6=QO),M9#!>%/&"F\M*)Y5QQ4S&08Q7+Y#S/
M3OYQ%S(#MF\`@^OL*97E#*\()/](-0"M(V,<F8;4HV&!&30L%^>];2Z':-&8
M?/QE(:_!SGL@R6X-)$D5H?&3))'FJ$#R\.Q"WZ.B*B1,(74,21I!O&:EP1EJ
M5R9OM4P)EHZM`:"[_GH3>DK;<9M*MS,@[3+S"<L2YY5#&>A@J66F\=DP@>O9
M%EBJ[VB=Q"B1CEZ(]GW^UW*(,Y6GLE;[4O:%H6)O#`]'D#"2U!#J+WC-'?5H
M1<PTM!SRSX]&60&$8.78[6P+EX(L56?AX'1,_U4U#R!,+YK]X6`H\+PUDP!9
M%(<)J4!;>K72EH*)ZGB'<&_VADK_RE5BC"3*H7'<T0YTLE\UG?SY]@)PB-_O
M#,6_[<OBW]G\U^E\O7C*6^>;?-V.N:HW'.K]2&!45-H>#,655*9,G#\SC`9]
M4K]^AC[2,533G0-OL7F"0G)>82ZE*!UB)LN9JT0"N-@WD]1"FV8$IY:)9H3!
M;[;S^\S""99[`4*W+:[(BX(""52$$IY:IIX1"`^&9;A;H'^R;?W24(;B`E,*
M"B30$4IX:IG8TB`WJMZR":6([%L9B*<?3G4U'1XEZO`YPQ5)M%%`R#E,[5Z&
MJ:LO=ZOIW[_`4+4Q10%KSDMIZ2T9F"-6_]K(#'[Z#;5#F+GN(;K4Z?^+S]$Z
MO9ZX2VET-.0WR+3QUW"TX+@>\M@OA<<C#5QL.*](0W-FATN.DWT>LA<2@'"4
M/9''Z6YOVN\@JIM2VEWJO?W3OQ6N?VF0A_J7PDXMLZASEQXMN+U62UQE<M*L
M!8K!3D?T3_XA#\-K\<#O;C"]2*(ZA@SF)7:1YZ0?3132+V[53YRVZ$(_?0..
M9KAQ_T%=-D,:081&I8%\N@ZG<"-''1B-3ATWR2&WV.L/KZ!2C\6+8_`I$5[!
M]/N#@[;]`<0YN%@=OW<=BDEO*OU^IRN.16:"1*AOBCQ/+J7G1R[0[8'<*_TK
M<)[M`FO])8YB;HQPMXMX+4V",+M!?B&\U*A$K4^M,<K&)5#RH=Q*7BR<12N=
M7[_<:@VN&4Q0[QGD6+K)#"7%@L2U7HZ`D)5W<DR?PO@Y4G*PG<\W7T-SV7RS
M4/$1`2BK&D8DW^P;9M'&=KM7`@K%MZ>55IN]A5K88K=A;QIAD]U&T&6WX5=:
MHU_Y$5XCUFD7@:(W/+L1-=MMA"4NC1]0O]T?&WOXM_@/?^3<JNTZG8$%M'\3
MDCV(:/]&B^J=ZAI:4QET!@-A_#'1PL7#,@@R=#?Y`:O&]B=S4I2-H9@"PVL9
MPSTJ_0N[L<4$/-;_?7`]7+NN#*!3%L9I3JJN9"`7210/$&M92Y/@.9*@0;[#
MOT%_36>;1(UD[I8*M&I4VY`<;O$8L4,H85@O)O_?6#^-YZOQ9#U;S'/6,&2\
M:\`>37U5'3W*-CM=<:=F)S,5V%;&M[U5W&5YMP<0"%_AC_><[]Z/GPDN..&Y
MCP18^M)4K5COP.YP(/"X4`#%?#Q"JNRCU%8PX!)O:TQ,U75A>(F,[IC2C_KB
MCF&(,^8WEMA]'=];^Z<*Z(Z.N$PI85(N*DLG$<)UI23V:YH7I.(DY@X;7\U=
MJ6C;P;]IYAC:\7J9TNOWQ%V;2)I6O/)>=G6B0:"6L7K\)`A9+'I"9;&)&7-3
MZ7:[XFX$9<Y?@C:P85*1ZF%&M?!#BQ"S$(6)[7IN4^D,1+9G2)FZ#&6@1:*6
M%W"+E$>(633**2QA7$Z*H5;5:[/?2S$*+#3491B2UQJQ.IBLC#<UX?T5N%YD
M7@HTHO:@+:ZFC2.I)21HPI"N1GD0>PT<$2_$.?':@D@=*V,)R^8^D/M(;KE?
MRQ^=GH^.#]X6XO$G7MD[Q&><2G9*2?1*HVN\,`]WG5K?]11AYE<*S2S7<PY^
M8N-M@;/>JE80?'R"0WCNS/)=/8*R)2[9NQ8;5=+J(A(*E5WR/=9K.V4$IFJ:
M&,T'VSD)9IKMMM*GOH@HE)0J:2DSM*%JUFO_-#=^V(CQ\[6X+N"@FFO@[#!B
M](\^\IV\2NI'`5\UJB*NJF_WJ@<>5,/!700Q6*2=?0&Z=C)QY?0L&;;0J=5,
MR5+W+Y,RP[XB;O<N!T72[?MFXQ;M\/5JI$SWP=@)AO>;X6UGEFZ\&CITXGZS
M28C<A36B)Q66-HR)@6<XOLD""VP,5!*S1L5@*!0)A\%%-DI'$?>P7%E<Y3_E
MOQ@.T?@$3$RZNS7V:WMJ>5#APDM@BB+N(APC,5QL61Y%#/U%`9%(7,GUO5?3
M]UY-9XK^O5>3O+(G\A@V-_+?,0)GK8Y:HQ9UCIHVDG#=9.GCE,EJ-<H7F=]E
M#*\=XN#U[AU'O/Y-U.Z@1>I(P^MQO,2)N:@%$V.%K]C*?C\^#QA))>L2]_-)
M3=?$O)R<NQ17B,RR`)#C>3DAK,L0WD>F<>4$ONR[/.6<#8JZRT.N7P/.QG9V
MJ/;3W\\)(H3.L"^P:(T\*1__<A6%B$K=LN&K9WR%'%@<8`08Q.T)0!=C:.AJ
M)_I$&&ZV%6())'E'GF7H"JI,?NAJ>5,#,[NU33V*2.>V=VQ[WAT-!78P39V;
MCVXQLG=\UYHJ5I`C3B?GVF]`PV\N+38;0P-.H-#*4.#^*WE.+H(LO,\<)>:9
MN,@LU&`?P3VZI[Y"$&?JG@G/Y9Z?6%(X*S<U+-I,0"&T$DCO-A624JCWT\4S
MQ%P;-%6F)PWJ(P13UV5<CRT]_=5NB-2=B2[D]5L"N2U"&1?;S=&<AA>:50W*
MB_N"B]9SL0?\&.P^]FQ?;BNOZ7M]QT&/JH<>H[LJ/WPMM=CC6EF`?+O&V,GN
M\<.R%I]W]LEMF919B[B:J&))&0-/1-WL]P>=*_,GRG)9)7FR2\&,UK=KR=W,
M!\=8#/GL`93\=ISUDLHU&M[S?]S&/=&^D<!K:$GS\K%-:NDD](A.P.%;M4+"
MZ]29;95QEO#.I]LQC(7]X;[GO=J_YJH'1;#8+/;`\3=C?&R.*MN&\0_UJ4#F
M<&5EI&Q\5M4T:;8XSL![/\<!IM_B*L?H:"AYVX(!H5J>]82]W,,^9.?\#P<"
MHY*,R<M2#09,JGKSJ^BZ3NJ%F[6NXY,R3J\8H$U$/-SW=3U^,)G:21\#%@M/
M>\..N/VO7#259?#%`:QJ$%'<#Z1M7N>Q^=@N=D$+K]=>]E%'H^$G!P<IQX5:
M#@8"6ZE2DE'>'G<NH+Y5^VUA^UW!7^.J*OCU9#&_G\Y7TWOTU0HNWO?C-?SF
M;OPXGD^FC=4OTRG3QMG$AN9JX4(NRX4.68=3Z7>JZ=?G`5!@*RWP].Y2?4>2
M'5LZ_(ES@&`:ZK-A&A[T(8'HCTO`2%PXFX.>_/[@;+*UH^H@&+S9Z_;$;<"E
M3,QS_2XDU>AB`1U(5;5^%@7!K7V.O'?%+1$I$\NN($D@U3+U#WE_`AHP7A'[
M<^!=`B<\%THEH+B#)(V.C%_<ZU)I,W.U`";)G:M\%BZU=(K8P(^<NS'6E8XB
M,&Y.GKA\C:`$I9Y.T'5A"'J.5&\D<'DDS9C?S4U4=PN70/0?*@IX54U\;NE-
M5,=Y-ZP7OY-07^05<2H2^*@YE;2B*XJLT%3=Y?&%C]&GU-(]1%L(D/6FHG05
M<7E5?*H2C"61TZH><5"X_1@H`J/<DZDX2C:1^LB`,Q2@ZNZ.*-E[L#$LH`=7
MJ?%%/@S#@^V@;\(KUG/;TH(89S`2N%O"3,XU%:005F7=0!?]=L@>.-X[8M^#
ML0.*&_9H9Q1[Q:[(PK:TJ:^I%-00?$,+PTB2A2&%Y&9O.&P)IE6@&H[(BU><
MJXH\?X8.0'+FGY!;_X:Z0!ERW75@$26!QXJD#&P23=F%;H^(U95\Q%OPD"E+
MUBQL)>RN,^[4US4\Q6,_`9AN':+#J$%_(&X_FCQG:5J1#4%%_`*;Y"F@$N+V
M11P^7X[95)1^?WA%)JZEOA>K60;O%8F*<Z]IQV0P#I6XM"AUZOP:?.:$XBEN
MOR]N\S]Q6M[J3".F!(=,QJ*6J_&C;;V@USSNP;,78UMIMP66!Y(G+5,!*&"H
MY9*\!);KMZO`1Z"GS1B#[HQ^F]Y8=T:T+^(2@6XJG:'`TG'.U):I<"*!K\@"
MG#MX1,U5+FZ"QR#OBGM#CY8*WJK%R')RI$9*3JJ^L%T5QW0C_VYZUTB`BIL>
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ME31K_H3Z?$34<4B#VGQOF`>(6G/8'XESCQF3<_&,]()*ZJR3`DG5_6/"=0)H
M22"REZ,7ZRDBVU$0)\VOV,$Y(<R1>[V!N/..<!HNNDJ-?*BJ1"9KJ93X".:3
M:ECNHPVC%1<]1=DG=4D@=@$\_^MRI)7*0U4#@T*NI-NNA"^9V"Z,$`-C:PZ4
M05\<\2=S745/CWP<MY:2^)7\\&3D:ZD%7E#(QT]/A>PC<%?33PYT*TO'WA@P
MNFEU>N(JW6(S745%+S8WDEBMY6G'$P0/SH*N"=]#FS1M?--E^H9>@@-PZ6^/
M.N+\4>KD)?DG!D`D/Q7)Z[`^.:J_[_\$C-WS`2[*.+7U;T$#?1'KE("C#%(.
M1XR4&`8N)XC*RWDMST$R3:=7B84KM.>8,:,[?=:+80'@P%P\,&UTN0_*U"_!
M/^>-J,X,(U_'E_62?!DS[Y(?[9QZMC7;BO<)6,!137071]\9EH%01$\?1BZ^
MU1YVQ:UY&=.7M.HQ@2+Y@4[>=2_8N;5>?/A0'MU4.BV!ETH),Y83\F:Q'DA\
M)*G$\X6^#[8#C!?+KXS4WF./5*%]%(3!'=C`SZS5-ZC_(A^G8:"DG,`H+U3A
M=F%+<L5ABXS@<AFWD_9@(*X@X&2N<IQ#,KNA>&7?#D[T"]P-A>9$*$2M7MNQ
MQ,;Q9\=;?A?YQ<%S/=72(4Y'0&'T2>K/1@R\"TU5C@/EATZH/;)NDW+4GN#9
M@1@BY\>ERD!D>]9\1'%1,-[6E*J';#A7]0BP>)5)C['*!!693'X9SS]-5XW9
MO+'Z9?PT_67Q>#]]6OU/8_KW+[/U/QL_3,;+V7K\V+B?/J!G8N:3?[(\%I%>
MCK+83+:J]0+<F84E?%)!-%'W!AP-M<#2#!35Y:]7\<>S=WO;@K,&K]HK`_\)
MSKX(TR1.6>00;K>S+5QE]1D@DT`;_^*HOYB.3S4*G1CB-=Z)/)=EY#0-@W3=
M\&=?JH8^LP(]#GCH]A5A8DN=N0P1TD)1UOD_38U8*L=B*L/X^HXGX*FHB6`8
M^H?H=P76_I+GO((*$JJ$LKB7_%@_[R618(G%3^J@,MZ6,+=S.E=^18W&.1.Q
M.WXS7,3"0#P+I*GY%JDG".1XIX42!(E7P(@'&*2"&?P2$]X6+[UHOG)$1F17
MXK4MA7"E)9&@$HA/OOPEBGHAMYVHI$!SY0U]NAH]?_<`4H;20,=C6-+.MQ,@
MY]UV1Z"\SR<L0=SI/$?2'O1J)^UDF,3>5N/EFF:N>P#Z_0&5,2Q]!+`PY^`K
M_I6+#+<M\OH=#1&B59I\9Y<-FZBN46J?EN<6]R4.^,63$QA:XA)-*AIDT9`4
M9"I2^,K8YUS_]\'U6QRL[82-E/"*%MI>W:%"&"R`*>[+!0`&<GEPM"W\Q-*Q
M7QQU]P1@T.`:'E@!Y]70@(_M$]#L%PO/T.SU^P(?7BN'J:OKL`3"D[SXEZO7
M]%</_,L%YLN=O@%',UQT--3O=\15QK`3)(L_I<4L*K7\5E;?)$AZ(W$W0)GI
MD46+*!&3O%ZWX![K)7Q#V5.4A)HI(73S+Q&C03ZC.FPH?9EPH)2OP'FV.:FE
MHLBNEZG[6X*HO_JNGD)TKBE<5Z.\V=_GF5H,)>UI^UMBI'WU/;U+8:?S7)&2
MY#S"3@DA_!\_V$Z0VO@)ON">=K2T2!5LI2,5!5I2[PCSS/I(>/2&5]><!&)D
M41T:K"+=&0[KI#M1K6%*DS((9U?\\70:"7P5A8W9BX/LBP-O.0ZQJ=FG*R")
M[D1D%;656VI1O"ZX+Z`NF%@8W/AAB3G:`L_05+.L0N$3(G)7#;,9D^@6FB(:
MRE/M4A_7$_2O:FD`=<AQF[V^P-/8(I25X$GS[?]3(%O5NPP<#4OL5IH8PXJ5
MKD-?M'#P='[X'EZ\:_:'@Z$P_B@(*,%,+O;F&'&J1ILXY@V[&`I^F#X^>%O(
MVY]`1]R/KJ$EYQ-+IAUIN%2C?IND%<4CNT&>OL*3\>J7QL/CXC>N?84GJKM]
M,.VO^=L*GRR:Z%3;T@P3G.S?KVTTS=*Q7PTXYMW[%TC0S(JZ0XPUSWCU>U)'
MVC44UY%8!,$%MLZ)]00PPV]W!4:HQ$FY>(^KJ,/)IFPZ>+6,Q>X!'%XS?"'L
M;,<S_O2_MG3<&'^VVZN&@X30;"NM`74K-?IQJZ<K.3&K1O12I$J-,_!B^EO)
MY;2S&]=\L1P`EV(4](Q&?8'-=UE(D=YH+SN(Y49:\O@R;S>QU!=>@P==H^YJ
MG>%0W&8/`R72ZQW;0[HI,->RIID&#/28FV,\'W`U&8+$[^TOQN<Q$R2]`EXZ
MOH*@2UY'G+N)<.#T%]9*-<%B`Z&&X'KOZ`UK?'Z$NY$VE98R$KCFTE%10:7+
M`Z_D78KS:EJX,8+>J(5?SJQ7X&(X+3UX=RL.[;WA:J;M'F*MV88C<5>`BA*7
M/_*%:@?#+1?,K-A38C!(.]$4U`TX4A:83!&C$&("RCP\%R/C+NO0GHJA5<NM
MB]5AOS?Q(J::B\T&]XL.GZ([/5!#4)!,B*@XU,/*K3#YT*GE'@7"V`1N=#4A
M.(T(+BPTVVVE2[KQ1M2.]+'D5@D&'"3/>7,_&(!]Z#T(?6D4V@1'\L<&A7V%
MU.V3VQ,"E'047UV/<]P'R(8O&T&K[XD[&LF<GXNI%)'H^<I*AU0M5](<,`I[
MO*P$RQAKFGV(GE'!I8](Y`+?%:*AH2P#N<SEV!&3/(PH\%+:&1!H<;:@7`Q4
M2@T#A:O:1FQRF94E$2/)@PQ^6A*:RU)]1[:"S@DUS3G`08^Y'#*@@;C&"_F(
MDGB19L:TEAOJ<^"1MNP(>4*$<:?3%]>1G)V>_`LYG$0#0'<?H*:%&>UB$RL:
M@\0L-L'9"DYS!Z0+_,0TCVUL+F;"0Y31EG]^:&H9X!;`5M2-^%+,)*%10[?7
M$\=KYOQE6\]%W2D;8I+'NGF+DA,`/>Y&D0`="CRJ92>H@,VH[^'=#>V/@^&`
MY&UVI3,8"'S.FYX2D6;$)O7(CG*B*/D2E+O@)H##/[6)/`P^E"<`##$).D"(
MU2Q*<N15KUQX2NZU\^I8`8"OF0^(<=KQ9?L_W1W+CMHP\%?X@68);XYH%RI4
MM:SH7GK,@D%((9'"%I6_[S@A@8#CC!,;3[@L*&3'\[8]8\_<'SK(^YM>WV!Q
M"05,;)N5=.N@PL7,:3]3F;@"QLI.Q`!CS66.U/&I;DX%=;-,T:6Y0I@.R954
M$'O6S?+UI?OT3M?U93USLX5L9-T7$A&D7<F_ABXU74?,\-3P&6SBRSM+3*\6
MB2>>IC'HY(PT3*[MY&JN5.();&2,/#PBC_/HHH[15;C5D!12Y6[26J='Y.Z#
M^/4"K?L&852B,^P:[<Z.1(2>-99QB_AU`5K6B$PC/F6=;CQ+N'[UVH^V1@$B
M]*RQC%O-**9=;(U"S9EN-FP59\I7<?FY)3!T$7#V3((U_^"QL*/G\VV,,QJZ
MYNILJ&!B<:M<E6'-*'!=X=[!/=E)/=;;K9@SZ(_&QAR/"B8674]5AC6D9+:B
M\T'QT'"?3JU[5+%X)S#=1-$)9I:X[AO(M3\P1QD*A\>9P'W'1W4FI=I//,)8
MKPNDE(EFNUK8M`$CE%&S@;L.">I,2FV`>,!7WC3!S)),XW7"E,N-"P77+[3H
MMKZUWL+5WW.=Q>RK%ZQ;TP!>.[7FP2:,]KGZ=XBZBBDDGEB/X0C`*%=2E`&]
MA/C;X_9(4/1>7,\-`;&Z5TRA?\!_.AVWK%/\@:V<;7A\6;-=XO7@RZVS@T<Y
ML%K\646^9H7CQ&3:+2\O+^\&Z*XYRC/?VSINKZQ)`E8R.;@41%-$*(W&!U*C
M>4\GE3>8'APW:0"JT7IR\"G(JHQP6PE+!9G-8)KU_#_,BV;PY`#$#C5+[68$
M2G(K)MY6@DU9<HGJI>B+9M'ZLKL:@Y[TQ`RPE<Q#R.\C\GBOM=^G_6?H\^8N
MFF26@TM!3D6$VDJ78<+L,9E+MMUQZH*O7]X>_/E(EXA$X"E(JH1L6[DXM,!>
M`4KD^7/8E/S[P4Z`NBY'*(1/1V3%A-O*@F$B3W'AVZO)-ULX)8$##6(K&H*"
MY!#DVTI"H0UNMO-9]`I(;\.(:YTNN0F@4Q"9G&AK21^\?[SM7Y+K^3K6%>4H
M'XR.,)$LL9;2T!4N[%7IR[)XGRXG'W-XP5@?O<-B<S[D"+_J:9.7]4T$T/SJ
MW>5(<7B(E26I,O"=!?#<CSLQNNU!MT3Y:S4U4L2G1C8'-Q9?V*5=)=O#,KLW
M3OH%'2V.08<"7+5\JLY0PG'4);`0WN59K3=V9'X87Z`[4_.3[3]9Y/2ZH[+0
M77750"#P2&60642J"XH\(RS]5/6#]62]WP7Q=N]K=V1Y6CI=@SV(42A0TP!E
MOA&.UG/J%YMS2<E#BOK`37+8F!2<"`(UB95223@VG]P\RY9*ES5MWQT;L\N"
M0:LO28I[>.M'/C^6%EU$"P'=L]SRA(`^U%$@+\654<$JBP8OY`H+^R@VAZ]Q
MIW9SB^3[\?0>=2J1HYQ<PA.8!'&SE\'5Y"0^QN#';\-&6-CF,>V_U!]VS)W@
MQ^&@5Q<EHLH./BBSIJD7VHNC.N=?^)]/8``\^0]02P,$%`````@`TX!G05/3
M,)2*"0```E8``!``'`!P;'@M,C`Q,C`Y,S`N>'-D550)``->S9I07LV:4'5X
M"P`!!"4.```$.0$``.U;WY/:.!)^OZK['W2\7/+`,`S)WF4JDST&/(EK";#`
M9'>?4L)N0+5&<B1Y?NQ??RT9@PW,C,TX-=Y=7A(C=TM?=W]NM332^Q_OE@&Y
M`:F8X!>UYLEIC0#WA,_X_*)V/:ZWQQW7K1&E*?=I(#A<U+BH_?CAG_]X_Z]Z
M?=CZ]7+4J]=7/U?]D#<GS9.S)EFW+[0.SQN-V]O;D[!U-Y7!B2>6Z[>A%'[D
M@4]0\^RT>59O-NNG;\G_2//LO/5?,OP<2]XI_UQY"UA2HJF<@^[3):B0>@@I
M/8`4F@;LS@S1,-V=OFL9HP)8`M=70BZ[,*-1H"]JWR(4G#'P:P2]P-5Y&-SE
MZ2L6-G:PC+BU3,@YBIZV&HP;IWF0R/-HN5_:U[*A[T-HH`1(YJT5!,^A(WA]
M2\\(^7JMET;UMA&_7(LJ/]/_;2N1;#9^_=P;6W?7T/N$6/]3SM$C&F-LVY+6
M,&1\)E9-V!@P_ONY^6=*%8Q@1NYLBQ0!/.(P\[KAT<"+`CM$;]-!;=7#0L+L
MHH9AJB?1^(H*)VA,(F&<<E%3;!D&D+11Z>T,O;*T^>[=NX:5:F"P0Y":@6HD
MT-=N,@V/JR>B.Y)9&S<]-TIQEP\SQEE^;Z'\W]A;`9U"D,]1*/HW=E0H06&V
M+/`9HL9?PE\&X03!$_-P/7(?G@^LHSJ"^\`5^/B@1,!\JL&_I(%)_.,%@%8U
MPOS85YXW547QK=$E^#8?_(?3TS-2)V.,DIW:\+DSZ'>=_MCIFJ?QH.=VVQ/\
M<=GNM?L=AXP_.<YD_+ZQW='V&!':,^`?[/-6/EXIKR0>4\QFIOQZV]3+K[G^
MNO.K((]!8KT##ZNM6A->?`>ZK".H!K,.58NK0-QF:./-RJ7-?_+19CS!_SX[
M_<F8#*Y(ISW^1*YZ@U^.!*HL@9`_"\KGH%P^7E`)"Q'X6)([WR*F[SLT9-@;
M5K_,8PCY/DVQ39(MAV)O"U+,,NQ3N__1&1.WCYFJ/7(^#7I=9S3^-W%^OG8G
MOY%7G?;0G;1[I.M<N1W7Z7=^>WWDXE^#BT.4X'H!FF&,LL0,RV7F#]^!F7NI
M25YEC#I2M;)4Q7EW@#6G-3TS\2I1+O=:ATR\@Z$S:D]<%#@RZ$_!H(=SF2@Y
ME[UY'I^.&:HZ_.H*+S)1;'/?X1JG2)?/A%Q:8S<<\H'Q<BG41-HD8Z<?*?=)
M#(2DD!P9\G(,<?D-VB8D`]4%35F0FJH8O_'+Y,6;T[.8&4QY@5"1!/SA]K]@
M#AF,7*R$7JT@''-&-1B1H8(NDPI-N\OT$!&.X:]$^"=T&FR3H%06M!YE`7D5
M`SAF@Q>DPYC-.</U-,4BPO-$A),WGP^Q5/7VS1B*AB7/&,W=&8.,W8]]%U?$
M;5Q'MSN=P75_XO8_DB&6IIWC-/)G($Z&,:4NA_?PY0FZ'$E249+8_^\S5"EU
MI;NG&'TRL\28CHFEDIP!98Z6^%$`@]DOP.8+#7[[!B2=0S]:3D$.9G;36`TB
M;8\>H>(U(IV(SBI"X%#)L57UA%)#D%9\WRRGFV5/<SN5T--D3*PE8D82>\G*
M8!);;%[%-I.4T<3$AVA!UG:3Q'#RRIC^FH2H:Q5?'Z?3:K-^3Z%N"'I6;J%>
M/%4>B_>7)XT6WN\32;FBGMU$WDUE6I=<L.^CRF30^8E,1NW^N-U9[1$?<TH%
MZ9'AA2RW+&\]S8HC%UZ0"]%4P;<([7/,_D^:"A'<E$N%-SM4N+X<.S]?F[^+
M.V;[Y\B$"C%A=\Y`0I0\:;S9,VEL<^(X9Y3*CO>-[4/VJY;L87Q[%)\M0R$U
MX3M7(VRP%7@G<W'3L%6IO+=7&NJGS7H+UTCQU8J>\&R/3^LE/^J;3DX007*B
MM@B:2!J_'``GK;C^]7Q`/K#"6!(=\_!\!'#G+0I#6"O9I^>#8/P&E"X,(Z6V
M>GX^%$Z9ITR7S2)(-EKQ8WW307X<VYGR79Q[.<S-"9`'@634`BDS6G733]W<
M=/JA!""Z,`C]?`#[+R#EP9'6[,>*9<(Y#,HS<&0HIYA7F*:)CGDXB*+9WG0H
MBT-(E.S302!F5$VM4R-5GU,:YLX;>Q4;$&B5M!R4/]+=FABKD@#9O@[/:#L7
M\?+P-*5@*/KV\*21OI:8<^26';F>Z!D`+?.-/">)IF_@%(.1Z#T&8W77T^*X
MJ)DK%0$HY=R!])B"P<RNI@=A=B']]2DYSH+`;)1=U+2,S'%Y<__S?!K?];FH
M^3!E.FD-,9L(?V(O0?F17)WB4EBO:Z8C\^NC%%%X48O%F89EC<1WIN*6I<`L
M3>6]BV],-X_9)PPN80:Y@;:4YM"U>3V48L:TW1D>HD6FSIU#RMQB:ONM3]L9
M$T3G-!,SKM$V_>>R4>G!;`2XS(E`?0:S89XV9=_;;<0444GJZ8<M*!BI^'[N
MN2^6E/$<1G0!UQL>LT.TE_BAL#_B9^ZWE0+M+D/*I%'8F%9$IZH$?>QH8WL5
ME)3%N:2_>W#C%NR4\7D.&YUE&(A[`$3=1\^L?FT3]7&IRA'6><*,R@/?R10[
M+RH'_2,F8JV0("-@RVDD57R^?`0>8)[V!S)^,I@W9A52>B)->!+\E\D3+L>Q
M<6IW>8_1*0N8N01\)>0POA%\/PQHG!:^12S,ILD#5"OKAL\,JQ"-\D-ZG[5R
M]TU54WZ?ZDA"YE*$/8XQ@3M]&6!5M3$JA^C3M<=A'Z5.ALAC47(L`?MG/J.9
M0[=?][\M'?>JA6N8@\P!.JY=DX)V.QGN?UNYC#C0"Y`?4=8>]4A[??=-93_J
MX8S]@2'CGI"AB(?:#L<C(I6+">95#\!75U(L7:4BX][!K".6Z!*[:NH#5N3.
M76BN3*4B5E2OJOEMN/I;S"43$^0@#0$'\-3C\2V@4[F`CT`!E=ZBBXNL0(3K
M`GW..("ID5<QZT-JOBJD5-50CW&)BOE<#/A.`MWSJG*!2S!.;L5#\%.OJ@??
M[$-<8F7G8Y(P9(G7@9OMBLO[C<BJ+&K?4NG;DKA+-5SA^O@+#:)4N5QJIX?R
MMMAV27':/LM&>\W51CZBP03DLBSG[>GX.U5)/GAL28/OZ:JDZG--*(/`KKEP
MT?$%BW1SY,]:4(+C\@WS\FY\[-QC#U.^Z2-5"^25K]I6S]/G.W/:.-F_'B_!
M/E^?+^[-[FHTM5X\U%)3D:7):I;1=I?!=.'9"_`HL3.O%%.KWIR3VO;/PK;'
ML_>:^[1X]<R,PC!NH,%@-K,%&>*WYB2UN=E93W^R^54JNQ+;>]T`<R[ST)(N
M"Z)UY%+'\'>WJ9_9S0LFM?CP4/Q7-_SY?U!+`0(>`Q0````(`-.`9T&"Q#TA
M;S@``$J)`@`0`!@```````$```"D@0````!P;'@M,C`Q,C`Y,S`N>&UL550%
M``->S9I0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TX!G0<6@`-I7"P``
M2GX``!0`&````````0```*2!N3@``'!L>"TR,#$R,#DS,%]C86PN>&UL550%
M``->S9I0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TX!G0812I5&T$```
M=N8``!0`&````````0```*2!7D0``'!L>"TR,#$R,#DS,%]D968N>&UL550%
M``->S9I0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TX!G0<2PI;J"1P``
M!?T#`!0`&````````0```*2!8%4``'!L>"TR,#$R,#DS,%]L86(N>&UL550%
M``->S9I0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TX!G089#0^/#'P``
ML<\!`!0`&````````0```*2!,)T``'!L>"TR,#$R,#DS,%]P<F4N>&UL550%
M``->S9I0=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`TX!G05/3,)2*"0``
M`E8``!``&````````0```*2!0;T``'!L>"TR,#$R,#DS,"YX<V155`4``U[-
GFE!U>`L``00E#@``!#D!``!02P4&``````8`!@`4`@``%<<`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 2 - INVENTORIES</strong></p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Inventory at September 30, 2012 and December 31, 2011 consisted of the following:</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">September 30,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 74%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,294</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">279</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">298</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 466</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,058</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 279</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">Prior to the FDA&#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses</font>. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T
M8C`P,3=E,C@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T
M,#8T8C`P,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(U
M9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]35$%414U%/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$
M7T-/3E-/3$E$051%1%]35$%414U%,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]3
M5$%414U%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM?5%)!3E-!0U1)
M3TY3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U5"
M4T51545.5%]%5D5.5%,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y324=.249)0T%.5%]!0T-/54Y424Y'7U!/3$E#244Q/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^24Y614Y43U))15-?
M5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4TE'3DE&24-!3E1?04-#3U5.5$E.1U]03TQ)0TE%,CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q
M-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]224537T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2U]4
M4D%.4T%#5$E/3E-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E-50E-%455%3E1?159%3E137T1E=&%I;',\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\
M+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B
M5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\
M+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\
M+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L
M<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\
M+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4
M:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E
M;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T8C`P
M,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(U9#0X8C5?
M96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X+U=O<FMS:&5E=',O4VAE970P
M,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15!#044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,#0L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@06YD
M($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&
M;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y397`@,S`L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!&:7-C86P@4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y1,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/E!,6#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4%)/5$%,25@@0DE/
M5$A%4D%0155424-3+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$P,#8R.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U
M<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^06-C96QE<F%T960@1FEL
M97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L-#8U+#$V.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V(U9#0X8C5?
M96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V-B-60T.&(U7V5B-#)?-#,Y-U]B965A7S0P-C1B,#`Q
M-V4R."]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.,T%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@
M0D%,04Y#12!32$5%5%,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-54E)%3E0@05-31513
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#4P+#(Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,C<L,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1S
M(')E8V5I=F%B;&4Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R861E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#@S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YV96YT;W)I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,#4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y+#4X,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#0Y
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1E5.1%,@24X@4D534$5#5"!/1B!%35!,3UE%12!224=(5%,@55!/3B!2
M151)4D5-14Y4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$S
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y04D]015)462!!3D0@15%525!-14Y4+"!.150\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#8V-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#(W,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<L,S<X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L
M.#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U86QS.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT,C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`S,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#0T-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M-30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$969E<G)E9"!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PU-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#$R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#0S-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X+#8Y
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY,3TY'(%1%4DT@3$E!0DE,251)15,Z/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N
M=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPT.3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PY
M,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQO;F<@=&5R;2!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-SDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPU-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!F;W(@96UP;&]Y964@
M<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PX-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&QO;F<@=&5R;2!L:6%B:6QI
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(L,3<Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DL
M,3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<R+#8P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<W+#@X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-34E4345.5%,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4TA!4D5(3TQ$15)3)R!%455)5%D@*$-!4$E404P@1$5&24-)14Y#62D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-S<R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8L,#<W*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&QI86)I;&ET:65S(&%N9"!S:&%R96AO;&1E<G,G(&5Q=6ET>2`H
M;F5T(&]F(&-A<&ET86P@9&5F:6-I96YC>2D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-S<L,S<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,2PX,#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-B-60T.&(U7V5B-#)?-#,Y-U]B
M965A7S0P-C1B,#`Q-V4R.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@O5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T-!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#3TY$14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@
M3T8@3U!%4D%424].4R`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T
M(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#0^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$-#XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CY397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY3
M97`N(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y4
M4R!/1B!/4$52051)3TY3(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4D5614Y515,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,RPW,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S,RPV.3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L,#(T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#3TU004Y9)U,@4TA!4D4@24X@0T],3$%"
M3U)!5$E/3B!!1U)%14U%3E0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-C8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C,U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,L-S0U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0T]35"!/1B!2159%3E5%4SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,BPS-C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#DV-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,3,P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1U)/4U,@4%)/1DE4
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`R,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(W+#0Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y215-%05)#
M2"!!3D0@1$5614Q/4$U%3E0@15A014Y315,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#@L,S(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.2PS-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-RPW,3<I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R."PV-S$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S
M=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/FQE<W,@+2!G
M<F%N=',@86YD(')E:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#DV,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV-34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$V,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)%4T5!4D-(($%.1"!$159%3$]0345.5"!%
M6%!%3E-%4RP@3D54/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M+#,V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#DQ."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,BPP-C(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C,L-3`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1T5.15)!3"!!3D0@041-24Y)4U12051)5D4@15A014Y3
M15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,C(P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS
M73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PU,C8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS
M=7`^6S-=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M+#,U,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/'-U<#Y;,UT\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4L,S$T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3U!%4D%424Y'($Q/4U,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#4L-38P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@L-S8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,#`U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W+#8W,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9)3D%.0TE!3"!)3D-/344@*$58
M4$5.4T53*2`M($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M150@3$]34R!&3U(@5$A%(%!%4DE/1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@U+#0W.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#@L.#<U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,2PW
M-#$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R-RPV,38I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQ/4U,@4$52
M(%-(05)%($]&($-/34U/3B!35$]#2SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0D%324,@04Y$($1)3%54140\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^)"`H,"XP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,#(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C`S,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5T5)1TA4140@059%
M4D%'12!.54U"15(@3T8@4TA!4D53($]&($-/34U/3B!35$]#2R!54T5$($E.
M($-/35!55$E.1R!,3U-3(%!%4B!32$%213H\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0D%324,@04Y$($1)3%54140\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDQ+#DR.2PT-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX-2PU.#4L-S<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.3`L-#DQ+#0R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T
M+#,U,2PT,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT9"!C;VQS<&%N/3-$.3X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX]
M,T1T;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0X('9A;&EG
M;CTS1'1O<#Y);F-L=61E<R!S:&%R92UB87-E9"!C;VUP96YS871I;VX@,C(P
M(#`@,C(P(#`\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S)=
M/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0X('9A;&EG;CTS1'1O<#Y)
M;F-L=61E<R!S:&%R92UB87-E9"!C;VUP96YS871I;VX@,2PR-#<@.3(@,RPV
M.3`@,S0X/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I
M;FYE<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELS73PO
M=&0^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$."!V86QI9VX],T1T;W`^26YC
M;'5D97,@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(#@T,"`Q,3<@,BPQ-34@
M,S@R(#PO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R
M7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8V(U9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X
M+U=O<FMS:&5E=',O4VAE970P-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y,044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%4
M14U%3E13($]&($]015)!5$E/3E,@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\
M8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E
M<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S
M960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$L,C0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,RPV.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#,T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@061M:6YI
M<W1R871I=F4@17AP96YS92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@T,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T
M(&]F(%)E=F5N=65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(R,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V(U9#0X8C5?96(T
M,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V-B-60T.&(U7V5B-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R
M."]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!,4)'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,B!R
M;W=S<&%N/3-$,3X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!
M5$5-14Y4($]&($-(04Y'15,@24X@4TA!4D5(3TQ$15)3)R!%455)5%D@*$-!
M4$E404P@1$5&24-)14Y#62D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X
M8V5P="!3:&%R92!D871A/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^5&]T86P\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I=&%L(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA
M=&5D($1E9FEC:70@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E(&%T($1E8RX@,S$L(#(P
M,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T:#X\<W5P/CPO<W5P/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PS,C,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3(T+#`T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,3,U+#0T."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E("AI;B!S:&%R
M97,I(&%T($1E8RX@,S$L(#(P,3`\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T:#X\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#$L,C0X+#0W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@8V%S
M:"`H;F5T(&]F(&ES<W5A;F-E(&-O<W1S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,"PU.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C`L-3@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D(&9O
M<B!C87-H("AN970@;V8@:7-S=6%N8V4@8V]S=',I("AI;B!S:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^/'-U<#Y;,5T\+W-U<#X\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<W1O8VL@;W!T:6]N<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,S`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F
M(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T:#X\<W5P/CPO<W5P/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M
M<&QO>65E<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1H/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-3`L,#0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@;&]S<R!F;W(@=&AE('!E<FEO9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R-RPV,38I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<L-C$V*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A
M;&%N8V4@870@4V5P+B`S,"P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-RPS-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-#4L-C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,38S+#`V-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E
M("AI;B!S:&%R97,I(&%T(%-E<"X@,S`L(#(P,3$\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T:#X\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#4L-3DX+#4Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@
M870@1&5C+B`S,2P@,C`Q,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1H
M/CQS=7`^/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R
M-BPP-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#4L.#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3<Q+#DW-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E("AI
M;B!S:&%R97,I(&%T($1E8RX@,S$L(#(P,3$\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T:#X\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#4L-C,P+#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F
M;W(@8V%S:"`H;F5T(&]F(&ES<W5A;F-E(&-O<W1S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-2PS.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,S@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S
M=65D(&9O<B!C87-H("AN970@;V8@:7-S=6%N8V4@8V]S=',I("AI;B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^/'-U<#Y;,5T\+W-U
M<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3<U+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<W1O8VL@;W!T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1H/CQS=7`^/"]S=7`^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#(Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,C$W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S(&%N9"!N
M;VXM96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&@^/'-U
M<#X\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,3,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y
M965S(&%N9"!N;VXM96UP;&]Y965S("AI;B!S:&%R97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&@^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,34V+#$X-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@T.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@T-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C
M:R!A=V%R9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1H/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&@^/'-U<#X\+W-U<#X\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S0Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S0Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A
M;&%N8V4@870@4V5P+B`S,"P@,C`Q,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1H/CQS=7`^/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0L-S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,3<X+#,Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<S+#<Q."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"
M86QA;F-E("AI;B!S:&%R97,I(&%T(%-E<"X@,S`L(#(P,3(\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T:#X\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L-#8Q+#,T,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O
M;'-P86X],T0U/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;
M,5T\+W1D/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!3=&]C:RP@)#`N,#`Q('!A<B!V86QU93L@075T:&]R:7IE9"`M
M(&%S(&]F(%-E<'1E;6)E<B`S,"P@,C`Q,B!A;F0@4V5P=&5M8F5R(#,P+"`R
M,#$Q("T@,34P+#`P,"PP,#`@<VAA<F5S+CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(U9#0X8C5?96(T,E\T
M,SDW7V)E96%?-#`V-&(P,#$W93(X+U=O<FMS:&5E=',O4VAE970P-BYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P13)%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.
M4T5$($-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!32$%2
M14A/3$1%4E,G($5154E462`@*$-!4$E404P@1$5&24-)14Y#62D@*%!A<F5N
M=&AE=&EC86PI("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA
M<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0T].1$5.4T5$
M($-/3E-/3$E$051%1"!35$%414U%3E0@3T8@0TA!3D=%4R!)3B!32$%214A/
M3$1%4E,G($5154E462`H0T%0251!3"!$149)0TE%3D-9*2!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:R!I<W-U960@9F]R(&-A<V@L(&ES<W5A;F-E(&-O<W1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-S@P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0Q,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N(%-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VLL($%U=&AO
M<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V-B-60T.&(U7V5B-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C5D-#AB-5]E8C0R
M7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@O5V]R:W-H965T<R]3:&5E=#`W+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%04Q!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY$
M14Y3140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@0T%32"!&3$]74R`H
M55-$("0I/&)R/DEN(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C
M:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0T%32"!&3$]74R!&4D]-($]015)!5$E.1R!!0U1)5DE42453.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#<T,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(W+#8Q-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@<F5Q=6ER960@=&\@<F5C
M;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#`V-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N
M9"!W<FET92!D;W=N(&]F(&9I>&5D(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPW-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#8Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN86YC:6%L(&EN8V]M92P@
M;F5T("AM86EN;'D@97AC:&%N9V4@9&EF9F5R96YC97,I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VAA;F=E<R!I;B!A8V-R=65D
M(&QI86)I;&ET>2!F;W(@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN
M(&]N(&%M;W5N=',@9G5N9&5D(&EN(')E<W!E8W0@;V8@96UP;&]Y964@<FEG
M:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y,;W-S(&]N('-A;&4@;V8@9FEX960@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA8FEL
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1E8W)E87-E(&EN(&1E9F5R<F5D(')E=F5N=65S("AI;F-L=61I;F<@
M;F]N+6-U<G)E;G0@<&]R=&EO;BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0L.3@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#DY,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI;F-R96%S92D@:6X@86-C
M;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BPP.3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPX,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI;F-R96%S92D@:6X@:6YV96YT
M;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S<Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^26YC<F5A<V4@:6X@86-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5A;',@
M*&EN8VQU9&EN9R!L;VYG('1E<FTI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M,3@V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$V+#DU."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0T%32"!&3$]74R!&4D]-($E.5D535$E.
M1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#@Q-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#`P,2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@<V%L92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;6]U;G1S(&9U;F1E9"!I;B!R97-P96-T(&]F(&5M<&QO>65E(')I9VAT
M<R!U<&]N(')E=&ER96UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L
M.3$P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#4L,3(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@1DE.04Y#24Y'
M($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DES<W5A;F-E(&]F('-H87)E<RP@;F5T(&]F(&ES<W5A;F-E
M(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#,R.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P
M+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PP.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B>2!F
M:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C8L-#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C`L.3$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%1D9%0U0@3T8@15A#2$%.1T4@4D%412!#
M2$%.1T53($].($-!4T@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3D54($E.0U)%05-%("A$14-214%312D@24X@0T%32"!!
M3D0@0T%32"!%455)5D%,14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C,L,C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,2PS,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"04Q!3D-%($]&($-!4T@@04Y$($-!4T@@
M15%5259!3$5.5%,@050@0D5'24Y.24Y'($]&(%!%4DE/1#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4L.3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"04Q!3D-%($]&
M($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,@050@14Y$($]&(%!%4DE/1#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L,C$V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L-38T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-54%!,14U%3E1!4ED@24Y&3U)-051)3TX@3TX@24Y615-424Y'
M($%.1"!&24Y!3D-)3D<@04-4259)5$E%4R!.3U0@24Y63TQ624Y'($-!4T@@
M1DQ/5U,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!U<F-H87-E(&]F('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#<W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!C
M;W-T(&YO="!Y970@<&%I9"!A;F0@86-C<G5A;',@+2!O=&AE<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C
M:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?
M8F5E85\T,#8T8C`P,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO8V(U9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X+U=O<FMS
M:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3
M24=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TE'3DE&
M24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O
M1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW
M,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@
M+2T^#0H\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^3D]412`Q("T@4TE'3DE&24-!
M3E0@04-#3U5.5$E.1R!03TQ)0TE%4SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TP+C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%2
M1TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=.
M.B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SX\<W1R;VYG/F$N/"]S=')O
M;F<^/"]T9#X@/'1D/CQS=')O;F<^1V5N97)A;#PO<W1R;VYG/CPO=&0^(#PO
M='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)FYB<W`[/"]P/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XW-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#`N,C5I;B<^/'-T<F]N9SXQ+CPO<W1R;VYG/CPO=&0^(#QT9#Y/<&5R871I
M;VX\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P
M="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B!0<F]T86QI>"!":6]4:&5R87!E=71I8W,L($EN8RX@*&-O;&QE8W1I
M=F5L>2!W:71H(&ET<R!S=6)S:61I87)I97,L('1H92`B0V]M<&%N>2(I+"!A
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M=7`^('!R;W1E:6X@97AP<F5S<VEO;B!S>7-T96T@*")0<F]#96QL17@B*2X@
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M/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P
M="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!/;B!-87D@,2P@,C`Q
M,BP@=&AE(%4N4RX@1F]O9"!A;F0@1')U9R!!9&UI;FES=')A=&EO;B`H/&9O
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M92`H1T-$*2!T:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#
M96QL17@N(%1A;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E9"!B
M>2!T:&4@27-R865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`B27-R865L
M:2!-3T@B*2!I;B!397!T96UB97(@,C`Q,BX@5&%L:6=L=6-E<F%S92!A;&9A
M(&ES('1H92!F:7)S="!P;&%N="!C96QL+6)A<V5D(')E8V]M8FEN86YT('1H
M97)A<&5U=&EC('!R;W1E:6X@87!P<F]V960@8GD@96%C:"!O9B!T:&4@1D1!
M(&%N9"!T:&4@27-R865L:2!-3T@N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
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M87)K971S($5,14Q94T\@:6X@27-R865L+CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@4')O=&%L:7@@3'1D+B!G<F%N=&5D(%!F
M:7IE<B!A;B!E>&-L=7-I=F4L('=O<FQD=VED92!L:6-E;G-E('1O(&1E=F5L
M;W`@86YD(&-O;6UE<F-I86QI>F4@=&%L:6=L=6-E<F%S92!A;&9A('5N9&5R
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M('5P9G)O;G0@<&%Y;65N="!O9B`D-C`N,"!M:6QL:6]N(&EN(&-O;FYE8W1I
M;VX@=VET:"!T:&4@97AE8W5T:6]N(&]F('1H92!09FEZ97(@06=R965M96YT
M(&%N9"!S:&]R=&QY('1H97)E869T97(@86X@861D:71I;VYA;"`D-2XP(&UI
M;&QI;VX@8VQI;FEC86P@9&5V96QO<&UE;G0M<F5L871E9"!M:6QE<W1O;F4@
M<&%Y;65N="X@5&AE($-O;7!A;GD@<F5C96EV960@86X@861D:71I;VYA;"`D
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M86QF82!O;B!A(#0P)2!A;F0@-C`E(&)A<VES+"!R97-P96-T:79E;'DL(&5X
M8V5P="!W:71H(')E<W!E8W0@=&\@=&AE('!R;V9I=',@86YD(&QO<W-E<R!R
M96QA=&5D('1O(&-O;6UE<F-I86QI>F%T:6]N(&5F9F]R=',@:6X@27-R865L
M+B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/DEN(&-A;&-U;&%T:6YG
M('1H92!N970@<')O9FET<R!U;F1E<B!T:&4@86=R965M96YT+"!T:&5R92!A
M<F4@8V5R=&%I;B!A9W)E960@=7!O;B!L:6UI=',@;VX@=&AE(&%M;W5N=',@
M=&AA="!M87D@8F4@9&5D=6-T960@9G)O;2!G<F]S<R!S86QE<R!F;W(@8V5R
M=&%I;B!E>'!E;G-E<R!A;F0@8V]S=',@;V8@9V]O9',@<V]L9#PO9F]N=#XN
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/
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M:6-I;F%L(%!R;V1U8W1S(&9O<B!(=6UA;B!5<V4@*$-(35`I($IU;F4@,C`Q
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M9B!T86QI9VQU8V5R87-E(&%L9F$N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B!);B!A9&1I=&EO;B!T;R!T86QI9VQU8V5R87-E
M(&%L9F$L('1H92!#;VUP86YY(&ES('=O<FMI;F<@;VX@=&AE(&1E=F5L;W!M
M96YT(&]F(&-E<G1A:6X@;W1H97(@<')O9'5C=',@=7-I;F<@4')O0V5L;$5X
M+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@0W5R
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M=F5D('1R96%T;65N=',N($]N($IU;'D@,3,L(#(P,3`L('1H92!#;VUP86YY
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M<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($]N
M($%U9W5S="`Q,"P@,C`Q,"P@4&9I>F5R(&5N=&5R960@:6YT;R!A('-H;W)T
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M:6YD97(@;V8@,C`Q,"!A;F0@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q,2P@
M=&AE($-O;7!A;GD@86YD(%!F:7IE<B!C;VUP;&5T960@=&AE('-U<'!L>2!O
M9B!P<F]D=6-T<R!D96QI=F5R86)L92!U;F1E<B!T:&4@<VAO<G0M=&5R;2!S
M=7!P;'D@86=R965M96YT+B!$=7)I;F<@,C`Q,2P@4&9I>F5R(')E8V]R9&5D
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M<75A<G1E<B!O9B`R,#$R(')E<W5P<&QY(&9O<B!C97)T86EN('9I86QS('=A
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M(&]F('1H92!09FEZ97(@06=R965M96YT+CPO<#X@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF;F)S
M<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"
M3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W
M:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P
M)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=724142#H@,"XR-6EN)SX\<W1R;VYG/C(N/"]S=')O;F<^
M/"]T9#X@/'1D/DQI<75I9&ET>2!A;F0@1FEN86YC:6%L(%)E<V]U<F-E<SPO
M=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
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M8V5I=F5D(&$@)#(U+C`@;6EL;&EO;B!M:6QE<W1O;F4@<&%Y;65N="!I;B!C
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M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@0F%S
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M;G1H<RX\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN.R!-
M05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)FYB<W`[/"]P/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,"XR-6EN)SX\<W1R;VYG/F(N/"]S=')O;F<^/"]T9#X@/'1D/CQS=')O;F<^
M0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]S=')O;F<^/"]T9#X@/"]T<CX@/"]T
M86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@-38N
M-W!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M(&)Y($=!05`@9F]R(&%N;G5A;"!F:6YA;F-I86P@<W1A=&5M96YT<RX@26X@
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M<R!T:&%T(&UA>2!B92!E>'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A<BX\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(%1H
M97-E('5N875D:71E9"!C;VYD96YS960@8V]N<V]L:61A=&5D(&9I;F%N8VEA
M;"!S=&%T96UE;G1S('-H;W5L9"!B92!R96%D(&EN(&-O;FIU;F-T:6]N('=I
M=&@@=&AE(&%U9&ET960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(&EN('1H92!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M2R!F;W(@=&AE
M('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3$L(&9I;&5D(&)Y('1H92!#
M;VUP86YY('=I=&@@=&AE(%-E8W5R:71I97,@86YD($5X8VAA;F=E($-O;6UI
M<W-I;VXN(%1H92!C;VUP87)A=&EV92!B86QA;F-E('-H965T(&%T($1E8V5M
M8F5R(#,Q+"`R,#$Q(&AA<R!B965N(&1E<FEV960@9G)O;2!T:&4@875D:71E
M9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A="!T:&%T(&1A=&4N/"]P/B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3$W+C@U<'0[($U!4D=)3CH@,'!T(#!P
M>"`P<'0@-3,N.#5P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.
M+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D52
M5$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,S9P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q-RXX-7!T)SX\<W1R
M;VYG/F,N/"]S=')O;F<^/"]T9#X@/'1D/CQS=')O;F<^3F5T(&QO<W,@<&5R
M('-H87)E/"]S=')O;F<^/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`U,RXX-7!T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S
M='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4S+C@U<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!"87-I8R!A;F0@
M9&EL=71E9"!L;W-S('!E<B!S:&%R92`H(DQ04R(I(&%R92!C;VUP=71E9"!B
M>2!D:79I9&EN9R!N970@;&]S<R!B>2!T:&4@=V5I9VAT960@879E<F%G92!N
M=6UB97(@;V8@<VAA<F5S(&]F('1H92!#;VUP86YY)B,S.3MS(&-O;6UO;B!S
M=&]C:RP@<&%R('9A;'5E("0N,#`Q('!E<B!S:&%R92`H=&AE(")#;VUM;VX@
M4W1O8VLB*2P@;W5T<W1A;F1I;F<@9F]R(&5A8V@@<&5R:6]D+CPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`U,RXX-7!T.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4S+C@U<'0[($9/
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M=6QD(&)E(&%N=&DM9&EL=71I=F4N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#4S+C@U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@1&EL=71E9"!,4%,@9&]E<R!N;W0@
M:6YC;'5D92`W+#0Y."PP,C8@86YD(#<L,38Y+#`S-2!S:&%R97,@;V8@0V]M
M;6]N(%-T;V-K('5N9&5R;'EI;F<@;W5T<W1A;F1I;F<@;W!T:6]N<R!A;F0@
M<F5S=')I8W1E9"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&9O<B!T:&4@;FEN
M92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q(&%N9"`R,#$R+"!R
M97-P96-T:79E;'DL(&%N9"`W+#0R."PR,#$@86YD(#<L-3`X+#(T,"!S:&%R
M97,@;V8@0V]M;6]N(%-T;V-K('5N9&5R;'EI;F<@;W5T<W1A;F1I;F<@;W!T
M:6]N<R!A;F0@<F5S=')I8W1E9"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&9O
M<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q,2!A
M;F0@,C`Q,BP@<F5S<&5C=&EV96QY+CPO<#X@/"$M+45N9$9R86=M96YT+2T^
M/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?8V(U9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B-60T.&(U7V5B-#)?
M-#,Y-U]B965A7S0P-C1B,#`Q-V4R."]7;W)K<VAE971S+U-H965T,#DN:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/
M4DE%4SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/DE.5D5.5$]22453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y614Y43U))15,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"
M3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@
M(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS
M:71I;VYA;"YD=&0B("TM/@T*/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N
M="TM/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/DY/5$4@
M,B`M($E.5D5.5$]22453/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!);G9E;G1O<GD@870@4V5P=&5M
M8F5R(#,P+"`R,#$R(&%N9"!$96-E;6)E<B`S,2P@,C`Q,2!C;VYS:7-T960@
M;V8@=&AE(&9O;&QO=VEN9SH\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G5TE$
M5$@Z(#@U)3L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4Q%1E0Z
M(#`N-S5I;B<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X@/'1R
M('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W
M<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U7
M14E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L
M9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/E-E<'1E;6)E<B`S,"P\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z
M(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
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M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)
M1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R
M(&YO=W)A<#TS1&YO=W)A<#XR,#$R/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`Q<'0[($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N
M;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B
M;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,3PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS
M1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^
M*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@-S0E)SY287<@;6%T
M97)I86QS/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$P)2<^,2PR.30\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SXD/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT.R!724142#H@,3`E)SXR-SD\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\+W1R/B`\
M='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^5V]R:R!I;B!P<F]G<F5S<SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR.3@\+W1D/B`\=&0@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/BT\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#%P="<^1FEN:7-H960@
M9V]O9',\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#%P="!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@-#8V/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M<FEG:'0G/B`M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!W:&ET93L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,BXU<'0G/E1O=&%L(&EN=F5N=&]R>3PO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/B`R+#`U.#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,BXU<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`D/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@<FEG
M:'0G/B`R-SD\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].
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M;'5C97)A<V4@86QF82!O;B!-87D@,2P@,C`Q,BP@=&AE($-O;7!A;GD@8V%P
M:71A;&EZ97,@86QL(&UA;G5F86-T=7)I;F<@8V]S=',@87-S;V-I871E9"!W
M:71H('1A;&EG;'5C97)A<V4@86QF82X\+W`^(#PA+2U%;F1&<F%G;65N="TM
M/CPO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V-B-60T.&(U7V5B-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R
M.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C8C5D-#AB-5]E8C0R
M7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@O5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TL@
M5%)!3E-!0U1)3TY3/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4U1/0TL@5%)!3E-!0U1)3TY3(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4U1/
M0TL@5%)!3E-!0U1)3TY3/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"CQD:78^
M(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@<W1Y;&4],T0G34%21TE.
M.B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@/'-T<F]N9SY.3U1%(#,@+2!35$]#2R!44D%.4T%#5$E/3E,\
M+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,C$N,C5P
M=#L@34%21TE..B`P<'0@,'!X(#!P="`W,"XY<'0[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B9N8G-P.SPO<#X@/'1A8FQE
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@
M/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4]
M,T0G5TE$5$@Z(#0Y+C8U<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=7
M24142#H@,C$N,C5P="<^/'-T<F]N9SYA+CPO<W1R;VYG/CPO=&0^(#QT9"!S
M='EL93TS1"=#3TQ/4CH@8FQA8VLG/D]N($9E8G)U87)Y(#(R+"`R,#$R+"!T
M:&4@0V]M<&%N>2!I<W-U960@86YD('-O;&0@-2PQ-S4L,#`P('-H87)E<R!O
M9B!#;VUM;VX@4W1O8VL@:6X@86X@=6YD97)W<FET=&5N('!U8FQI8R!O9F9E
M<FEN9R!A="!A('!R:6-E('1O('1H92!P=6)L:6,@;V8@)#4N,C4@<&5R('-H
M87)E+B!4:&4@;F5T('!R;V-E961S('1O('1H92!#;VUP86YY('=E<F4@87!P
M<F]X:6UA=&5L>2`D,C4L,S@X+#`P,"`H;F5T(&]F('5N9&5R=W)I=&EN9R!C
M;VUM:7-S:6]N<R!A;F0@:7-S=6%N8V4@8V]S=',@;V8@87!P<F]X:6UA=&5L
M>2`D,2PW.#`L,#`P*2X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3(Q+C(U<'0[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M-S`N.7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!
M3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`T.2XV-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!724142#H@,C$N
M,C5P="<^/'-T<F]N9SYB+CPO<W1R;VYG/CPO=&0^(#QT9#X\9F]N="!S='EL
M93TS1"=#3TQ/4CH@8FQA8VLG/D1U<FEN9R!T:&4@;FEN92!M;VYT:',@96YD
M960@4V5P=&5M8F5R(#,P+"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@82!T
M;W1A;"!O9CPO9F]N=#X@,2PQ-38L,3@T(#QF;VYT('-T>6QE/3-$)T-/3$]2
M.B!B;&%C:R<^<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE(&5X97)C:7-E(&]F(&$@=&]T86P@;V8\+V9O;G0^(#$L,34V
M+#$X-"`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/F]P=&EO;G,@8GD@
M8V5R=&%I;B!O9F9I8V5R<R!A;F0@96UP;&]Y965S(&]F('1H92!#;VUP86YY
M+B!4:&4@0V]M<&%N>2!R96-E:79E9"!A9V=R96=A=&4@8V%S:"!P<F]C965D
M<R!E<75A;"!T;R!A<'!R;WAI;6%T96QY("0\+V9O;G0^,2PQ,S<L,#`P(#QF
M;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^:6X@8V]N;F5C=&EO;B!W:71H
M('-U8V@@97AE<F-I<V5S+CPO9F]N=#X\+W1D/B`\+W1R/B`\+W1A8FQE/B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3(Q+C(U<'0[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@-S`N.7!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF;F)S<#L\+W`^(#QT86)L92!S='EL93TS1"=-05)'
M24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`T.2XV
M-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0T],3U(Z(&)L86-K.R!7
M24142#H@,C$N,C5P="<^/'-T<F]N9SYC+CPO<W1R;VYG/CPO=&0^(#QT9#X\
M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/D9O;&QO=VEN9R!&1$$\+V9O
M;G0^(&%P<')O=F%L(&]F('1A;&EG;'5C97)A<V4@86QF82!O;B!-87D@,2P@
M,C`Q,CQF;VYT('-T>6QE/3-$)T-/3$]2.B!B;&%C:R<^+"!T:&4@0V]M<&%N
M>2!S=&%R=&5D(')E8V]G;FEZ:6YG(&-O;7!E;G-A=&EO;B!C;W-T<R!I;B!R
M96QA=&EO;B!T;R!P97)F;W)M86YC92UB87-E9"!A=V%R9',@=&AA="!W97)E
M(&=R86YT960@:6X@1F5B<G5A<GD@,C`Q,"!T;R!C97)T86EN(&]F9FEC97)S
M(&%N9"!E;7!L;WEE97,@;V8@=&AE($-O;7!A;GDL('=H:6-H('9E<W0@;W9E
M<B!A('1H<F5E+7EE87(@<&5R:6]D(&-O;6UE;F-I;F<@=7!O;B!T:&4@1D1!
M)B,S.3MS(&%P<')O=F%L(&]F/"]F;VYT/B!T86QI9VQU8V5R87-E(&%L9F$\
M9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/BX@1'5R:6YG('1H92!S96-O
M;F0@86YD('1H:7)D('%U87)T97(@;V8@,C`Q,BP@=&AE($-O;7!A;GD@<F5C
M;W)D960@86X@97AP96YS92!I;B!T:&4@86UO=6YT(&]F(&%P<')O>&EM871E
M;'D@)#,L.3`P+#`P,"!F;W(@=&AE(&-U;75L871I=F4@<&5R:6]D(&9R;VT@
M=&AE(&1A=&4@;V8@9W)A;G0N/"]F;VYT/CPO=&0^(#PO='(^(#PO=&%B;&4^
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,C$N,C5P=#L@34%21TE..B`P
M<'0@,'!X(#!P="`W,"XY<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#0Y
M+C8U<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=#3TQ/4CH@8FQA8VL[
M(%=)1%1(.B`R,2XR-7!T)SX\<W1R;VYG/F0N/"]S=')O;F<^/"]T9#X@/'1D
M/D]N($IU;'D@,38L(#(P,3(L('1H92!#;VUP86YY)B,S.3MS($)O87)D(&]F
M($1I<F5C=&]R<R!A<'!R;W9E9"!T:&4@9W)A;G0@;V8@,2PU,#`L,#`P('-H
M87)E<R!O9B!R97-T<FEC=&5D($-O;6UO;B!3=&]C:R!T;R!I=',@;V9F:6-E
M<G,@86YD(&-E<G1A:6X@;W1H97(@96UP;&]Y965S+B!/9B!S=6-H(')E<W1R
M:6-T960@<VAA<F5S+"`Q+#$P,"PP,#`@;V8@=&AE('-H87)E<R!W97)E(&ES
M<W5E9"!T;R!T:&4@0V]M<&%N>28C,SD[<R!N86UE9"!E>&5C=71I=F4@;V9F
M:6-E<G,@86YD('9E<W0@:6X@,38@97%U86PL('%U87)T97)L>2!I;F-R96UE
M;G1S(&]V97(@82!F;W5R+7EE87(@<&5R:6]D+"!C;VUM96YC:6YG('5P;VX@
M=&AE(&1A=&4@;V8@9W)A;G0L(&%N9"!A<F4@<W5B:F5C="!T;R!A(#(T+6UO
M;G1H(&QO8VLM=7`@<&5R:6]D+"!C;VUM96YC:6YG('5P;VX@=&AE(&%P<&QI
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M="!T;R!C97)T86EN(&5X8V5P=&EO;G,N(%1H92!R96UA:6YI;F<@-#`P+#`P
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M(&)E(&%P<')O>&EM871E;'D@)#@L-3@P+#`P,"X\+W1D/B`\+W1R/B`\+W1A
M8FQE/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R
M7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO8V(U9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X
M+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-50E-%455%3E0@159%3E13/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U5"4T51545.
M5"!%5D5.5%,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y354)315%514Y4($5614Y44SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^#0H\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT+2T^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^3D]412`T("T@
M4U5"4T51545.5"!%5D5.5%,\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XU:6X[($9/
M3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8V(U9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W
M93(X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B-60T.&(U7V5B
M-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R."]7;W)K<VAE971S+U-H965T,3(N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5+2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY324=.
M249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A0;VQI8WDI/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4TE'3DE&
M24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@
M4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%
M3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R
M86YS:71I;VYA;"YD=&0B("TM/@T*/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G
M;65N="TM/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM
M0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O
M<"<^(#QT9"!S='EL93TS1"=724142#H@,"XU:6XG/CQS=')O;F<^82X\+W-T
M<F]N9SX\+W1D/B`\=&0^/'-T<F]N9SY'96YE<F%L/"]S=')O;F<^/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U
M:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF;F)S<#L\+W`^(#QT86)L92!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$
M)U=)1%1(.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=72414
M2#H@,"XR-6EN)SX\<W1R;VYG/C$N/"]S=')O;F<^/"]T9#X@/'1D/D]P97)A
M=&EO;CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@
M,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^(%!R;W1A;&EX($)I;U1H97)A<&5U=&EC<RP@26YC+B`H8V]L;&5C
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M;VUP86YY)B,S.3MS('!R;W!R:65T87)Y(%!R;T-E;&Q%>#QS=7`^)G)E9SL\
M+W-U<#X@<')O=&5I;B!E>'!R97-S:6]N('-Y<W1E;2`H(E!R;T-E;&Q%>"(I
M+B!);B!397!T96UB97(@,C`P.2P@4')O=&%L:7@@3'1D+B!F;W)M960@86YO
M=&AE<B!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!U;F1E<B!T:&4@;&%W<R!O
M9B!T:&4@3F5T:&5R;&%N9',L(%!R;W1A;&EX($(N5BXL(&EN(&-O;FYE8W1I
M;VX@=VET:"!T:&4@175R;W!E86X@365D:6-I;F5S($%G96YC>2`H(D5-02(I
M(&%P<&QI8V%T:6]N('!R;V-E<W,@:6X@=&AE($5U<F]P96%N(%5N:6]N+B!4
M:&4@0V]M<&%N>28C,SD[<R!T=V\@<W5B<VED:6%R:65S(&%R92!R969E<G)E
M9"!T;R!C;VQL96-T:79E;'D@:&5R96EN(&%S('1H92`B4W5B<VED:6%R:65S
M+B(\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@
M,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($]N($UA>2`Q+"`R
M,#$R+"!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T:6]N("@\
M9F]N="!S='EL93TS1"=415A4+51204Y31D]233H@=7!P97)C87-E)SXB/"]F
M;VYT/D9$03QF;VYT('-T>6QE/3-$)U1%6%0M5%)!3E-&3U)-.B!U<'!E<F-A
M<V4G/B(\+V9O;G0^*2!A<'!R;W9E9"!T86QI9VQU8V5R87-E(&%L9F$@9F]R
M(&EN:F5C=&EO;BP@=&AE($-O;7!A;GDF(S,Y.W,@9FER<W0@87!P<F]V960@
M9')U9R!P<F]D=6-T+"!A<R!A;B!E;GIY;64@<F5P;&%C96UE;G0@=&AE<F%P
M>2`H15)4*2!F;W(@=&AE(&QO;F<M=&5R;2!T<F5A=&UE;G0@;V8@861U;'0@
M<&%T:65N=',@=VET:"!A(&-O;F9I<FUE9"!D:6%G;F]S:7,@;V8@='EP92`Q
M($=A=6-H97(@9&ES96%S92X@5&%L:6=L=6-E<F%S92!A;&9A(&ES(&$@<')O
M<')I971A<GDL(')E8V]M8FEN86YT(&9O<FT@;V8@9VQU8V]C97)E8G)O<VED
M87-E("A'0T0I('1H870@=&AE($-O;7!A;GD@9&5V96QO<&5D('5S:6YG(%!R
M;T-E;&Q%>"X@5&%L:6=L=6-E<F%S92!A;&9A('=A<R!A;'-O(&%P<')O=F5D
M(&)Y('1H92!)<W)A96QI($UI;FES=')Y(&]F($AE86QT:"`H=&AE("))<W)A
M96QI($U/2"(I(&EN(%-E<'1E;6)E<B`R,#$R+B!486QI9VQU8V5R87-E(&%L
M9F$@:7,@=&AE(&9I<G-T('!L86YT(&-E;&PM8F%S960@<F5C;VUB:6YA;G0@
M=&AE<F%P975T:6,@<')O=&5I;B!A<'!R;W9E9"!B>2!E86-H(&]F('1H92!&
M1$$@86YD('1H92!)<W)A96QI($U/2"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)
M3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^(%1A;&EG;'5C97)A<V4@86QF82!I<R!B96EN
M9R!M87)K971E9"!I;B!T:&4@56YI=&5D(%-T871E<R!U;F1E<B!T:&4@8G)A
M;F0@;F%M92!%3$5,65-/)G1R861E.R!B>2!09FEZ97(@26YC+B`H/&9O;G0@
M<W1Y;&4],T0G5$585"U44D%.4T9/4DTZ('5P<&5R8V%S92<^(CPO9F]N=#Y0
M9FEZ97(\9F]N="!S='EL93TS1"=415A4+51204Y31D]233H@=7!P97)C87-E
M)SXB/"]F;VYT/BDL('1H92!#;VUP86YY)B,S.3MS(&-O;6UE<F-I86QI>F%T
M:6]N('!A<G1N97(L(&%S('!R;W9I9&5D(&EN('1H92!E>&-L=7-I=F4@;&EC
M96YS92!A;F0@<W5P<&QY(&%G<F5E;65N="!B>2!A;F0@8F5T=V5E;B!0<F]T
M86QI>"!,=&0N(&%N9"!09FEZ97(@*'1H92`\9F]N="!S='EL93TS1"=415A4
M+51204Y31D]233H@=7!P97)C87-E)SXB/"]F;VYT/E!F:7IE<B!!9W)E96UE
M;G0\9F]N="!S='EL93TS1"=415A4+51204Y31D]233H@=7!P97)C87-E)SXB
M/"]F;VYT/BDN(%1H92!#;VUP86YY+"!T:')O=6=H(%!R;W1A;&EX($QT9"XL
M(&UA<FME=',@14Q%3%E33R!I;B!)<W)A96PN/"]P/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
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M;G0@86YD('-H;W)T;'D@=&AE<F5A9G1E<B!A;B!A9&1I=&EO;F%L("0U+C`@
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M;&EZ871I;VX@;V8@=&%L:6=L=6-E<F%S92!A;&9A(&]N(&$@-#`E(&%N9"`V
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M;W-T<R!O9B!G;V]D<R!S;VQD/"]F;VYT/BX\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
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M($AU;6%N(%5S92`H0TA-4"D@2G5N92`R,#$R(&]P:6YI;VX@<F5C;VUM96YD
M:6YG(&%G86EN<W0@=&AE(&UA<FME=&EN9R!A=71H;W)I>F%T:6]N(&]F('1A
M;&EG;'5C97)A<V4@86QF82X@5VAI;&4@=&AE($-(35`@9V%V92!A('!O<VET
M:79E(')I<VLM8F5N969I="!A<W-E<W-M96YT(&9O<B!T86QI9VQU8V5R87-E
M(&%L9F$L(&ET<R!R96-O;6UE;F1A=&EO;B!W87,@8F%S960@<V]L96QY(&]N
M('1H92!O<G!H86X@;6%R:V5T(&5X8VQU<VEV:71Y(&=R86YT960@=&\@5E!2
M258\<W5P/B9R96<[/"]S=7`^+"!3:&ER92!P;&,F(S,Y.W,@1V%U8VAE<B!D
M:7-E87-E('1R96%T;65N="X@270@=V%S(&YO="!B87-E9"!O;B!T:&4@<V%F
M971Y(&%N9"!E9F9I8V%C>2!P<F]F:6QE(&]F('1A;&EG;'5C97)A<V4@86QF
M82X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF;F)S
M<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@
M1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($EN
M(&%D9&ET:6]N('1O('1A;&EG;'5C97)A<V4@86QF82P@=&AE($-O;7!A;GD@
M:7,@=V]R:VEN9R!O;B!T:&4@9&5V96QO<&UE;G0@;V8@8V5R=&%I;B!O=&AE
M<B!P<F]D=6-T<R!U<VEN9R!0<F]#96QL17@N/"]P/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G
M34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
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M2G5L>2`Q,RP@,C`Q,"P@=&AE($-O;7!A;GD@86YN;W5N8V5D('1H870@=&AE
M($9R96YC:"!R96=U;&%T;W)Y(&%U=&AO<FET>2!H860@9W)A;G1E9"!A;B!!
M=71O<FES871I;VX@5&5M<&]R86ER92!D)B,S.3M5=&EL:7-A=&EO;B`H0515
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M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^
M(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@3VX@075G=7-T
M(#$P+"`R,#$P+"!09FEZ97(@96YT97)E9"!I;G1O(&$@<VAO<G0M=&5R;2!S
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M9B`R,#$P(&%N9"!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$Q+"!T:&4@0V]M
M<&%N>2!A;F0@4&9I>F5R(&-O;7!L971E9"!T:&4@<W5P<&QY(&]F('!R;V1U
M8W1S(&1E;&EV97)A8FQE('5N9&5R('1H92!S:&]R="UT97)M('-U<'!L>2!A
M9W)E96UE;G0N($1U<FEN9R`R,#$Q+"!09FEZ97(@<F5C;W)D960@86X@86QL
M;W=A;F-E(&9O<B!S86QE<R!R971U<FYS(&EN(&-O;FYE8W1I;VX@=VET:"!T
M:&4@<W5P<&QY(&%G<F5E;65N="!B96-A=7-E('1H92!"<F%Z:6QI86X@36EN
M:7-T<GD@;V8@2&5A;'1H(')E<75E<W1E9"!T:&%T(%!F:7IE<B!C;VYS:61E
M<B!T:&4@<F5P;&%C96UE;G0@;V8@8V5R=&%I;B!V:6%L<R!T:&%T(&UI9VAT
M(&5X<&ER92!D=7)I;F<@,C`Q,BX@1'5R:6YG('1H92!T:&ER9"!Q=6%R=&5R
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M(%!F:7IE<B!!9W)E96UE;G0N/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B9N8G-P.SPO<#X@
M/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@
M,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$
M,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@
M<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U=)1%1(.B`P+C(U:6XG/CQS=')O;F<^,BX\+W-T<F]N9SX\+W1D/B`\
M=&0^3&EQ=6ED:71Y(&%N9"!&:6YA;F-I86P@4F5S;W5R8V5S/"]T9#X@/"]T
M<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M82`D,C4N,"!M:6QL:6]N(&UI;&5S=&]N92!P87EM96YT(&EN(&-O;FYE8W1I
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M961I8W0@=&AE(&]U=&-O;64@;V8@=&AE<V4@86-T:79I=&EE<RX\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!"87-E9"!O
M;B!I=',@8W5R<F5N="!C87-H(')E<V]U<F-E<R!A;F0@8V]M;6ET;65N=',L
M('1H92!#;VUP86YY(&)E;&EE=F5S(&ET('=I;&P@8F4@86)L92!T;R!M86EN
M=&%I;B!I=',@8W5R<F5N="!P;&%N;F5D(&1E=F5L;W!M96YT(&%C=&EV:71I
M97,@86YD('1H92!C;W)R97-P;VYD:6YG(&QE=F5L(&]F(&5X<&5N9&ET=7)E
M<R!F;W(@870@;&5A<W0@=&AE(&YE>'0@,3(@;6]N=&AS+"!A;'1H;W5G:"!N
M;R!A<W-U<F%N8V4@8V%N(&)E(&=I=F5N('1H870@:70@=VEL;"!N;W0@;F5E
M9"!A9&1I=&EO;F%L(&9U;F1S('!R:6]R('1O('-U8V@@=&EM92X@268@=&AE
M<F4@87)E('5N97AP96-T960@:6YC<F5A<V5S(&EN(&=E;F5R86P@86YD(&%D
M;6EN:7-T<F%T:79E(&5X<&5N<V5S(&]R(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E<RP@=&AE($-O;7!A;GD@;6%Y(&YE960@=&\@<V5E:R!A
M9&1I=&EO;F%L(&9I;F%N8VEN9R!D=7)I;F<@=&AE(&YE>'0@,3(@;6]N=&AS
M+CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:7,@
M;V8@4')E<V5N=&%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@
M,2XP(%1R86YS:71I;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X
M:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"CQD:78^
M(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$
M)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N
M,C5I;B<^/'-T<F]N9SYB+CPO<W1R;VYG/CPO=&0^(#QT9#X\<W1R;VYG/D)A
M<VES(&]F(%!R97-E;G1A=&EO;CPO<W1R;VYG/CPO=&0^(#PO='(^(#PO=&%B
M;&4^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@-38N-W!T.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB
M<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P
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M87-E)SXB/"]F;VYT/D=!05`\9F]N="!S='EL93TS1"=415A4+51204Y31D]2
M33H@=7!P97)C87-E)SXB/"]F;VYT/BD@9F]R(&EN=&5R:6T@9FEN86YC:6%L
M(&EN9F]R;6%T:6]N+B!!8V-O<F1I;F=L>2P@=&AE>2!D;R!N;W0@:6YC;'5D
M92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N9"!N;W1E<R!R97%U:7)E9"!B
M>2!'04%0(&9O<B!A;FYU86P@9FEN86YC:6%L('-T871E;65N=',N($EN('1H
M92!O<&EN:6]N(&]F(&UA;F%G96UE;G0L(&%L;"!A9&IU<W1M96YT<R`H;V8@
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M=&AA="!M87D@8F4@97AP96-T960@9F]R('1H92!F=6QL('EE87(N/"]P/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4V+C=P=#L@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`U-BXW<'0[($9/
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M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+"!F:6QE9"!B>2!T:&4@0V]M
M<&%N>2!W:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S
M:6]N+B!4:&4@8V]M<&%R871I=F4@8F%L86YC92!S:&5E="!A="!$96-E;6)E
M<B`S,2P@,C`Q,2!H87,@8F5E;B!D97)I=F5D(&9R;VT@=&AE(&%U9&ET960@
M9FEN86YC:6%L('-T871E;65N=',@870@=&AA="!D871E+CPO<#X@/"$M+45N
M9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16%R;FEN9W,@*&QO<W,I('!E
M<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/
M0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N
M<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T14
M1"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H\9&EV/B`\9&EV/CPA
M+2U3=&%R=$9R86=M96YT+2T^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0
M.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!
M3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(.B`Q-RXX-7!T)SX\
M<W1R;VYG/F,N/"]S=')O;F<^/"]T9#X@/'1D/CQS=')O;F<^3F5T(&QO<W,@
M<&5R('-H87)E/"]S=')O;F<^/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`U,RXX-7!T.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4S+C@U<'0[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!"87-I8R!A
M;F0@9&EL=71E9"!L;W-S('!E<B!S:&%R92`H(DQ04R(I(&%R92!C;VUP=71E
M9"!B>2!D:79I9&EN9R!N970@;&]S<R!B>2!T:&4@=V5I9VAT960@879E<F%G
M92!N=6UB97(@;V8@<VAA<F5S(&]F('1H92!#;VUP86YY)B,S.3MS(&-O;6UO
M;B!S=&]C:RP@<&%R('9A;'5E("0N,#`Q('!E<B!S:&%R92`H=&AE(")#;VUM
M;VX@4W1O8VLB*2P@;W5T<W1A;F1I;F<@9F]R(&5A8V@@<&5R:6]D+CPO<#X@
M/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`U,RXX-7!T.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#4S+C@U<'0[
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M('=O=6QD(&)E(&%N=&DM9&EL=71I=F4N/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#4S+C@U<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@1&EL=71E9"!,4%,@9&]E<R!N
M;W0@:6YC;'5D92`W+#0Y."PP,C8@86YD(#<L,38Y+#`S-2!S:&%R97,@;V8@
M0V]M;6]N(%-T;V-K('5N9&5R;'EI;F<@;W5T<W1A;F1I;F<@;W!T:6]N<R!A
M;F0@<F5S=')I8W1E9"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&9O<B!T:&4@
M;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R(#,P+"`R,#$Q(&%N9"`R,#$R
M+"!R97-P96-T:79E;'DL(&%N9"`W+#0R."PR,#$@86YD(#<L-3`X+#(T,"!S
M:&%R97,@;V8@0V]M;6]N(%-T;V-K('5N9&5R;'EI;F<@;W5T<W1A;F1I;F<@
M;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S:&%R97,@;V8@0V]M;6]N(%-T;V-K
M(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B`S,"P@,C`Q
M,2!A;F0@,C`Q,BP@<F5S<&5C=&EV96QY+CPO<#X@/"$M+45N9$9R86=M96YT
M+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?8V(U9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W
M93(X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V-B-60T.&(U7V5B
M-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R."]7;W)K<VAE971S+U-H965T,3,N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%
M3E1/4DE%4R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DE.5D5.5$]22453(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV96YT
M;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E0
M12!H=&UL(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I
M;VYA;"\O14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH
M=&UL,2UT<F%N<VET:6]N86PN9'1D(B`M+3X-"CQD:78^(#QD:78^/"$M+5-T
M87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`X-24[($)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`P+C<U:6XG(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS1"=6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A
M<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD
M)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X]
M,T0R(&YO=W)A<#TS1&YO=W)A<#Y397!T96UB97(@,S`L/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R
M87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&-E;G1E<CL@1D].5"U714E'2%0Z(&)O;&0G(&-O;'-P86X],T0R(&YO
M=W)A<#TS1&YO=W)A<#Y$96-E;6)E<B`S,2P\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D
M/B`\+W1R/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!N;W=R87`],T1N;W=R87`^("9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT
M97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N
M;W=R87`^,C`Q,CPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@
M5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A
M;CTS1#(@;F]W<F%P/3-$;F]W<F%P/C(P,3$\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A
M<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P
M="<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&-E
M;G1E<B<@8V]L<W!A;CTS1#8@;F]W<F%P/3-$;F]W<F%P/BA5+E,N(&1O;&QA
M<G,@:6X@=&AO=7-A;F1S*3PO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T<CX@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z(')G8B@R,#0L,C4U+#(P
M-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5TE$5$@Z(#<T)2<^4F%W(&UA=&5R:6%L<SPO=&0^
M(#QT9"!S='EL93TS1"=724142#H@,24G/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B0\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0[(%=)1%1(.B`Q,"4G/C$L,CDT
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q
M)2<^)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$
M5$@Z(#$P)2<^,C<Y/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/E=O<FL@:6X@
M<')O9W)E<W,\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^,CDX/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXM/"]T9#X@/'1D('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS
M1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/D9I;FES:&5D(&=O;V1S/"]T9#X@
M/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@<V]L:60[
M(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!R
M:6=H="<^(#0V-CPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#%P="<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F="<^("9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX@+3PO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG
M/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#(N-7!T)SY4;W1A;"!I;G9E;G1O<GD\+W1D/B`\=&0@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,BPP
M-3@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE.R!415A4+4%,24=.
M.B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX@,C<Y/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]4
M5$]-.B`R+C5P="<^)FYB<W`[/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\(2TM16YD1G)A9VUE
M;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
M+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T8C`P
M,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(U9#0X8C5?
M96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X+U=O<FMS:&5E=',O4VAE970Q
M-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I
M;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M
M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P13--04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R`H1&5T86EL<RD@*%53
M1"`D*3QB<CY);B!-:6QL:6]N<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS-"!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0T/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^16YT:71Y/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$R/&)R/E!R;W1A;&EX($)I;R!4:&5R87!E=71I
M8W,@26YC;W)P;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/E!F:7IE<B!);F-O<G!O
M<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^3W!T:6]N<R!A;F0@4F5S=')I8W1E9"!3
M:&%R97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,3QB<CY/<'1I;VYS(&%N9"!297-T<FEC=&5D(%-H
M87)E<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$R/&)R/D]P=&EO;G,@86YD(%)E<W1R:6-T960@4VAA
M<F5S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3$\8G(^3W!T:6]N<R!A;F0@4F5S=')I8W1E9"!3:&%R
M97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,CQB<CY5<&]N($9I;&EN9R!O9B!0961I871R:6,@26YV
M97-T:6=A=&EO;B!0;&%N('1O($5-02!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/E5P;VX@96%C
M:"!&1$$@86YD($5U<F]P96%N($UE9&EC:6YE($%G96YC>2!A<'!R;W9A;"!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@4W5B<VED:6%R:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(@06=R965M96YT+"!U<&9R;VYT('!A
M>6UE;G0@<F5C96EV960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;&5S=&]N92!P87EM96YT('1R:6=G97)E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&9I>F5R($%G<F5E;65N
M="P@9G5T=7)E(')E=F5N=65S(&%N9"!E>'!E;G-E('-H87)I;F<@<&5R8V5N
M=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92!P97(@<VAA<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3W!T:6]N<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL@;F]T(&EN8VQU
M9&5D(&EN(&1I;'5T960@3%!3(&)E8V%U<V4@=&AE(&5F9F5C="!W;W5L9"!B
M92!A;G1I+61I;'5T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#4P."PR-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW+#0R."PR,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+#$V.2PP,S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#0Y."PP,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V-B-60T.&(U7V5B
M-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R.`T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T8C`P,3=E
M,C@O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D5!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY)3E9%3E1/4DE%4R`H1&5T86EL<RD@*%53
M1"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF
M:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/DE.5D5.5$]22453(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%W(&UA=&5R:6%L
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#(Y-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y7;W)K(&EN('!R;V-E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1FEN:7-H960@9V]O9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C0V-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&EN=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M+#`U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T,#8T8C`P,3=E,C@-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(U9#0X8C5?96(T,E\T,SDW
M7V)E96%?-#`V-&(P,#$W93(X+U=O<FMS:&5E=',O4VAE970Q-BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14)&04D^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4U1/0TL@5%)!
M3E-!0U1)3TY3("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y&96(N(#(Y+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y&96(N(#(R+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^4&5R
M9F]R;6%N8V4M8F%S960@07=A<F1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3(\8G(^4&5R9F]R;6%N
M8V4M8F%S960@07=A<F1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;"X@,38L(#(P,3(\8G(^4W1O8VL@0V]M<&5N<V%T
M:6]N(%!L86X@86YD(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5L+B`S,2P@,C`Q,CQB<CY3
M=&]C:R!#;VUP96YS871I;VX@4&QA;B!A;F0@4F5S=')I8W1E9"!3=&]C:R!;
M365M8F5R73QB<CY%>&5C=71I=F4@3V9F:6-E<B!;365M8F5R73QB<CY-;VYT
M:#QB<CY);G-T86QL;65N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6PN(#$V+"`R,#$R/&)R/E-T;V-K($-O;7!E;G-A=&EO;B!0;&%N
M(&%N9"!297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/&)R/D5X96-U=&EV92!/
M9F9I8V5R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,S$L(#(P,3(\8G(^4W1O8VL@0V]M<&5N<V%T:6]N(%!L86X@
M86YD(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\8G(^16UP;&]Y965S(%M-
M96UB97)=/&)R/DEN<W1A;&QM96YT/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^0V5R=&%I;B!%;7!L;WEE97,@
M86YD($YO;BUE;7!L;WEE97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5N9&5R=W)I='1E;B!P=6)L:6,@;V9F97)I;F<L(&-O;6UO;B!S
M=&]C:R!I<W-U960@86YD('-O;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,3<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^56YD97)W<FET=&5N('!U8FQI8R!O9F9E<FEN
M9RP@8V]M;6]N('-T;V-K('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@;V8@8V]M;6]N('-T
M;V-K(&ES<W5E9"P@;&]C:R!U<"!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y5;F1E<G=R:71T96X@<'5B;&EC(&]F9F5R:6YG
M+"!N970@<')O8V5E9',@9G)O;2!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R-2PS.#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;F1E<G=R:71T96X@<'5B
M;&EC(&]F9F5R:6YG+"!C;VUM:7-S:6]N<R!A;F0@:7-S=6%N8V4@8V]S=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S@P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N
M+65M<&QO>65E<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ-38L,3@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R;V-E961S(&9R;VT@97AE<F-I
M<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PP.38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C8S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,3,W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"!I;B!C;VYN96-T:6]N('=I=&@@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PQ-38L,3@T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&ES<W5E9"P@=F5S=&EN9R!P97)I;V0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP-C4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S,P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A<'!R;W9E9"!F
M;W(@9W)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E
M<B!O9B!I;G-T86QL;65N=',@9F]R('9E<W1I;F<@;V8@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@
M8V]M;6]N('-T;V-K(&%T(&=R86YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@."PU.#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]C8C5D-#AB-5]E8C0R7S0S.3=?8F5E85\T
M,#8T8C`P,3=E,C@-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8V(U
M9#0X8C5?96(T,E\T,SDW7V)E96%?-#`V-&(P,#$W93(X+U=O<FMS:&5E=',O
M4VAE970Q-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P155&04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4U5"4T51545.5"!%5D5.5%,@*$1E=&%I;',I("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R
M=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y.;W8N(#,P+"`R,#$R/&)R/D]P=&EO;B!%>&5R8VES
M92!;365M8F5R73QB<CY#97)T86EN($5M<&QO>65E(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E
M<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!I<W-U960@:6X@
M8V]N;F5C=&EO;B!W:71H(&5X97)C:7-E(&]F(&]P=&EO;G,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#(X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R;V-E961S(&9R
M;VT@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+#`Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#$X-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?8V(U9#0X8C5?96(T,E\T,SDW7V)E
M96%?-#`V-&(P,#$W93(X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V-B-60T.&(U7V5B-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R."]7;W)K<VAE
M971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M
M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL
M92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'10
L87)T7V-B-60T.&(U7V5B-#)?-#,Y-U]B965A7S0P-C1B,#`Q-V4R."TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</strong></p> <p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.5in"><strong>a.</strong></td> <td><strong>General</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>1.</strong></td> <td>Operation</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On May 1, 2012, the U.S. Food and Drug Administration (<font style="TEXT-TRANSFORM: uppercase">"</font>FDA<font style="TEXT-TRANSFORM: uppercase">"</font>) approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. <font style="COLOR: black">In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency&#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV<sup>&reg;</sup>, Shire plc&#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in Israel shortly. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. Notwithstanding the EC&#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, will continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities. In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.</p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>2.</strong></td> <td>Liquidity and Financial Resources</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to the FDA approval of taliglucerase alfa, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>b.</strong></td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (<font style="TEXT-TRANSFORM: uppercase">"</font>GAAP<font style="TEXT-TRANSFORM: uppercase">"</font>) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.</p> <p style="TEXT-INDENT: -17.85pt; MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 36pt">&nbsp;</td> <td style="WIDTH: 17.85pt"><strong>c.</strong></td> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s common stock, par value $.001 per share (the "Common Stock"), outstanding for each period.</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> Shares of restricted Common Stock and the shares of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the effect would be anti-dilutive.</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Diluted LPS does not include 7,498,026 and 7,169,035 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September 30, 2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the three months ended September 30, 2011 and 2012, respectively.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EN3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 50,216<span></span></td>
        <td class="nump">$ 27,001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrentAbstract', window );"><strong>Accounts receivable:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade</a></td>
        <td class="nump">4,025<span></span></td>
        <td class="nump">1,374<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other</a></td>
        <td class="nump">3,281<span></span></td>
        <td class="nump">3,837<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">2,058<span></span></td>
        <td class="nump">279<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">59,580<span></span></td>
        <td class="nump">32,491<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,134<span></span></td>
        <td class="nump">1,043<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">16,664<span></span></td>
        <td class="nump">18,271<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">77,378<span></span></td>
        <td class="nump">51,805<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">4,427<span></span></td>
        <td class="nump">5,032<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">11,444<span></span></td>
        <td class="nump">7,540<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">4,564<span></span></td>
        <td class="nump">6,121<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">20,435<span></span></td>
        <td class="nump">18,693<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">47,499<span></span></td>
        <td class="nump">50,923<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term liability</a></td>
        <td class="nump">2,794<span></span></td>
        <td class="nump">6,566<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">1,878<span></span></td>
        <td class="nump">1,700<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">52,171<span></span></td>
        <td class="nump">59,189<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">72,606<span></span></td>
        <td class="nump">77,882<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
        <td class="nump">4,772<span></span></td>
        <td class="num">(26,077)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity (net of capital deficiency)</a></td>
        <td class="nump">$ 77,378<span></span></td>
        <td class="nump">$ 51,805<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E2EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  (CAPITAL DEFICIENCY) (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issued for cash, issuance costs</a></td>
        <td class="nump">$ 1,780<span></span></td>
        <td class="nump">$ 1,410<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EALAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (1,741)<span></span></td>
        <td class="num">$ (27,616)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">6,065<span></span></td>
        <td class="nump">730<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">2,772<span></span></td>
        <td class="nump">2,698<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
        <td class="nump">14<span></span></td>
        <td class="nump">156<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">218<span></span></td>
        <td class="nump">115<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(24)<span></span></td>
        <td class="num">(12)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of fixed assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues (including non-current portion)</a></td>
        <td class="num">(4,981)<span></span></td>
        <td class="num">(991)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
        <td class="num">(2,099)<span></span></td>
        <td class="nump">2,810<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
        <td class="num">(1,779)<span></span></td>
        <td class="nump">762<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals (including long term)</a></td>
        <td class="nump">369<span></span></td>
        <td class="nump">4,388<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(1,186)<span></span></td>
        <td class="num">(16,958)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(1,817)<span></span></td>
        <td class="num">(5,001)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(93)<span></span></td>
        <td class="num">(122)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(1,910)<span></span></td>
        <td class="num">(5,121)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
        <td class="nump">25,328<span></span></td>
        <td class="nump">20,650<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="nump">1,096<span></span></td>
        <td class="nump">263<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">26,424<span></span></td>
        <td class="nump">20,913<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="num">(113)<span></span></td>
        <td class="num">(170)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="nump">23,215<span></span></td>
        <td class="num">(1,336)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">27,001<span></span></td>
        <td class="nump">35,900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">50,216<span></span></td>
        <td class="nump">34,564<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">821<span></span></td>
        <td class="nump">1,477<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalOfferingAndStockIssuanceCosts', window );">Issuance cost not yet paid and accruals - other</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">60<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="nump">$ 72<span></span></td>
        <td class="nump">$ 12<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cashless exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of common stock net of expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalOfferingAndStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental offering and stock issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalOfferingAndStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitContributions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESCAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="4">3 Months Ended</th>
        <th class="th" colspan="4">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 3,724<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 1,132<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 33,698<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 6,024<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="nump">1,666<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(235)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">678<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(3,745)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(2,367)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">(220)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">(6,966)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">(1,130)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump">3,023<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">677<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">27,410<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,149<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(8,326)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="num">(9,340)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="num">(27,717)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="num">(28,671)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">less - grants and reimbursements</a></td>
        <td class="nump">1,963<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,422<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,655<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,163<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(6,363)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(7,918)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(22,062)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(23,508)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(2,220)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="num">(1,526)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="num">(7,353)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="num">(5,314)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(5,560)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(8,767)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(2,005)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(27,673)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">FINANCIAL INCOME (EXPENSES) - NET</a></td>
        <td class="nump">81<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(108)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">264<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">57<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
        <td class="num">$ (5,479)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (8,875)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (1,741)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (27,616)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER SHARE OF COMMON STOCK:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (0.1)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (0.02)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (0.033)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED</a></td>
        <td class="nump">91,929,445<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">85,585,777<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">90,491,421<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">84,351,420<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="9"></td>
      </tr>
      <tr>
        <td colspan="9">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Includes share-based compensation 220 0 220 0</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">Includes share-based compensation 1,247 92 3,690 348</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">Includes share-based compensation 840 117 2,155 382 </td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GrantsAndReimbursementsReceivedOrReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_WeightedAverageNumberBasicAndDilutedSharesOutstandingAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EUFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2012

</div>
          <div>Option Exercise [Member]

</div>
          <div>Certain Employee [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common Stock issued in connection with exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,828<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 1,096<span></span></td>
        <td class="nump">$ 263<span></span></td>
        <td class="nump">$ 5,187<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Nov. 04, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,465,169<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 1,247<span></span></td>
        <td class="nump">$ 92<span></span></td>
        <td class="nump">$ 3,690<span></span></td>
        <td class="nump">$ 348<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">840<span></span></td>
        <td class="nump">117<span></span></td>
        <td class="nump">2,155<span></span></td>
        <td class="nump">382<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Cost of Revenues [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 220<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 220<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"><strong>a.</strong></td> <td><strong>General</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>1.</strong></td> <td>Operation</td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On May 1, 2012, the U.S. Food and Drug Administration (<font style="TEXT-TRANSFORM: uppercase">"</font>FDA<font style="TEXT-TRANSFORM: uppercase">"</font>) approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was recorded as revenue during the period in which it was received. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits and losses related to commercialization efforts in Israel. <font style="COLOR: black">In calculating the net profits under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed for Brazil and other countries. The European Commission issued a Commission Decision refusing the marketing authorization for taliglucerase alfa in the European Union. This decision is an endorsement of the European Medicines Agency&#39;s Committee for Medicinal Products for Human Use (CHMP) June 2012 opinion recommending against the marketing authorization of taliglucerase alfa. While the CHMP gave a positive risk-benefit assessment for taliglucerase alfa, its recommendation was based solely on the orphan market exclusivity granted to VPRIV<sup>&reg;</sup>, Shire plc&#39;s Gaucher disease treatment. It was not based on the safety and efficacy profile of taliglucerase alfa.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States, and are anticipated to be treated on a commercial basis in Israel shortly. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. [Notwithstanding the EC&#39;s decision not to approve the market authorization of taliglucerase alfa in the EU, the Company, together with Pfizer, is prepared to continue to supply taliglucerase alfa as required by physicians under the ATU process for as long as it is authorized by the French regulatory authorities.] In addition to the United States and France, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On August 10, 2010, Pfizer entered into a short-term supply agreement with the Ministry of Health of Brazil pursuant to which the Company and Pfizer have provided taliglucerase alfa to the Brazilian Ministry of Health for the treatment of Gaucher patients. During the remainder of 2010 and the first quarter of 2011, the Company and Pfizer completed the supply of products deliverable under the short-term supply agreement. During 2011, Pfizer recorded an allowance for sales returns in connection with the supply agreement because the Brazilian Ministry of Health requested that Pfizer consider the replacement of certain vials that might expire during 2012. During the third quarter of 2012 resupply for certain vials was completed. Revenue, net of allowance for sales returns, generated from the Brazilian Ministry of Health was recorded by Pfizer, and the Company recorded its share of such revenues in accordance with the terms and conditions of the Pfizer Agreement.</p> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>2.</strong></td> <td>Liquidity and Financial Resources</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to the FDA approval of taliglucerase alfa, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"><strong>b.</strong></td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (<font style="TEXT-TRANSFORM: uppercase">"</font>GAAP<font style="TEXT-TRANSFORM: uppercase">"</font>) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 56.7pt; FONT: 10pt Times New Roman, Times, Serif"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2011, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2011 has been derived from the audited financial statements at that date.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (loss) per share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 17.85pt"><strong>c.</strong></td> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s common stock, par value $.001 per share (the "Common Stock"), outstanding for each period.</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> Shares of restricted Common Stock and the shares of Common Stock underlying outstanding options of the Company were not included in the calculation of diluted LPS because the effect would be anti-dilutive.</p> <p style="MARGIN: 0pt 0px 0pt 53.85pt; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Diluted LPS does not include 7,498,026 and 7,169,035 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the nine months ended September 30, 2011 and 2012, respectively, and 7,428,201 and 7,508,240 shares of Common Stock underlying outstanding options and restricted shares of Common Stock for the three months ended September 30, 2011 and 2012, respectively.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accounting policy related to the nature of operations of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NatureOfOperationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 4 - SUBSEQUENT EVENTS</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> During October and November 2012, the Company issued a total of 3,828 shares of Common Stock in connection with the exercise of options to purchase 3,828 shares of Common Stock by an employee of the Company. The aggregate cash proceeds in connection with the exercise of the options were $5,187.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INVENTORIES (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
        <td class="nump">$ 1,294<span></span></td>
        <td class="nump">$ 279<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
        <td class="nump">298<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
        <td class="nump">466<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump">$ 2,058<span></span></td>
        <td class="nump">$ 279<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoodsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterialsNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386940&amp;loc=d3e100047-122729<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section BB<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcessNetOfReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <table style="WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">September 30,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 74%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1,294</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">279</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">298</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">-</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 466</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 2,058</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 279</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E3MAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">34 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="4">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Entity</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Protalix Bio Therapeutics Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Pfizer Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Options and Restricted Shares [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Options and Restricted Shares [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Options and Restricted Shares [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011

</div>
          <div>Options and Restricted Shares [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Upon each FDA and European Medicine Agency approval [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 25.0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40.00%<span></span></td>
        <td class="nump">60.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,508,240<span></span></td>
        <td class="nump">7,428,201<span></span></td>
        <td class="nump">7,169,035<span></span></td>
        <td class="nump">7,498,026<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NumberOfSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EBFAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Feb. 29, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 22, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Performance-based Awards [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Performance-based Awards [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2012

</div>
          <div>Stock Compensation Plan and Restricted Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Stock Compensation Plan and Restricted Stock [Member]

</div>
          <div>Executive Officer [Member]

</div>
          <div>Month

</div>
          <div>Installment</div>
        </th>
        <th class="th">
          <div>Jul. 16, 2012

</div>
          <div>Stock Compensation Plan and Restricted Stock [Member]

</div>
          <div>Executive Officer [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Stock Compensation Plan and Restricted Stock [Member]

</div>
          <div>Employees [Member]

</div>
          <div>Installment</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Certain Employees and Non-employees [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Underwritten public offering, common stock issued and sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Underwritten public offering, common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm', window );">Shares of common stock issued, lock up period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Underwritten public offering, net proceeds from issuance</a></td>
        <td class="nump">$ 25,388,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwritten public offering, commissions and issuance costs</a></td>
        <td class="nump">1,780,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,156,184<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,096,000<span></span></td>
        <td class="nump">263,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,137,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued in connection with exercise of options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,156,184<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Shares of common stock issued, vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,065,000<span></span></td>
        <td class="nump">730,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,900,000<span></span></td>
        <td class="nump">3,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock approved for grant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod', window );">Number of installments for vesting of stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Fair value of common stock at grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,580,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award grant date fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award granted contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantedContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of installments for vesting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallmentsForVestingPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:decimalItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section H<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph b(2)(c)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EA1BG">
      <tr>
        <th class="tl" colspan="2" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) (USD $)<br>In Thousands, except Share data</strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2010</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="num">$ (11,323)<span></span></td>
        <td class="nump">$ 81<span></span></td>
        <td class="nump">$ 124,044<span></span></td>
        <td class="num">$ (135,448)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2010</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">81,248,472<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">20,590<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="nump">20,586<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">730<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">730<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">266<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">265<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350,045<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="num">(27,616)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(27,616)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2011</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="num">(17,353)<span></span></td>
        <td class="nump">86<span></span></td>
        <td class="nump">145,625<span></span></td>
        <td class="num">(163,064)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2011</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85,598,517<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="num">(26,077)<span></span></td>
        <td class="nump">86<span></span></td>
        <td class="nump">145,814<span></span></td>
        <td class="num">(171,977)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2011</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">85,630,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">25,388<span></span></td>
        <td class="nump">5<span></span></td>
        <td class="nump">25,383<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">4,217<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,217<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">1,137<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,136<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,156,184<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">1,848<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="nump">1,847<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Share-based compensation related to restricted stock award (in shares)</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="num">(1,741)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,741)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2012</a></td>
        <td class="th" style="border-bottom: 0px;"><sup></sup></td>
        <td class="nump">$ 4,772<span></span></td>
        <td class="nump">$ 93<span></span></td>
        <td class="nump">$ 178,397<span></span></td>
        <td class="num">$ (173,718)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2012</a></td>
        <td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,461,341<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Common Stock, $0.001 par value; Authorized - as of September 30, 2012 and September 30, 2011 - 150,000,000 shares.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to employee stock purchase programs during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 3 - STOCK TRANSACTIONS</strong></p> <p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 49.65pt">&nbsp;</td> <td style="WIDTH: 21.25pt"><strong>a.</strong></td> <td style="COLOR: black">On February 22, 2012, the Company issued and sold 5,175,000 shares of Common Stock in an underwritten public offering at a price to the public of $5.25 per share. The net proceeds to the Company were approximately $25,388,000 (net of underwriting commissions and issuance costs of approximately $1,780,000).</td> </tr> </table> <p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 49.65pt">&nbsp;</td> <td style="COLOR: black; WIDTH: 21.25pt"><strong>b.</strong></td> <td><font style="COLOR: black">During the nine months ended September 30, 2012, the Company issued a total of</font> 1,156,184 <font style="COLOR: black">shares of Common Stock in connection with the exercise of a total of</font> 1,156,184 <font style="COLOR: black">options by certain officers and employees of the Company. The Company received aggregate cash proceeds equal to approximately $</font>1,137,000 <font style="COLOR: black">in connection with such exercises.</font></td> </tr> </table> <p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 49.65pt">&nbsp;</td> <td style="COLOR: black; WIDTH: 21.25pt"><strong>c.</strong></td> <td><font style="COLOR: black">Following FDA</font> approval of taliglucerase alfa on May 1, 2012<font style="COLOR: black">, the Company started recognizing compensation costs in relation to performance-based awards that were granted in February 2010 to certain officers and employees of the Company, which vest over a three-year period commencing upon the FDA&#39;s approval of</font> taliglucerase alfa<font style="COLOR: black">. During the second and third quarter of 2012, the Company recorded an expense in the amount of approximately $3,900,000 for the cumulative period from the date of grant.</font></td> </tr> </table> <p style="TEXT-INDENT: -21.25pt; MARGIN: 0pt 0px 0pt 70.9pt; FONT: 10pt Times New Roman, Times, Serif">&nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 49.65pt">&nbsp;</td> <td style="COLOR: black; WIDTH: 21.25pt"><strong>d.</strong></td> <td>On July 16, 2012, the Company&#39;s Board of Directors approved the grant of 1,500,000 shares of restricted Common Stock to its officers and certain other employees. Of such restricted shares, 1,100,000 of the shares were issued to the Company&#39;s named executive officers and vest in 16 equal, quarterly increments over a four-year period, commencing upon the date of grant, and are subject to a 24-month lock-up period, commencing upon the applicable vesting dates. Immediately and automatically in the event of a Change in Control, as such term is defined in the Company&#39;s 2006 Stock Incentive Plan, as amended, all of the shares of restricted Common Stock issued to the named executive officers shall vest, and the lock-up periods shall terminate, subject to certain exceptions. The remaining 400,000 shares of restricted Common Stock were issued to other employees of the Company and vest in 12 equal, quarterly increments over a three-year period, commencing upon the date of grant. The Company estimated the fair value of the restricted stock on the date of grant to be approximately $8,580,000.</td> </tr> </table> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>58</ContextCount>
  <ElementCount>106</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInShareholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>104 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>40101 - Disclosure -  SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40301 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40401 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY  (CAPITAL DEFICIENCY) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20120930.xml</File>
    <File>plx-20120930.xsd</File>
    <File>plx-20120930_cal.xml</File>
    <File>plx-20120930_def.xml</File>
    <File>plx-20120930_lab.xml</File>
    <File>plx-20120930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
